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ABSTRACT 
Background 
The tissue damage resulting from myocardial ischaemia/reperfusion (I/R) leads 
to a large proportion of the deaths in the developed world.  Even if patients 
survive a myocardial infarction, I/R injury is associated with decreased cardiac 
function  and  a  higher  incidence  of morbidity,  and consequently,  a reduced 
quality of life.  Leptin is a cytokine produced by white adipose tissue that has 
been shown to activate the PI3K-Akt and p44/42 MAPK signalling cascades and 
protect the murine myocardium.  The studies described in this thesis focused on 
the molecular mechanisms  underlying leptin-induced cardioprotection with 
particular reference to cell signalling. 
Methods & Results 
Using an isolated rat heart model of I/R injury, it was confirmed that leptin given 
at reperfusion protects the myocardium.  This protection was abolished by the 
administration of specific blockers of the survival kinases PI3K, JAK and p44/42 
MAPK.  The time-points at which maximal phosphorylation of Akt, p44/42 MAPK 
and STAT3 occur in response to leptin given at reperfusion were identified.  The 
key role played by  the leptin receptor in leptin-induced cardioprotection was 
established by employing the Zucker obese rat (fa/fa), which has a mutation in 
the leptin receptor, and its Zucker lean  (fa/+)  counterpart that possesses a 
functional OB-R.  It was found that the Zucker fatty rats were non-responsive to 
leptin-induced cardioprotection.  Furthermore, it was shown that whilst leptin 
inhibited  mitochondrial  permeability transition pore  (MPTP) opening in Richard A Dixon  Abstract 
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cardiomyocytes from Wistar and Zucker lean rats, MPTP  opening in OB-R 
deficient Zucker fatty rats was unaffected. Finally, leptin was shown to protect 
against ischaemia-reperfusion injury in an in vivo rat model of I/R injury. 
Conclusion 
The present study has yielded information concerning the mechanisms 
underlying the cardioprotective actions of leptin; including the importance of the 
OB-R.  Extending the studies employing in vivo models of I/R injury will assist in 
establishing the potential of leptin as a therapeutic agent 
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CHAPTER 1 - GENERAL INTRODUCTION 
1.1  Coronary Artery Disease 
Cardiovascular disease (CVD) is the principal cause of mortality in the United 
Kingdom, accounting for approximately 1 in 5 deaths in males and 1 in 6 in 
females.  Apart from the human cost, CVD places a large economic burden on 
the national health system.  In 2003  CVD  cost the UK healthcare system 
approximately £15,000 million.  Therefore it is clear that a concerted effort is 
needed to prevent, treat and understand CVD in order to limit its consequences.  
Basic scientists aim to understand CVD disease at the molecular level and to 
investigate potential treatments that can then be translated to clinical practice.  
CVD ranges in severity from sub-clinical coronary artery disease to acute 
myocardial infarction (MI), with congestive heart failure and death featuring as 
the worst manifestations of the disease (Shah & Forrester 1991).  According to 
the  leadership of the European Society of Cardiology (ESC), the American 
College of Cardiology (ACC), American Heart Association (AHA) and the World 
Heart Federation (WHF), the term myocardial infarction should be used when 
there is evidence of myocardial necrosis in a clinical setting consistent with 
myocardial ischaemia.  This information was published in an Expert Consensus 
Document published by the Journal of the American College of Cardiology in 
2007 (Thygesen et al. 2007).  Myocardial ischaemia is defined as the limitation 
of blood flow, with increased resistance, to a portion of the heart, which leads to 
the oxygen demands of the tissue exceeding that provided by the decreased 
blood flow.  Coronary artery disease starts with a gradual build-up of plaque in Richard A Dixon  General Introduction 
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the arteries of the heart.  This build-up is often exacerbated in sedentary 
individuals who consume a diet rich in fats and who smoke, however this can 
also be as a result of genetic factors (Genest, Jr. & Cohn 1995; Poirier et al. 
2006; Shah 2006). Blocking of an artery occurs when an unstable 
atherosclerotic plaque ruptures, resulting in the formation of a thrombotic plug 
which occludes the vessel and prevents canonical blood flow (figure 1.1.1) 
(Shah 2002).  Cessation of blood flow in one or more coronary arteries presents 
clinically as an acute myocardial infarction.  Rapid reperfusion of ischaemic 
tissue by application of either thrombolysis or primary percutaneous transluminal 
coronary angioplasty (PCTA) has been found to be the most effective way of 
salvaging myocardial tissue at risk (Faxon 2005).  Limitation of ischaemic tissue 
and optimisation of patient prognosis and quality of life is the main goal of these 
therapies.  In the clinical setting reperfusion of the ischaemic myocardium is 
associated with the following complications: myocardial stunning (Braunwald & 
Kloner 1982; Bolli & Marban 1999), reperfusion arrhythmias (Manning & Hearse, 
1984), endothelial and mircovascular dysfunction (Ito, 2006) and cardiomyocyte 
death.  These pathologies are the consequence of a phenomenon known as 
reperfusion injury (Piper et al, 1998) (see 1.2). 
The goal of scientists working in the field of ischaemic heart disease is to 
understand the mechanisms by which the disease manifests itself and to identify 
treatments that will improve patient prognosis.  Myocardial infarctions are 
difficult to predict  and therefore it is difficult to apply treatments prior to the Richard A Dixon  General Introduction 
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ischaemic insult.  Consequently, treatments are usually targeted at either the 
ischaemic phase or the reperfusion-phase. 
 
Figure 1.1.1 - Schematic diagram depicting the progression of coronary artery disease.  (A) Plaque 
formation begins with cholesterol adhering to walls of coronary vessels.  (B) As plaque becomes larger 
artery expands and lumen of the vessel decreases. (C) Plaque rupture leads precipitation of a clotting 
reaction and consequential occlusion of vessel  by a thrombotic plug. Figure adapted from 
www.nationalgeographic.com.   
 
1.2  Myocardial Ischaemia-Reperfusion (I/R) Injury 
The heart is a complex biomechanical pump, efficient in the conversion of 
chemical to mechanical energy.  Blood flow via the coronary vasculature 
provides fuel for oxidative metabolism, which in the form of adenine-triphosphate 
(ATP)  provides the majority of the energy required to produce the powerful 
rhythmic contractions needed to pump the blood around the body.  If blood flow 
is interrupted for a short period, the energy requirements of the heart can be met 
by glycolytic ATP production until normal oxidative metabolism can be restored 
(Das & Harris 1990).  However, prolonged periods of interrupted blood flow, 
known as ischaemia, leads to the production of lactate and hydrogen ions (H
+).  
A  B  C Richard A Dixon  General Introduction 
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The accumulation of these by-products  of  glycolytic ATP production  can 
irreversibly damage the myocardium (Dennis et al. 1991).   
Reperfusion of the ischaemic myocardium is a necessary event  in order  to 
salvage cardiac tissue at risk.  Although reperfusion provides washout of the 
damaging lactate and restores  pH levels  to normal, paradoxically,  it is also 
responsible for damage to ischaemic cells that were previously viable before 
reperfusion (Piper et al. 1998).  Hence, reperfusion has been referred to as a 
“double edged sword,” not only  salvaging myocardial tissue but also 
exacerbating and accelerating injury caused by ischaemia alone (Braunwald & 
Kloner 1985).  This phenomenon, termed reperfusion injury, was first described 
by Jennings et al. in 1960. They conducted detailed histological examinations of 
the damaged reperfused ischaemic canine myocardium and identified cellular 
swelling, disruption of sarcolemma, contracture of myofibrils and the emergence 
of intramitochondrial calcium phosphate particles as key features (Jennings et 
al. 1960).         
The existence of reperfusion injury was contested for some time, with sceptics 
suggesting that reperfusion just exacerbates the  damage sustained during 
ischaemia (Gross & Auchampach 2007).  Nonetheless, studies demonstrating 
that infarct size can be reduced by pharmacological agents delivered at 
reperfusion have provided evidence for the existence of I/R injury (Bell & Yellon 
2003; Mocanu et al. 2000; Andreadou et al. 2008). Studies using animal models 
of myocardial infarction indicate that lethal reperfusion injury may account for up 
to 50% of the infarct size.  The damage caused by myocardial reperfusion leads Richard A Dixon  General Introduction 
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to four different types of cardiac dysfunction.  The first of these is myocardial 
stunning, which is defined as “prolonged post-ischaemic mechanical dysfunction 
and  continues after reperfusion in the absence of irreversible damage” 
(Braunwald & Kloner 1982).  The myocardial dysfunction persists much longer 
than the time of the original index-ischaemic period.  Hence, just 15min of 
myocardial ischaemia in dogs leads to 24 hours of depressed cardiac function.  
However, stunning is not usually a major clinical problem unless a significantly 
large portion of the myocardium is affected (Piper et al. 1998). The second type 
of cardiac dysfunction  associated with myocardial reperfusion  are potentially 
lethal  myocardial arrhythmias  (Manning & Hearse 1984), however their 
incidence is low, and should they occur, are easily treated by the clinician (Piper 
et al. 1998).  Mircovascular dysfunction, the third type of cardiac dysfunction, is 
the result of a combination of endothelial damage, oedema, oxidative stress and 
microvascular obstruction  by  microemboli  (Ito 2006).  No-reflow is the most 
severe form  of microvascular dysfunction  in which perfusion of the 
microvasculature is either reduced or completely prevented (Ito 2006).  Lethal 
reperfusion injury is the last type of cardiac dysfunction (Piper et al. 1998).  This 
is defined as cell death that occurs in the reperfusion-phase and should not be 
confused with “oncosis,” which is defined as cell death which occurs during the 
ischaemic phase (Majno & Joris 1995). In the following sections the molecular 
mechanisms contributing to the four clinical manifestations of reperfusion injury 
will be examined in detail. Richard A Dixon  General Introduction 
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1.2.1  Metabolic and biochemical consequences of myocardial 
ischaemia 
In cardiac ischaemia the myocardium must adopt strategies in order to survive 
the decrease in  blood flow and consequent reduction in oxygen supply 
(Hochachka et al. 1996).  These strategies include a decrease in myocardial 
contracture  coupled with the activation of compensatory metabolic changes, 
both  processes  occurring  within  10-120 seconds of the onset of severe 
myocardial ischaemia (Guth et al. 1993).  Oxygen deprivation leads to a 
decrease in the availability of cellular  energy.  This is reflected by a sharp 
decline in creatine phosphate levels, which in turn stimulate  glycolysis and 
glycogenolysis (Solaini & Harris 2005).  In the canine heart, anaerobic glycolysis 
is activated within 8 seconds of coronary artery ligation (Kloner & Jennings 
2001).  Anoxia will allow ATP production to continue via glycolysis (Das & Harris 
1990), however, during ischaemia this process leads to the production of lactate 
and hydrogen ions, i.e. a decrease in intracellular pH, which, in turn, inhibits 
glycolysis (Solaini & Harris 2005).   
Oxygen deprivation also leads to the inhibition of the tricarboxylic acid (TCA) 
cycle, and results in no energy being available from oxidative phosphorylation, 
and an accumulation of cytoplasmic nicotinamide adenine dinucleotide (NADH) 
and  flavin adenine dinucleotide (FADH)  (Solaini & Harris 2005).  During 
ischaemia  ATP levels decline slowly  with 40-50%  being  still available after 
30min of ischaemia (Ambrosio et al. 1993).  In the heart ATP consumption is 
closely associated with contraction. In cardiomyocytes, for example, the 
actomyosin contractile apparatus consumes approximately two thirds of the Richard A Dixon  General Introduction 
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available ATP (Opie, 1991).  The remaining third is used to maintain ionic 
homeostasis by a variety of ATP-dependent membrane pumps  (Opie, 1991).  
When ATP levels become depleted, as in myocardial ischaemia, these ATP 
dependent pumps fail and cellular ionic homeostasis is lost.  Intracellular levels 
of Na
+ and Ca
2+ rise in proportion to the severity of ischaemia (Steenbergen et 
al. 1990).  It is thought that at least part of the cellular burden of Na
+ results from 
increased activity of the Na
+/H
+ exchanger (NHE) during ischaemia, which is 
stimulated by acidosis (i.e. increased H
+  levels)  (Karmazyn et al. 1999).  
Recently, however, it has been demonstrated that Na
+ channels are, in part, 
also responsible for increased intracellular Na
+ levels (Williams et al. 2007).  In 
turn, increased levels of Na
+ trigger the Na
+/Ca
2+ exchanger, which expels Na
+ 
from the cell in return for an influx of Ca
2+ (Anderson et al. 1990).   
Increases  in both Na
+  and Ca
2+  are detrimental to the cell.  Increased 
sarcoplasmic Na
+ levels can cause mitochondrial damage and also lead to an 
increase in osmolarity which can ultimately lead to cellular swelling and even cell 
rupture (Takeo & Tanonaka 2004).  High intracellular Ca
2+ levels are thought to 
lead  to damage to the contractile apparatus, mitochondrial damage and 
activation of phospholipases (Bernardi & Rasola 2007).     
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Figure 1.2.1 – Schematic representing the changes in the levels of ions, ATP, Pi and NADH during 
ischaemia and reperfusion.  Figure adapted from: (www.heartandmetabolism.org) 
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1.2.2  Metabolic and biochemical consequences of myocardial 
reperfusion 
 
Upon reperfusion  oxidative phosphorylation and ATP synthesis recommence.  
Despite reactivation of these processes  and the restoration of  normal 
intracellular pH (~7.0), cellular dysfunction is exacerbated (Dennis et al. 1991).  
The factors contributing to reperfusion injury are discussed below. 
1.2.2.1 Calcium overload 
 
Reperfusion of the ischaemic myocardium leads to re-energization  of the 
mitochondria, providing ATP to cation pumps that were inactive during 
ischaemia (Javadov & Karmazyn 2007).  The Ca
2+-ATPase of the sarcoplasmic 
reticulum (SR) is reactivated and Ca
2+ is sequestered to the SR (Siegmund et al. 
1992).  If the levels of Ca
2+, however, exceed the capacity of the SR, Ca
2+ is re-
released, leading to a cycle of release and uptake (Siegmund et al. 1994).  Only 
if Na
+  homeostasis is achieved, i.e. a Na
+ gradient  is re-established, will the 
Na
+/Ca
2+ exchanger function again and remove excess calcium from the cell 
(Siegmund et al. 1994).  
The cardiomyocytes that are carrying high intracellular calcium are vulnerable to 
cell death via hypercontracture and or mitochondrial permeability transition pore 
(MPTP)  opening  (see section 1.2.2.4)  (Halestrap et al. 1998).  Experimental 
data have demonstrated that inhibitors of the sarcolemmal Ca
2+ ion channel, the 
mitochondrial Ca
2+ uniporter, or the sodium-hydrogen (Na
+/H
+) exchanger (NHE) 
can block the surge of Ca
2+ at reperfusion and result in an approximately 50% Richard A Dixon  General Introduction 
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reduction in myocardial infarct size (Klein et al. 1989; Carry et al. 1989; Gumina 
et al. 1999)  However, it must be noted that inhibition of the NHE reduces infarct 
size only when the antagonist is administered during or prior to ischaemia, not at 
reperfusion (Zeymer et al. 2001).  Hence, this approach to infarct size reduction 
has its limitations in the clinical arena. 
1.2.2.2 Oxidative stress 
At low concentrations reactive oxygen species (ROS)  act as cellular 
messengers, however, at higher concentrations they are extremely deleterious 
(Bandyopadhyay et al, 1999).  Approximately,  1-2% of normal oxidative 
phosphorylation leads to ROS production  (Gnaiger & Kuznetsov 2002).  
Paradoxically, the decreased availability of O2, i.e. decreased partial pressure, 
leads to increased ROS generation  (Solaini & Harris 2005).  This effect, also 
known as the oxygen paradox, is thought to be a result of the action of O2 within 
the mitochondrial inner membrane, however, very little is known about the 
underlying mechanism of this phenomenon (Guzy & Schumacker 2006).  
Ischaemia leads to increased ROS production (Becker et al. 1999; Vanden Hoek 
et al. 1997), which is exacerbated on reperfusion (Bolli & Marban 1999).  The 
adverse effects of ROS on cellular function include lipid peroxidation and the 
oxidation of cardiac proteins  (Ferrari et al. 2004).  Protective  mechanisms, 
include the enzymes superoxide dismutase (SOD) and manganese superoxide 
dismutase (Mn-SOD)  (in the mitochondria), which act to remove ROS  by 
catalysing the conversion  of superoxide to  oxygen and hydrogen peroxide 
(H2O2) (Kinnula & Crapo 2004).  Furthermore, the H2O2 by-product, which is Richard A Dixon  General Introduction 
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also deleterious, can be removed by glutathione peroxidase and peroxiredoxin 
(Nohl & Jordan 1980).  Low levels of ROS lead to lipid peroxidation, protein 
modification and mitochondrial deoxyribonucleic acid (DNA) oxidation (Ferrari et 
al. 2004).  However, high levels of  ROS can overwhelm  these scavenging 
systems and lead to cell death by apoptosis or necrosis, thereby contributing 
significantly to I/R injury (Kang & Izumo 2000).  In the ischaemic heart the main 
sources of ROS include the electron transport chain (ETC), xanthine oxidase 
and the NADPH oxidase system (Szocs 2004).     
1.2.2.3 The pH paradox 
The cellular acidosis (pH<7.0) which occurs during ischaemia has been 
demonstrated to protect against necrotic cell death in practically all cell types 
examined (Penttila & Trump 1974; Gores et al. 1988; Inserte et al. 2008).  By 
contrast, the rapid return to a normal intracellular pH (pH(i)) that occurs during 
reperfusion is, in fact, detrimental, contributing to reperfusion injury (Bond et al. 
1993).  This phenomenon, which is facilitated by the activation of the Na
+/H
+ 
exchanger and the sodium-bicarbonate symporter, and washout of lactic acid at 
reperfusion is known as “The pH paradox” (Bond et al. 1994).  It is now thought 
that a mechanism involving the opening of the mitochondrial permeability 
transition pore (MPTP) may underlie the pH paradox (Lemasters 1999).  Return 
of pH(i) to normal physiological values upon reperfusion has been shown to be 
associated with MPTP opening, which in turn can lead to cell death (see section 
1.2.2.4).  In rat hepatocytes, reperfusion with either an acidic buffer (pH=6.2) or 
with Cyclosporin A (CsA) abrogated the increase in MPTP opening and Richard A Dixon  General Introduction 
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preserved cell viability (Qian et al. 1997).  Bond el al performed a similar study 
that demonstrated that ischaemic neonatal rat cardiomyocytes were protected 
against I/R injury when reperfused with an acidic buffer (Bond et al. 1991).  
Furthermore, methods that delay the return to a physiological pH level, and thus 
allow the cell time to recover, have been shown to be protective.  For example, 
treatment of cardiomyocytes with dimethyl amiloride or HOE694, which are 
inhibitors of the Na
+/H exchanger facilitate cell viability by prolonging the time 
taken for pH(i) change to occur. 
1.2.2.4 Mitochondrial permeability transition 
The mitochondrial permeability transition pore (MPTP) is a non-specific pore that 
occurs between the inner and outer mitochondrial membranes  (Bernardi & 
Petronilli 1996).  Under conditions of stress, such as  those  occurring  after 
reperfusion of the ischaemic myocardium (elevated matrix Ca
2+, ROS elevation, 
elevated Pi  and depleted ATP, see  sections above) the MPTP  opens.  
Consequently, proteins and metabolites <1.5KDa are allowed to flow down their 
respective gradients (Halestrap et al. 2004).  In the absence of the H
+ gradient, 
used to drive the F1F0-ATPase, mitochondria become depolarised and oxidative 
phosphorylation  is uncoupled (Solaini & Harris. 2005).  Furthermore, the 
ATPase can function in reverse, hydrolysing ATP  and  leading to a rapid 
decrease in cellular  ATP  levels  (Jennings et al. 1991).  ATP is required to 
maintain cellular ionic and metabolic homeostasis.  Pore closure must occur in 
cells subjected to I/R to avoid necrotic cell death and so that homeostasis can 
be re-established (Halestrap 2006).  The amount of available ATP is thought to Richard A Dixon  General Introduction 
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dictate whether a cell undergoes necrotic, ATP-independent or apoptotic, ATP 
requiring, cell death (Halestrap et al. 2000)(see section 1.3).       
The structure of the pore remains to be fully elucidated.  However, it has been 
comprehensively shown that cyclophilin D (Cyp-D) is, if not the main component, 
one of the major components of the pore.  Thus, it was demonstrated that Cyp-D 
-/- mice subjected to myocardial I/R develop smaller infarcts than wild-type mice 
(Baines et al. 2005),  indicating that  formation of the pore is required for 
canonical mitochondrial death signalling to occur. 
A growing amount of data indicates that inhibition of the MPTP  protects 
myocardial tissue against I/R injury.  Cyclosporin A (CsA) and Sanglifehrin A 
both protect the ischaemic myocardium by binding to Cyp-D, albeit at different 
locations, and inhibit pore opening (Shanmuganathan et al. 2005; Clarke et al. 
2002).   Furthermore, it has been demonstrated in isolated cardiomyocytes that 
cells treated with insulin, which stimulates Akt phosphorylation, are less likely to 
undergo pore opening and subsequent rigor contraction (Davidson et al. 2006).  
This indicates that cardioprotectants that inhibit pore opening may do so via a 
mechanism that activates Akt.  The signalling mechanisms operating between 
Akt and the MPTP are, however, as yet unknown.   
Collectively, this body of data suggest  that the MPTP  may represent an 
important therapeutic target with regard to cell death, not only in the heart but 
also in other tissues such as the brain (Deniaud et al. 2006).  In a preliminary 
trial patients who presented with (acute ST-elevation) myocardial infarction were Richard A Dixon  General Introduction 
 
 
The Hatter Cardiovascular Institute  36 
   
randomised  to receive placebo or  Cyclosporin  A (CsA) by intravenous bolus 
(Piot et al. 2008).  This study yielded data  that mirrored those obtained  by 
experiments utilising CsA  in  in vivo  models  (Xie & Yu 2007).  For example 
creatine kinase levels were significantly reduced and the mass of the infarcted 
tissue was also reduced in the group treated with CsA (Piot et al. 2008).  The 
levels of troponin,  an important marker of tissue injury,  were, however,  not 
significantly reduced.  This is an important pilot study that when taken further 
should provide an important insight into the cardioprotective capacity of CsA in 
the human myocardium.     
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 Figure 1.2.2 – Schematic of the mitochondrial permeability transition pore (MPTP). The MPTP is a 
non-specific pore that forms between the inner mitochondrial membrane and the outer mitochondrial 
membrane (OMM).  Currently the true components that form the pore are unknown. However, cyclophilin 
D (Cyp D) has been shown to be a regulatory component of the pore.  Opening of the pore ultimately 
leads to cytochrome C release and apoptosis.  Figure adapted from:(Abou-Sleiman et al. 2006). 
 
1.2.3  Cell death 
Ischaemia-reperfusion injury ultimately leads to cell death.  Prior to 1971 cell 
death was  termed necrosis.  Subsequently, however, an alternative 
programmed form of cell death was identified in some tissues, which was 
ultimately termed apoptosis (Kerr et al. 1972).  Thus, it was suggested that cell 
death took two principle forms, namely necrosis and apoptosis  (Gottlieb & 
Engler 1999).    
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1.2.3.1 Necrosis 
Necrosis is a pathological form of cell death which is characterised by cellular 
swelling, organelle swelling, membrane permeabilisation  and  the  release of 
cellular contents, and provokes inflammation (Wei-Xing Zong Tompson 2006).  
Initially, necrosis was thought to be the predominant form of cell death in 
ischaemic heart disease (IHD).  Subsequently, however, evidence was obtained 
indicating that apoptosis is responsible for the generation of a larger proportion 
of infarcted tissue in the context of MI than necrosis (Kajstura et al. 1996).  This 
situation was clarified by studies showing that inhibition of caspases, enzymes 
integral to the process of apoptosis, leads to significant decreases in infarct size 
(Mocanu et al. 2000). 
1.2.3.2 Apoptosis 
In the context of I/R injury apoptosis in the heart was first identified in 1994 
(Gottlieb et al. 1994). Unlike necrosis, apoptosis is an energy-dependant, ATP-
requiring process that involves a number of biochemical steps (Leist et al, 1997).  
The process of apoptosis can be triggered by various signals, the origin of which 
can be intra- or extracellular.  Fas ligand and tumour necrosis factor-alpha (TNF-
α), for example, induce  apoptotic  signalling  by binding to their respective 
receptors located on the extracellular membrane (Fas et al. 2006).  By contrast, 
a wide range of intrinsic signals can also promote the apoptotic cascade.  These 
can include heat, radiation, viral infection (Cotran et al, 1998) and high Ca
2+ 
concentration (Mattson & Chan 2003).  Generally, both the intrinsic and extrinsic 
pathways stimulate the activation of a group of proteases known as the 
caspases (Nicholson 1999).  Receptor mediated apoptosis, however, typically Richard A Dixon  General Introduction 
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activates caspase-8, which in turn stimulates caspase-3 (Baines & Molkentin 
2005).  By contrast, the intrinsic pathway, which in the case of I/R injury is 
stimulated by hypoxia, leads to increases  in ROS and  Ca
2+  levels  and, 
ultimately,  mitochondrial permeability transition (Weiss et al. 2003).  Loss of 
mitochondrial membrane integrity leads to the release of a number of 
intermembrane proteins including cytochrome C, Smac/DIABLO and apoptosis 
inducing factor 1 (AIF1)  (Zhou et al. 2005).  Once released  to the cytosol, 
cytochrome C combines  with a protein called  apoptotic  protease-activating 
factor-1 (Apaf-1) (Hill et al. 2004) to form a multi-protein structure known as the 
“apoptosome”.  The apoptosome stimulates activation of caspase-9, which in 
turn activates caspase-3 (Adrain et al. 2006).  Ultimately the activation of these 
caspases leads to the cleavage of several caspase substrate proteins including 
(1) lamins, leading to the degradation of the nuclear lamina (Buendia et al. 
1999), (2) topoisomerases, histones, DNase inhibitors and DNA repair enzymes, 
resulting in the  degradation of cellular DNA (Sordet et al. 2004)  and (3) 
structural proteins such as actin and gelsolin, leading to the breakdown of the 
cytoskeleton (Gourlay & Ayscough 2005).  During apoptosis cells go through a 
series of morphological changes including membrane blebbing, cell shrinkage, 
nuclear fragmentation and DNA fragmentation (Kerr et al. 1972).  Contrasting 
with necrosis which results in the generation of debris through the lysis of cells, 
apoptosis creates small, well-defined  rounded cell bodies that are easily 
digested by phagocytosis, thus reducing  damage to the surrounding tissues 
(Zong & Thompson 2006).  Richard A Dixon  General Introduction 
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1.2.3.3 Other forms of cell death 
It is becoming increasingly clear that the processes of apoptosis and necrosis 
alone are not sufficient to describe the range of cell death mechanisms that 
have been observed.  In addition to apoptosis (type I cell death) and necrosis 
(type II cell death)  a third form of cell death is currently recognised, namely 
autophagic cell death (type II cell death) (Galluzzi et al. 2008). 
1.2.3.3.1 Autophagy 
Autophagy is known to fulfil the “self-killing” role when apoptosis is unavailable 
(Maiuri et al. 2007).  Autophagic cell death is characterised by the accumulation 
of double membrane vesicles, or autophagosomes, within the dying cell.  Protein 
aggregates, expired organelles and cytoplasmic components are sequestered to 
the autophagosomes where they are destroyed by lysosomal enzymes (Clarke 
1990).  
1.2.3.3.2 Necroptosis 
Necroptosis is another form of cell death that was recently proposed to occur in 
the ischaemic brain (Degterev et al. 2005).  Although characterised by the same 
morphological conditions as necrosis, necroptosis is described as a regulated 
form of cell death that occurs in apoptotic-deficient  conditions  (Hitomi et al. 
2008).  It is currently understood that necroptosis is activated by external ligands 
which bind to death receptors.  This in turn activates receptor interacting protein 
1 (RIP1), a kinase which has been demonstrated to be vital to the mechanism 
underlying necroptosis (Degterev et al. 2008).  Necrostatin, an agent that has 
been proposed to inhibit necroptosis (Degterev et al. 2005), has been shown to 
protect against myocardial I/R in both in vitro  and  in vivo  models in our Richard A Dixon  General Introduction 
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laboratory  (Smith et al. 2007a).  Furthermore, this protection has been 
demonstrated to involve modulation of MPTP opening (Lim et al. 2007b).  
1.3  Protection Against I/R Injury 
1.3.1  Ischaemic preconditioning 
In 1986 a revolutionary paper reported that the application of short periods of 
sublethal ischaemia interspersed with reperfusion prior to a period of severe 
ischaemia led to a considerable decrease in infarct size, as compared with 
control (Murry et al. 1986). This phenomenon, first demonstrated in a canine 
model, is now known as ischaemic preconditioning (IPC). IPC has now been 
demonstrated in various species, including mouse (Sumeray & Yellon 1998b), 
rat (Liu & Downey 1992), pig (Schott et al. 1990), sheep and human (Yellon et 
al. 1993).  Initially, the end-point for assessing protection afforded by IPC was 
infarct  size  (Murry et al. 1986).  However, IPC was subsequently  shown  to 
decrease the incidence of arrhythmias (Shiki & Hearse 1987)  and improve 
functional recovery (Asimakis et al. 1992).  
The preconditioned state achieved in the short-term has been demonstrated to 
last between 3-4 hours, after which time protection is lost, and has been termed 
classical preconditioning (Liu et al. 1991).  Classical IPC is rendered ineffective 
if the index ischaemic period continues beyond three hours (Murry et al. 1986).  
In addition to the protection afforded by IPC in the short term, however, there is 
also a delayed protective effect that occurs approximately 24 hours following the 
IPC protocol,  which is known as  the second window of protection (SWOP) Richard A Dixon  General Introduction 
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(Kuzuya et al. 1993; Marber et al. 1993).  The SWOP disappears after 
approximately 72 hours (Zacharowski et al. 1999).           
Considering the extent of the damage caused by myocardial infarction (see 
section  1.1) the potential of IPC as a treatment clinically is attracting 
considerable interest and has generated in excess of 4000 publications 
(www.pubmed.com).  Many  of  these  studies  have focused on possible 
underlying signalling mechanisms, the aim being to discover pharmacological 
treatments that activate these same pathways so that convenient therapeutic 
strategies can be developed.  Despite the large amount of research that has 
been carried out into this phenomenon the mechanisms that underlie IPC are 
still not fully understood.  Some of the proteins involved in transmitting the IPC 
signal, however, have been identified.  These include AKT  (also  known as 
protein kinase B, PKB), phosphatidylinositol-3’-OH kinase (PI3K), and protein 
kinase C (PKC)  (see section 1.3.4.1)  (Hausenloy et al. 2005; Hausenloy & 
Yellon 2007a).  For key reviews of cardioprotective agents see the following 
publications (Hausenloy & Yellon 2009; Hausenloy & Yellon 2004; Schultz & 
Gross 2001).  
1.3.2  Postconditioning 
IPC is clearly a powerful cardioprotective treatment. Unfortunately, it possesses 
one major pitfall with respect to the clinical setting, in as much as MI is difficult to 
predict.  It has been discovered, however, that a similar protocol of episodes of 
sublethal ischaemia and reperfusion but administered subsequent to the index 
ischaemia also produces a cardioprotective effect, a phenomenon which has Richard A Dixon  General Introduction 
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been termed postconditioning (IPost) (Zhao et al. 2003; Vinten-Johansen et al. 
2005).  Using a canine model of I/R injury Vinten-Johansen and colleagues 
demonstrated that following a three hour period of ischaemia, the application of 
three 30 second episodes of reperfusion followed by ischaemia significantly 
protected the myocardium (Zhao et al. 2003).  IPost has been shown to depend 
upon reperfusion injury salvage kinase (RISK) pathway activation (Tsang et al. 
2004).  Indeed, Sivaraman et al demonstrated in a human atrial muscle model of 
I/R that IPost could be abolished by the addition of LY294002 and UO126, 
inhibitors of phosphatidyl inositol 3-OH kinase (PI3K)  and  p44/42mitogen-
activated protein kinase (MAPK),  respectively  (Sivaraman et al. 2007).  
Furthermore, it has been shown that Janus kinases / Signal transducers and 
activators of transcription (JAK/STAT) signalling is also required for functional 
recovery in the  Langendorff-perfused  mouse heart  subjected to  IPOST 
(Goodman et al. 2008).  JAK/STAT signalling alone, however, was not sufficient 
to provide protection, PI3K-Akt activation also being required (Goodman et al. 
2008).  IPost  has already been shown to yield benefit in the clinic and recently, 
in the setting of coronary angioplasty, it was shown to reduce creatine kinase 
release over 72 hours (Staat et al. 2005).    
1.3.3  Pharmacological protection 
Various  chemically unrelated drugs  administered prior to ischaemia and at 
reperfusion have been shown to mimic the protection afforded by IPC and 
IPOST, including with respect to intracellular signalling mechanisms (Riess et al. 
2004; Gross & Gross 2006).  Potential cardioprotective agents, therefore, are Richard A Dixon  General Introduction 
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usually selected according to their ability to activate pro-survival pathways and 
or inhibit pro-apoptotic pathways.  Insulin,  for example, has been shown to 
activate the PI3K/Akt pathway, phosphorylate and inactivate the pro-apoptotic 
factor  Bcl-  XL /Bcl-2-associated death promoter  (BAD), and to stimulate 
endothelial  nitric  oxide synthase (eNOS)  (Jonassen et al.  2001; Gao et al. 
2002).  Agents released by the heart itself have also been found to be 
cardioprotective.  Urocortin, for example, is secreted by myocytes in response to 
ischaemia and has been demonstrated to protect the heart via stimulation of the 
PI3K/Akt and ERK 1/2 signalling pathways (Brar et al. 2000; Schulman et al. 
2002). As outlined above, stimulation of the JAK/STAT pathway has also been 
shown to be cardioprotective and cardiotrophin, which activates various 
protective signalling pathways, was also shown to increase JAK/STAT activity 
(Freed et al. 2003).  In the next section these signalling  pathways will be 
examined in more detail.   Richard A Dixon  General Introduction 
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1.3.4  Cellular signalling mechanisms: their roles in the heart and 
cardioprotection 
 
Many  signalling  pathways  have been identified in cardiomyocytes.  These 
pathways, activated in response to a number of different stimuli, ultimately lead 
to changes in growth and function.  Numerous  signalling pathways  in 
cardiomyocytes  are activated in response  to stress (see Figure  1.3.1).  This 
thesis will focus on the PI3K-Akt (RISK), MAPK and JAK/STAT pathways. 
 
Figure  1.3.1  –  Cardiomyocyte signalling pathways.  The figure shows a simplified scheme of the 
signalling pathways that occur in cardiomyocytes.  For simplicity, feedback loops and most of the 
crosstalk between individual pathways and have been omitted.  Binding of a ligand to its membrane 
receptor leads to activation of an associated kinase, which in turn may activate signalling nodes.  At this 
point pathways may converge.  In this diagram the examples of signalling nodes are Akt and glycogen 
synthase β (GSK3β).  Ultimately, the activated downstream components modulate cell growth or function.   
Anchor protein 1 (PKA); cyclic AMP (cAMP); forkhead-box O proteins (FOXO); Janus Kinase (JAK); 
mitogen-activated protein kinase (MAPK); phosphatidylinositol 3-OH-kinase (PI3K); cAMP-dependent 
protein  kinase  (PKA);  protein  kinase  C  (PKC);  phospholipases  C  (PLC);  phosphatase  and  tensin 
homologue (PTEN); Rho-associated (ROCK); signal transducer and activator of transcription (STAT).  
Figure  adapted from (Mudd & Kass 2008). Richard A Dixon  General Introduction 
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1.3.4.1 Reperfusion injury salvage kinase pathway 
The RISK pathway is a term that has been applied to a group of protein kinases 
that, when activated at reperfusion, are associated with protection against 
myocardial I/R injury (Schulman et al. 2002; Hausenloy & Yellon 2007b).  These 
pro-survival kinases include protein kinase B (PKB/Akt) and p44/42 MAPK (see 
sections  1.3.4.1.1  and  1.1.1.1.1  respectively).  Originally these kinases were 
found to be activated by ischaemia/reperfusion injury (Mockridge et al. 2000b; 
Omura et al. 1999).  It has, however, become apparent that additional activation, 
such  as that provided by a  pharmacological or mechanical stimulus, confers 
cardioprotection.  In vitro and in vivo animal studies have demonstrated that the 
RISK pathway can be stimulated by a myriad of agents including cytokines such 
as apelin (Simpkin et al. 2007), transforming growth factor beta-1TGFβ-1 (Baxter 
et al. 2001), erythropoietin (Bullard et al. 2005), leptin (Smith et al. 2006) and 
visfatin  (Lim et al. 2008),  and  G-protein coupled receptor (GPCR) ligands, 
including  bradykinin  (Bell & Yellon 2003),  glucagon-like peptide 1  (GLP-1) 
(Bose et al. 2005b; Bose et al. 2005a) and urocortin (Brar et al. 2002; Brar et al. 
2000; Schulman et al. 2002). Mechanical treatments that induce activation of 
RISK pathway kinases include IPC  (Hausenloy et al. 2005),  postconditioning 
(Sivaraman et al. 2007) and low pressure reperfusion (Bopassa et al. 2005).        
In order to confer cardioprotection, activation of the RISK pathway must occur 
within the first few minutes of reperfusion (Jonassen et al. 2001).  During these 
first few minutes  intracellular  accumulation of ROS and Ca
2+  leads  to  MPTP 
opening (see section 1.1.1), followed by mitochondrial uncoupling and swelling Richard A Dixon  General Introduction 
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and consequent cell death (section 1.2).  Inhibition of MPTP opening must occur 
within several minutes of reperfusion, in order for protection to be achieved 
(Hausenloy et al. 2003).  Hence, there exists a critical “window” in which pro-
survival kinase activation must occur in order to achieve cardioprotection.  
Figure 1.3.2 – Reperfusion injury salvage kinase (RISK) pathway components.   Growth factors are 
known to stimulate PI3K and ERK 1/2, the components of the RISK pathway, which ultimately stimulate 
cellular survival by inhibiting caspases and pro-apoptotic factors such as BAD and BAX.  Figure adapted 
from (Hausenloy & Yellon 2004). 
 
1.3.4.1.1 PI3K-AKT pathway 
The PI3K-AKT pathway was one of the first signalling transduction pathways to 
be associated with cardioprotection and is one of the key components of the 
RISK pathway (section 1.3.4.1).  The  PI3K’s are a family of conserved lipid 
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kinases that transduce  extracellular signals directly to  a broad array of 
intracellular functions.  A  key target for  PI3K-induced phosphorylation is the 
serine/threonine kinase Akt, of which there are three isoforms  (Datta et al. 
1999).  The expression of Akt1 and Akt2 occurs in almost all tissues, whilst Akt3 
expression occurs primarily in the brain and the testis (Konishi et al. 1995). The 
isoforms of Akt share 80% homology with respect to their amino acid sequence 
and have similar domain structures (Garofalo et al. 2003).  In the central portion 
of the protein there is a kinase domain with specificity for serine or threonine 
residues in target proteins  (Bellacosa et al. 1991).  The carboxyl terminus 
comprises proline-rich and hydrophobic domains  and  the amino terminus 
contains a pleckstrin-homology (PH) domain, which can facilitate lipid/protein 
and protein/protein interactions (Kumar & Madison 2005).  The Akt isoforms can 
phosphorylate and activate a large range of downstream proteins, of which, to 
date, 40 have been identified (Franke 2008).  Therefore, it is not surprising to 
learn that Akt plays many different roles.  Studies using transgenic and knock-
out Akt mouse models have allowed the elucidation of some of the functions of 
Akt.  These include the modulation of cell growth and proliferation (Skeen et al. 
2006), glucose homeostasis,  postnatal brain development, heart growth, skin 
growth, adipogenesis, bone development  and lipid metabolism in the mammary 
gland (Peng et al. 2003; Yang et al. 2004b).   
The PI3K-Akt pathway is activated by numerous  ligands including cytokines, 
growth factors, hormones and neurotransmitters (Downward 2004). A significant 
number of plasma membrane receptors, tyrosine kinase receptors in particular, Richard A Dixon  General Introduction 
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have the ability to  activate PI3K’s  (Paez & Sellers 2003).  Ligand-mediated 
receptor activation leads to autophosphorylation of the receptor on tyrosine 
residues,  and subsequent recruitment and activation of PI3K.  Active  PI3K 
catalyses the reaction converting membrane lipid phosphatidylinositol 3,4-
biphosphate [PI(3,4)P2] to phosphatidylinositol 3,4,5-triphosphate [PI(3,4,5)P3].  
Akt is then recruited, via its PH domain, to the membrane where it binds to 
PI(3,4,5)P3    and  is then  phosphorylated and activated by phosphoinositide 
dependent kinase (PDK) 1 and 2 (Stephens et al. 1998).  PI3K facilitated Akt 
activation can be controlled via the tumour suppressor protein phosphatase and 
tensin homolog (PTEN), which is a phosphatase (Leslie et al. 2008).  PTEN 
suppresses the Akt signal by catalysing the opposite reaction to that catalysed 
by PI3K, i.e. it de-phosphorylates PI(3,4,5)P3  to  PI(3,4)P2, hence preventing 
the formation of the Akt binding site and reducing Akt activation and downstream 
signalling (Leslie et al. 2008).   
Akt acts on a number of downstream targets, some of which function to inhibit 
apoptosis (Datta et al. 1999).  Thus, the cell survival promoting actions of Akt 
include inhibition of caspase 9 (conducted in  human embryonic kidney cells, 
293T HEK) (Cardone et al. 1998), inhibition of pro-apoptotic factors, such as 
Bcl-XL/Bcl-2-associated death promoter (BAD) and Bcl-2-associated X protein 
(BAX) (conducted in FL5.12 cells, a murine prolymphocytic cell line) (Yamaguchi 
& Wang 2001), and  altering gene transcription factors associated with survival 
and cell death  (conducted in 293T HEK cells)(Matsui & Rosenzweig 2005; 
Brunet et al. 1999).  It should be noted, however, that these studies have been Richard A Dixon  General Introduction 
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conducted in a range of cells and the results may not reflect how Akt functions in 
cardiomyocytes.  
 
Figure 1.3.3 – PI3K-Akt pathway. Once activated PI3K phosphorylates PIP2 to PIP3.  PTEN regulates 
Akt activity by catalysing the reverse reaction to that catalysed by PI3K, i.e. it de-phosphorylates PIP3 to 
PIP2.  Once formed PIP3 binds Akt where it is phosphorylated and activated by PDK1.  Once active, Akt 
inhibits various pro-apoptotic proteins; such as glycogen synthase kinase-3β (GSK-3 β), tumour protein 53 
(p53) and Ras-related C3 botulinum toxin substrate 1 (Rac1) and stimulates anti-apoptotic proteins; such 
as eNOS and murine double minute 2 (Mdm2).  Adapted from:(Vivanco & Sawyers 2002). 
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1.3.4.1.2 ERK 1/2 – p44/42 pathway 
The  p44/42  extracellular signal-regulated kinases (ERK) are members  of the 
mitogen activated protein kinase (MAPK) family (Schaeffer & Weber 1999).  The 
MAP kinases are  serine/threonine kinases that are greatly conserved in 
eukaryotic cells (Widmann et al. 1999).  At least three MAP kinases have been 
implicated in the MAPK signalling  cascade  (Schaeffer & Weber 1999).  
Signalling is initiated by a range of ligands and external stimuli which activate 
tyrosine kinase (TK) or G-protein receptors (Cross et al. 2000).  Stimulation of 
these receptors leads to activation of MAPK Raf1, which in turn phosphorylates 
and activates the MEK1/2-Erk1/2 kinase cascade (Kyriakis et al. 1992).  With 
regard to myocardial infarction it is interesting to note that stimulation of the ERK 
signalling pathway is associated with cardioprotection (Schulman et al. 2002).  
Furthermore, it has been demonstrated that ERK-mediated cardioprotection can 
be blocked with the MEK inhibitor, UO126 (Davies et al. 2000).  Like Akt, ERK 
activation has also been shown to be linked to inhibition of caspase 9, a key 
modulator of apoptosis (Allan et al. 2003), pharmacological inhibition of caspase 
9 being associated with infarct size reduction (Mocanu et al. 2000).  Apart from 
its influence on caspase activity, ERK activation also activates P90RSK, which 
in turn phosphorylates and inhibits the pro-apoptotic factor BAD (Tan et al. 
1999).  Furthermore, active ERK  translocates to the nucleus and stimulates 
gene transcription via activation of transcription factors such as c-Myc and E-26-
like protein-1 (Elk-1) (Davis 1995).   
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1.3.4.1.3 Downstream mechanisms of the RISK pathway 
Additional  downstream mechanisms possibly contributing to cytoprotection 
include regulation of sarcoplasmic reticulum Ca
2+ uptake and release (Abdallah 
et al. 2006), activation of NOS (Baxter & Burley 2008), inhibition of glycogen 
synthase kinase-3β  (GSK-3β)  (Murphy 2004)  and inhibition of the MPTP 
(Hausenloy et al. 2002).  How and if these various processes interact is currently 
unknown, however, evidence  has been obtained  indicating  that these 
mechanisms converge  on the mitochondrion  and  inhibit  the opening of the 
MPTP (Halestrap & Pasdois 2009).  Although it took some time for the role of 
the MPTP in cardioprotection to be accepted, the pore is now recognised as an 
important facilitator of cardiomyocyte death in the setting of I/R injury (Halestrap 
& Pasdois 2009).  However, despite many studies on the pore, the intermediate 
steps between stimulation of RISK signalling and inhibition of the pore have yet 
to be revealed (Davidson et al. 2006).  Nevertheless, several theories have been 
proposed.  For example, it has been suggested that eNOS may inhibit MPT  via 
the generation of NO (Kim et al. 2004a) or via a PKG-PKC-ε-mKATP channel 
signalling pathway (Costa & Garlid 2008; Costa et al. 2005). It has also been 
proposed that GSK-3β may inhibit the pore directly or induce activation of other 
factors that inhibit the pore (Miura et al. 2009).  In addition, inhibition of BAX 
translocation to the nucleus has been put forward as a mechanism that may 
prevent MPTP opening (Bagci et al. 2006).  
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1.3.4.2 JAK-STAT pathway 
1.3.4.2.1  JAK-STAT signalling mechanism 
The  JAK-STAT pathway is currently one of the most comprehensively 
understood  cell  signalling  mechanisms.  The current model of JAK-STAT 
signalling  holds that  the  interaction of a cytokine ligand with its cytokine 
transmembrane receptor leads to receptor dimerisation which juxtaposes and 
activates JAK proteins associated with the intracellular domain of the receptor 
(Schindler et al. 2007).  These JAK binding sites on the cytokine receptor are 
positioned in close proximity to the extracellular membrane (Behrmann et al. 
2004).  The association between JAK proteins and cytokine receptors was first 
documented with respect to interactions between JAK2 and erythropoietin and 
growth hormone receptors (Witthuhn et al. 1993; Argetsinger et al. 1993).  Once 
activated  JAK  proteins  phosphorylate sites on the cytosolic domain of the 
receptor, creating binding sites for the Src homology 2 (SH2) domains of STAT 
proteins.  Following their recruitment STAT proteins are phosphorylated at key 
tyrosine and/or serine residues by JAK proteins and other associated kinases 
(Schindler et al. 2007).  Phosphorylation leads to STAT dimerisation, via SH2 
phosphotyrosine interactions,  (Figure  1.3.4)  dissociation  and  subsequent 
translocation to the nucleus, a process which is yet to be fully understood 
(Murray 2007; Schindler & Darnell, Jr. 1995).  It has yet to be established if 
STAT proteins dimerise whilst bound to the receptor or upon their release (Lim & 
Cao 2006).  In the nucleus STATs bind to specific sequences in the genome and 
regulate gene expression (Murray 2007).  STAT monomers are unable to bind to Richard A Dixon  General Introduction 
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DNA, only STAT homodimers or certain  heterodimers  being capable of 
participation in such a reaction (Schindler & Darnell, Jr. 1995). 
Figure 1.3.4 – Structure of STATs.  Following activation by binding of ligands to specific receptors, 
STATs form dimers by binding to each other via their SH2 domains.  Once formed, the dimer migrates to 
the cell nucleus where it acts as a transcription factor.  Adapted from (Imada & Leonard, 1999)  
1.3.4.2.2 Negative regulation of JAK-STAT signalling 
To prevent cytokine signals from reaching excessive levels  the JAK-STAT 
signalling mechanism is negatively regulated by a number of proteins, including 
protein tyrosine phosphatases such as protein inhibitor of activated STAT 
(PIAS), Src homology 1–containing tyrosine phosphatase (SHP1) and 
suppressor of cytokine signalling (SOCS) (Heinrich et al. 2003).  Stimulation of 
these proteins leads to ubiquitin/proteasome mediated degradation, dissociation 
of receptor associated JAKs  and exportation of STATs from the nucleus.   
Furthermore, phosphorylation of JAK2 at its FERM (band 4.1, ezrin, radixin and 
moesin) domain, in response to cytokine stimulation, results in its inactivation 
(Funakoshi-Tago et al. 2006).  However, perhaps the most interesting 
mechanism  in relation to the regulation of JAK-STAT  signalling  involves  the 
inhibition of JAK-STAT by SOCS  proteins,  although it has yet to be fully 
elucidated (Croker et al. 2008).    Richard A Dixon  General Introduction 
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The majority of SOCS proteins are activated in response to cytokine signalling 
and therefore act in a negative feedback loop, dampening cytokine signal 
transduction.  Once active SOCS proteins, specifically SOCS 1 and 3, act to 
inhibit JAK-STAT  signalling  by either binding to and  inactivating JAK, or by 
competing with STAT for receptor docking sites (Cooney 2002)    
1.3.4.2.3 JAK-STAT and the heart 
The greater part of the literature concerning JAK/STAT signalling in the heart is 
concerned with the activation of STAT1 and STAT3.  Although the role of the 
JAK/STAT pathway in myocardial injury has yet to be fully elucidated, there are 
significant  data  indicating  that STAT1 is pro-apoptotic, whilst activation of 
STAT3 is anti-apoptotic (Stephanou 2004).  STAT1 activation is associated with 
increased  expression of the apoptotic target genes  cyclin-dependent kinase 
inhibitor 1A (p21), p53 and FAS ligand, and upregulation of caspases 1, 2, 3 and 
7 (Chin et al. 1997; Stephanou et al. 2001; Townsend et al. 2004; Sironi & Ouchi 
2004).  By contrast, a growing amount of data suggests that activation of STAT3 
is cardioprotective.  STAT3 activation, for example, confers protection against 
doxorubicin-induced cardiomyopathy  (Kunisada et al. 2000).  Furthermore, I/R 
injury has been shown to be enhanced in STAT3 cardiac-deficient mice 
compared to control animals, cardiac  function  also being impaired  (Hilfiker-
Kleiner et al. 2004).  
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1.4  Cardiometabolic Disease 
1.4.1  21
st Century obesity epidemic 
Obesity is now a global problem affecting developing countries as well as those 
in the western world  (Hossain et al. 2007).  According to the world health 
organisation  (WHO)  obesity is defined as having  body mass index (BMI) of 
greater than 30, where BMI is an index of weight and height (equation 1)(table 
Table 1.4.1)(World Health Organization, 2009).  Obesity is usually the result of a 
sedentary lifestyle combined with a poor diet.  These individuals experience a 
large increase in adiposity, particularly visceral adipose tissue, which places 
them at  an  increased risk of developing Type-2 diabetes  and cardiovascular 
disease (Despres et al. 2008; Kriketos et al. 2004).  It is currently estimated that 
there will be 300 million cases of obesity-related type-2 diabetes in the world by 
the year 2025 (Grant 2005). Since cardiovascular pathologies account for 80% 
of deaths of patients with type-2 diabetes,  this problem is set to increase unless 
steps are taken to prevent the occurrence of these disorders (Aronson et al. 
1997).  
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BMI 
 
Classification 
<18.5 
  underweight 
18.5-24.9 
  normal weight 
25.0-29.9 
  overweight 
>30 
  obesity 
 
Table 1.4.1 – The international classification of adult underweight, normal weight, overweight and 
obese according to BMI.  Source: Adapted from (World Health Organisation, 2009). 
 
 
BMI = WEIGHT (KILOGRAMS) / HEIGHT (METRES
2) 
Equation 1 – Equation for calculation of body mass index 
 
 
1.4.2  The metabolic syndrome (syndrome X) 
The metabolic syndrome (metS), also known as Reaven’s syndrome or 
syndrome X, is characterised by the co-occurrence of abdominal fat, dysfunction 
of glucose tolerance, dyslipidaemia and hypertension (Alessi & Juhan-Vague 
2008). MetS leads to alterations in metabolic homeostasis, which collectively 
lead  to  an  increased risk of developing type-2  diabetes and cardiovascular 
disease.  In the developed world the incidence of metS is growing rapidly.  It is 
currently estimated that 25% of the population of the USA have metS (Ford et al. 
2002). The mechanisms underlying this phenomenon are under close scrutiny 
and further studies are urgently required if we are to solve this growing problem.  
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namely interleukin-1, interleukin-6, TNF-α, leptin and adiponectin, and the MetS 
(Bullo et al. 2003).  These  substances are collectively known as the 
adipocytokines or adipokines (Matarese et al. 2007b; Tilg & Moschen 2006).  
1.5  The Adipose Tissue and Adipocytokines 
1.5.1  The adipose tissue 
Until recently adipose tissue was thought to be an inert storage depot.  Now, 
however, it is known that adipose tissue, especially white adipose tissue (WAT) 
constitutes  an active endocrine organ  that responds to a variety of signals, 
produces  a plethora of active peptides and plays  an active role in energy 
homeostasis (Ahima 2006).  The largest deposits of WAT are concentrated in 
the subcutaneous region and around  the viscera  (Fruhbeck 2008).  Gross 
increases in abdominal WAT, as observed in obese individuals, are associated 
with biochemical and histological alterations that  often  lead to inflammation, 
hypercoagulation, cardiovascular risk and the metabolic syndrome (Matsuzawa 
et al. 1995; Matsuzawa 2005).  Macroscopically, adipocytes are highly 
vascularised lipid-filled cells held in a scaffold of loose connective tissue in a 
supporting matrix of collagen (Fruhbeck 2008).  Proteins secreted by WAT show 
a great deal of pleiotropy and have roles in energy homeostasis, the regulation 
of neuroendocrine function and in autonomic and immune function  (Ahima 
2006). 
1.5.2  The adipocytokines 
The term adipocytokine has been used to describe a group of cytokines 
produced by white  adipose tissue  and includes peptides such as leptin, Richard A Dixon  General Introduction 
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adiponectin, apelin and visfatin (Trayhurn & Wood 2005).  Although WAT is the 
main source of adipocytokines, it must be noted, however, that adipocytokines 
are also produced  by other tissues  (Tilg & Moschen 2006).  For example, 
adiponectin is also produced by skeletal cells, cardiomyocytes and endothelial 
cells (Pineiro et al. 2005; Delaigle et al. 2004; Wolf et al. 2006).  Adipocytokines 
expressed by adipocytes    are  secreted directly into the circulation where, at 
least in the case of leptin and adiponectin, they have roles in modulating energy 
homeostasis (Havel 2002).      
1.5.2.1 Adiponectin 
Adiponectin, discovered in 1995, has become the subject of intense research 
due to the discovery that hypoadiponectinaemia is associated with visceral 
obesity and coronary artery disease (Kumada et al. 2003).  Furthermore, low 
serum levels of adiponectin have been related to insulin resistance (non-
alcoholic fatty liver disease), atherosclerosis and type-2 diabetes (Arita et al. 
1999b).      
Globular adiponectin is abundantly present in the blood plasma  of healthy 
patients, where it exists as either low molecular weight trimers and hexamers 
(dimer of trimers) or as high molecular weight 12- or 18- mers, accounting for 
approximately 0.01% of plasma proteins  (Arita et al. 1999b).  Adiponectin 
signals through two cell surface transmembrane receptors, adiponectin receptor 
1 (AdipoR1) and 2 (AdipoR2) (Yamauchi et al. 2003). The different oligomers of 
adiponectin trigger slightly different signalling  pathways  (Tsao et al. 2003).  
Adiponectin is known to stimulate  5’ AMP-activated protein kinase (AMPK), Richard A Dixon  General Introduction 
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cyclooxygenase-2  COX-2, p38 MAPK, and peroxisome proliferator-activated 
receptor-alpha (PPAR-α) and also stimulates fatty acid oxidation (Yamauchi et 
al. 2003).  Adiponectin has been shown to suppress PTEN signalling, thereby 
potentiating PI3K-AKT signalling (Chandrasekar et al. 2008).      
In 2005 Walsh’s group demonstrated that the  administration of adiponectin 
protected against myocardial  IR injury in a murine in vivo model via COX-2 and 
AMPK-dependent mechanisms  (Shibata et al. 2005).  This has important 
implications for myocardial infarction given that decreased adiponectin levels are 
associated with cardiovascular risk factors  including  obesity, hypertension, 
raised C-reactive protein (CRP) levels and hyperlipidaemia (Ouchi et al. 2003; 
Arita et al. 1999a; Kadowaki & Yamauchi 2005).   
1.5.2.2 Visfatin 
Visfatin acts to accelerate the conversion of triglycerides to glucose, inhibit 
glucose release and enhance glucose uptake (Adeghate 2008).  Visfatin was 
previously identified as pre-B  cell colony-enhancing factor (PBEF), and its 
expression is increased in obesity (Fukuhara et al. 2005).  During hypoxia 
visfatin expression and secretion is increased in adipocytes through a HIF1-α 
dependent mechanism (Segawa et al. 2006).  Visfatin binds to the insulin 
receptor at an alternative site to insulin itself and facilitates the activation of the 
PI3K-Akt and MAPK pathways (Murphy & Bloom 2006).  Current literature 
suggests that visfatin may act as an anti-diabetic drug (Hausenloy 2009).  In 
addition, studies conducted in our laboratory using an in vivo mouse model have 
demonstrated that visfatin is protective against myocardial I/R injury (Lim et al. Richard A Dixon  General Introduction 
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2008).  Further investigation is therefore required to establish whether visfatin 
may be used therapeutically in the clinic.    
1.5.2.3 Apelin 
Apelin, first isolated in 1998 by Tatemoto et al, is the ligand for the apelin 
receptor (APJ) (Tatemoto et al. 1998).  Apelin and its receptor are similar to the 
other adipocytokines, such as adiponectin and leptin, in that the peptide and its 
receptor are not only expressed by adipose tissue (O'Carroll et al. 2000).  Apelin 
and APJ, for example, have been found to be expressed in a variety of rodent 
tissues, including brain, skeletal muscle and the vasculature  (Hosoya et al. 
2000).  Apelin, like leptin, is thought to play a role in energy homeostasis.  This 
hypothesis is borne out by data indicating that apelin secretion is increased by 
insulin administration in human and mouse adipocytes, and by obesity in the 
mouse  (Boucher et al. 2005).  Furthermore, it has been demonstrated that 
apelin expression  is  abrogated by fasting (Boucher et al. 2005).  Further 
investigation, however, is required to elucidate the exact role apelin plays in the 
adipose tissue.   
Apelin and the APJ have  been  found to be expressed in cardiomyocytes 
(O'Carroll et al. 2000).  It has been demonstrated that apelin produces various 
effects in the heart and vasculature, including regulation of contractility (Szokodi 
et al. 2002), hypotensive actions (Tatemoto et al. 2001) and ionotropic actions 
(Berry et al. 2004).  Upon completion of gene transcription, the 77 amino acid 
pre-propeptide of apelin undergoes post-translational modification to yield the 
following several shorter active polypeptides apelin-36, apelin-17 and apelin 13 Richard A Dixon  General Introduction 
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(Tatemoto et al. 1998).  Apelin-36 and apelin-13 have both been tested for their 
potential as cardioprotectants in the isolated perfused heart and in an in vivo 
mouse model of myocardial I/R (Simpkin et al. 2007).  Both forms were found to 
be cardioprotective, however, apelin-13, the most physiologically active apelin 
polypeptide was found to elicit the more potent cardioprotective action (Simpkin 
et al. 2007).   
The levels of apelin and its receptor have  been  reported  to be reduced in 
patients with chronic heart failure, although in its early stages apelin levels were 
found to be increased (Foldes et al. 2003). These data combined with apelin’s 
observed regulatory effects on cardiac homeostasis has led to the adipocytokine 
being investigated as a potential treatment for  chronic heart failure  (Japp & 
Newby 2008). 
1.5.2.4 Resistin 
Resistin is a 12.5 KDa cysteine-based proinflammatory cytokine that is thought 
to have roles in insulin resistance, adipogenesis and atherosclerosis (Steppan et 
al. 2001; Kim et al. 2004b). Resistin levels are diminished upon fasting and 
recover with feeding, suggesting a role in energy homeostasis.  Whilst resistin 
receptors have been found to be located on cardiomyocytes the roles it plays in 
the heart are not clear (Gao et al. 2007).  With regard to myocardial infarction 
current data are paradoxical. For instance, resistin has been shown to both 
exacerbate and protect against cardiac reperfusion injury (Rothwell et al. 2006; 
Gao et al. 2007).     Richard A Dixon  General Introduction 
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1.6  Leptin 
1.6.1  Background 
First discovered in 1994 by positional cloning, leptin is the 16 KDa product of the 
Obese (ob) gene (Zhang et al. 1994).  Leptin was initially proposed as a “cure” 
for obesity, disappointingly, however, this turned out not to be the case (Bell-
Anderson & Bryson 2004).  Despite this early disappointment leptin has yielded 
valuable  insights  into the mechanisms  modulating  energy homeostasis and 
satiety, and is the focus of this thesis.  
Leptin is primarily produced by white adipose tissue,  nevertheless,  it is also 
secreted by a range of other tissues including the heart (Purdham et al. 2004).  
Adipocytes secrete leptin in a slow, continuous fashion, however, if stimulated 
(by insulin and glycolytic substrates,  for example) secretion is markedly 
increased (Cammisotto et al. 2005).  Leptin secretion is reduced as a response 
to starvation or cold with starvation leading to increased sympathetic nervous 
activity, and, as a consequence leptin production is reduced (Rayner & Trayhurn 
2001). Generally, the circulating levels of leptin correlate well with body adipose 
tissue mass (Schwartz et al, 1996).   
1.6.2  Function 
Under normal conditions the main function of leptin is to signal low fat mass 
stores by acting at several sites in the brain (Blevins et al. 2002).  However, the 
predominant site of action is the so-called hypothalamic pituitary axis (HPA) 
(Pralong & Gaillard 2001).  Leptin signalling  at the HPA alters the levels of 
various neuropeptides and neurotransmitters, many of which interact to control Richard A Dixon  General Introduction 
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over-feeding behaviour and energy expenditure.  The arcuate nucleus of the 
hypothalamus is the key region involved in these mechanisms, and is a major 
area of the brain where the expression of neuropeptide Y (NPY) and Agouti-
related peptide (AgRP) occurs (Figure 1.6.1). NPY and AgRP increase appetite 
and decrease energy expenditure, and  leptin  functions to counteract their 
actions (Claycombe et al. 2000; Wang et al. 1997; Parker et al. 2002).  Leptin 
also inhibits orexin  and  galanin  production  and  the synthesis of various 
cannabinoids, peptides which all stimulate appetite  (Wilding 2002).  The 
mechanisms underlying the control of energy homeostasis are complex and 
have yet to be fully elucidated.   Richard A Dixon  General Introduction 
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Figure 1.6.1 – Leptin and energy homeostasis.  This schematic represents homeostatic leptin signalling 
in the hypothalamus under normal conditions.  The direct action of leptin in the arcuate nucleus leads to 
the  suppression of neuropeptide Y (NPY) and agouti-related peptide (AgRP)  and stimulation of α  -
melanin-stimulating hormone (α-MSH) and cocaine and amphetamine-regulated transcript (CART), both 
of which ultimately lead to a reduction in food intake and an increase in thermogenesis.  NPY normally 
stimulates feeding by binding to Y1 (Y1-R) and Y5 (Y5-R) receptors.  AgRP blocks the anorectic effect of 
α-MSH by binding to melanocortin subtype-4 receptors (MC4-R).  Source: Adapted from (Ahima 2005).          
 
Leptin functions within a feedback mechanism.  Increases  in  plasma leptin 
concentrations  lead  to  the suppression of appetite and increased energy 
expenditure, whilst decreased leptin has the opposite effects (Bates & Myers, Jr. 
2003)  Plasma leptin levels  are influenced by various factors, for example 
increased BMI, food intake and glucose uptake all lead to increased leptin in the 
blood  (Grinspoon et al. 1996; Grinspoon et al. 1997)  .  On the other hand, 
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increases  in age and/or exercise leads to decreased  plasma leptin 
concentrations (Zheng et al. 1996).  Plasma leptin concentrations have been 
reported to correlate with BMI (Schwartz et al, 1996). 
The importance of leptin, with regard to energy balance and metabolic status, is 
clearly demonstrated in the presence of interrupted leptin signalling.  Thus, in 
rodent models of type 2 diabetes  abrogation of leptin signalling,  through 
mutation of the long form of the leptin receptor, leads to an obese phenotype 
characterised by hyperphagia, decreased energy expenditure and increased 
adiposity (Chua, Jr. et al. 1996; Chen & Wang 2005).  
Leptin  via a negative feedback mechanism  functions in healthy people to 
regulate body fat stores (Enriori et al. 2006).  In obese individuals, however, 
increased plasma leptin levels resulting from large adipose tissue deposits leads 
to hypothalamic leptin resistance (see section 1.6.6) (Enriori et al. 2006). 
Whilst the hypothalamic ARC has been shown to be an important site of the 
action of leptin, it should be noted that leptin has also been found to act at other 
sites in the hypothalamus and other locations in the brain.  In the rat brain the 
long form of the leptin receptor (OB-Rb) has been found to be located within 
particular nuclei of the hypothalamus  other than the arcuate, including the 
dorsomedial, ventromedial, and ventral premamillary nuclei  (Elmquist et al. 
1998).  Hence, indicating that homeostatic leptin signalling may occur at these 
particular locations.  Indeed,  a  group of neurons (SF-1 containing neurons) 
found in the ventromedial nucleus (VMN), for example, have been shown to be Richard A Dixon  General Introduction 
 
 
The Hatter Cardiovascular Institute  67 
   
involved in leptin-induced satiety (Dhillon et al. 2006).  A recent study 
demonstrated that mice with a specific deletion of leptin receptors from SF-1 
containing neurons in the VMN resulted in increased appetite, increased body 
weight and development of the metabolic syndrome (Bingham et al. 2008).  
In addition, data have been collected that indicate that leptin can suppress 
appetite by signalling within areas of the caudal brainstem (Grill et al. 2002). 
Other than the hypothalamus  in the rat brain, OB-Rb receptors have been 
shown to be present in the hindbrain and the hippocampus  (Elmquist et al. 
1998).  Furthermore, mesolimbic areas of the brain known to be involved in 
reward circuits, namely the substantia nigra and the ventral tegmental  area 
(VTA) have been demonstrated  to display OB-Rb receptors. Direct 
administration of leptin into the VTA has been shown to suppress food intake 
and reduce body weight (Hommel et al. 2006).  
In addition, a recent study by Farooqi et al indicates that leptin may act on 
mesolimbic areas in the brain to reduce the sensation of food reward (Farooqi et 
al. 2007).  In this study, Farooqi and colleagues used two patients with a 
congenital leptin deficiency and examined the effect that leptin repletion had on 
(1) food intake and (2) the activation of mesolimbic areas of the brain using 
functional magnetic resonance imaging (fMRI) in response to visual stimuli of 
food.  Congenital leptin deficiency in humans is a rare condition that results in 
hyperphagia, early onset diabetes and metabolic, neuroendocrine and immune 
dysfunction  (Gibson et al. 2004).  Results demonstrated that indeed leptin 
repletion caused a marked reduction in food intake. Interestingly, fMRI studies Richard A Dixon  General Introduction 
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revealed that the activation of mesolimbic areas of the brain in response to 
visual food stimuli could be observed in the fasted and fed states in the 
individuals with leptin deficiency.  However, in the leptin-replaced individuals 
activation of these areas could only be stimulated in the fasted state.  These 
results indicate the leptin may regulate food intake, at least partially, by altering 
the perception of food reward.     
A secondary major function of leptin has been shown to occur in the process of 
reproduction (Holness et al. 1999; Forhead & Fowden 2009).  It has been well 
established that leptin and OB-R (leptin receptors) are ubiquitous in the foetus 
and placental tissues.  The role leptin plays appears to go beyond signalling that 
the body has sufficient energy stores for reproduction to proceed, but also has 
an effect on foetal growth.  For example, it has been found that leptin 
concentration, prior to birth, correlate well with several measures of foetal 
growth (Hassink et al. 1997; Varvarigou et al. 1999).   
1.6.3  Functional pleiotropy 
Apart from its  role in energy homeostasis, leptin has been demonstrated to 
possess  a  great  deal  of functional pleiotropy  (Fruhbeck et al. 1998).  For 
example, leptin plays roles in angiogenesis (Sierra-Honigmann et al. 1998), 
bone formation (Ducy et al. 2000; Takeda et al. 2002), blood pressure control 
(Fruhbeck 1999) and haematopoiesis (Cioffi et al. 1996; Holness et al. 1999). 
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1.6.4  The leptin receptor 
The leptin receptor is a member of the class I cytokine family of cytokine 
receptors  (Tartaglia et al. 1995).  This group of receptors include various 
members of the interleukin receptor family, the granulocyte colony-stimulating 
factor (GCS-F) receptor and the erythropoietin receptor (Liongue & Ward 2007). 
They all share a similar three-dimensional folded structure and activate similar 
signalling pathways (Huising et al. 2006).  The leptin receptor (OB-R) occurs in a 
variety of isoforms; OB-Ra, OB-Rb, OB-Rc, OB-Rd, OB-Re and OB-Rf (Lee et 
al. 1996).  These isoforms all share a highly conserved extracellular receptor 
binding domain (Baumann et al. 1996).  All of the variants, except the secreted 
OB-Re isoform, have a conserved transmembrane domain (Yang et al. 2004a).  
By contrast, the intracellular portion of the different receptor isoforms varies 
(Fruhbeck 2006).  The OB-Rb receptor, which has the longest intracellular tail, is 
thought to be the fully functional  and physiologically dominant  receptor 
(Fruhbeck 2006).  This hypothesis is supported by the observation  that 
inactivation of the OB-Rb  receptor by point mutation leads to an obese 
phenotype in rodents (Chen et al. 1996).  This can be seen in models of type-2 
diabetes such as the Zucker (fa/fa) fatty rat and the db/db mouse (Chen & Wang 
2005). 
1.6.5  Signalling pathways stimulated by leptin 
To mediate its many physiological roles, leptin functions by stimulating several 
different signal  transduction pathways.  Like other cytokine receptors  leptin 
receptors have a proline rich box-1 motif (Ihle 1995).  Janus kinase (JAK) 
binding is vital to leptin signalling, due to the lack of an intrinsic kinase domain Richard A Dixon  General Introduction 
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within the OB-R itself. Binding of JAKs to the box-1 motif allows 
transphosphorylation between the JAKs and leads to phosphorylation of specific 
tyrosine residues within the receptor.  These phosphorylated tyrosine residues 
provide docking sites for the mediation of downstream signalling  (see  figure 
1.6.2).  Fruhbeck  (Fruhbeck 2006) recently reviewed leptin signalling in detail.   
1.6.5.1 JAK/STAT 
Leptin predominantly transmits its signal through the JAK/STAT pathway 
(Fruhbeck 2006).  As mentioned earlier, the long form of the receptor, which 
contains an additional motif, known as the box-2 motif, is required for maximal 
activation of the leptin signalling pathway (Fruhbeck 2006).  It has also been 
shown, however, if the box-1 motif alone or its proximal amino acids are present 
JAK activation occurs, suggesting that receptor isoforms possessing the box-1 
motif  alone  can  also  mediate  JAK activation (Bahrenberg et al. 2002).  
Nevertheless, it appears that the presence of both the box-1 and box-2 motif’s 
are crucial for maximal activation of leptin stimulated pathways to occur.        Richard A Dixon  General Introduction 
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Figure 1.6.2 – Leptin signalling mechanisms.  Leptin binding to its receptor leads to the phosphorylation 
and activation of an associated JAK2 protein.  In turn, this causes phosphorylation of various tyrosine 
residues on the OB-R and subsequent activation of PI3K-Akt, p44/42 MAPK and STAT3.  Figure adapted 
from (Fruhbeck 2006).  
 
1.6.5.2 MAPK 
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capable of stimulating MAPK pathway activation (Banks et al. 2000). OB-Ra-
induced MAPK activation, however, is not as marked as that induced by OB-Rb 
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the presence of an intact catalytic domain within the phosphatase SHP-2 
P
P
P
Extracellular
Intracellular
PI3K
JAK2
P
P
P
AKT
JAK2
P P
P P
SHP 2 Grb-2
P P
P44/42
P
P
STAT3 STAT3
P
P
PIP2
PIP3
P
P
P
Extracellular
Intracellular
PI3K
JAK2
P
P
P
AKT
JAK2
P P
P P
SHP 2 Grb-2
P P
P44/42
P
P
STAT3 STAT3
P
P
PIP2
PIP3Richard A Dixon  General Introduction 
 
 
The Hatter Cardiovascular Institute  72 
   
(Bjorbaek et al. 2001).  These data, therefore, suggest that leptin-induced MAPK 
activation is transduced via SHP-2. MAPK signalling has been demonstrated to 
be an important cascade with respect to leptin signaling.  All of the upstream 
and downstream components involved, however, have yet to be identified. 
1.6.5.3 PI3K-AKT (PTEN inhibition) 
The importance of PI3K with respect to leptin’s role in energy homeostasis was 
indicated by the observation that pharmacological inhibition of PI3K abrogates 
the anorectic effect of leptin by blocking hyperpolarisation of NPY 
/AgRP neurons (Niswender et al. 2001).  In the hypothalamus leptin has been 
shown to stimulate PI3K activity via activation of the insulin receptor subtype-2 
(IRS2).  Furthermore, PI3K activity was found to be required for leptin-induced 
activation of the sympathetic nervous system, which in turn has been 
demonstrated to induce changes in renal sympathetic outflow (Rahmouni et al. 
2003).  Downstream of PI3K, leptin is known to activate Akt and protein kinase 
C (PKC) isoforms (Sweeney 2002).  Interestingly, recent data indicate that leptin 
may potentiate the Akt signal by inhibiting PTEN activity (see section 1.3.4.1.1).  
This  observation was made  with  hepatocytes  in which leptin was found to 
activate casein kinase 2 (CK2), which leads  to phosphorylation  and  as a 
consequence inactivation of PTEN phosphatase activity (Ning et al. 2006).  With 
PTEN inactivated more PIP3 can be generated by PI3K, which can then lead to 
further Akt activation via PDK1/2.   Richard A Dixon  General Introduction 
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1.6.5.4 AMPK 
Leptin is associated with the activation of AMPK and consequential activation of 
fatty acid oxidation (Unger 2004; Minokoshi et al. 2002).  AMPK has been 
described as a “fuel monitor” and functions to increase nutrient intake through 
signalling  in the hypothalamus (Kahn et al. 2005).  A downward shift in the 
ATP/AMP ratio stimulates AMPK activation, which leads to increased catabolism 
and decreased  anabolism  (Kahn et al. 2005).  It is thought that leptin and 
adiponectin activate AMPK by altering the cellular ATP/AMP ratio (Kahn et al. 
2005).  
1.6.6  Leptin resistance 
Leptin resistance is associated with impaired leptin signalling, particularly in the 
hypothalamus,  and leads to  increased  appetite and decreased energy 
expenditure (Enriori et al. 2006).  Leptin resistance is thought to be an important 
step in the development of diet-induced obesity and its subsequent problems 
(Tschop et al. 2007).  Two mechanisms have been put forward to explain leptin 
resistance.  First, it has been  suggested  that  it may occur  as a result of 
decreased leptin transport to the brain (Banks et al. 2004) Alternatively, it has 
been hypothesised that leptin resistance may be caused by an impairment in the 
OB-Rb signalling cascade (Munzberg & Myers, Jr. 2005; Banks & Farrell 2003).  
This model of leptin resistance suggests that chronic activation of leptin 
signalling leads to the upregulation of suppressor of cytokine signalling 3 
(SOCS3), which acts to suppress leptin signalling (Munzberg & Myers, Jr. 2005).  
This theory is supported by an investigation conducted by Dunn and colleagues, 
that  demonstrated that overexpression of SOCS3 leads to reduced OB-Rb Richard A Dixon  General Introduction 
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signalling (Dunn et al. 2005).  Furthermore, this study also found that mutation of 
the STAT3 binding site on the OB-Rb  receptor abolished  leptin  resistance.  
These data, therefore, indicate that chronic STAT3 activation mediated by leptin 
leads to leptin resistance.  SOCS3 is further implicated in this mechanism by a 
study which showed that reduced levels of SOCS3 in the brain correlate with an 
increase in leptin sensitivity and resistance to diet induced obesity (Mori et al. 
2004).  Currently it is unknown whether  leptin resistance is a purely neural 
phenomenon or whether it occurs in other tissues in the body.  Recent data, 
however, suggest that leptin resistance may be tissue specific.  Somoza et al 
found that mice fed on a high fat diet for 8 weeks exhibit leptin resistance in the 
hypothalamus, but not in the heart (Somoza et al. 2007).  Therefore, cardiac 
tissue may be amenable to leptin-induced cardioprotection even if the subject 
exhibits hypothalamic leptin resistance.    
1.6.7  Leptin and the cardiovascular system 
As mentioned above,  the leptin receptor has  been  found to be present on 
cardiomyocytes (Purdham et al. 2004).  Our current understanding regarding the 
role  of leptin  signalling  in the heart is, however,  limited.  Leptin has, 
nevertheless, been implicated in a number of cardiac phenomena,  including 
cardiac hypertrophy and heart failure, and it has been shown to elicit various 
effects on the vasculature (Purdham et al. 2008; Maruyama et al. 2000; Park et 
al. 2001).  Richard A Dixon  General Introduction 
 
 
The Hatter Cardiovascular Institute  75 
   
1.6.7.1 Vascular effects of leptin 
In vivo administration of leptin has been demonstrated to cause an elevation in 
blood pressure and heart rate, which is mediated by the sympathetic nervous 
system (Shek et al. 1998; Correia et al. 2001).  In hyperleptinaemia, however, it 
is  thought that leptin may induce hypertension by alternative  mechanisms.  
Leptin is known, for example, to upregulate the production and secretion of pro-
inflammatory cytokines, such as interleukin 6 (IL-6) and TNF-α, which are known 
to increase blood pressure and promote atherosclerosis (Loffreda et al. 1998).  
Whilst leptin has been shown to promote hypertension, interestingly, it has also 
been found to produce vasodilatory effects (Leung & Kwan 2008). In endothelial 
cells and in anaesthetised rats, for example, leptin has been found to stimulate 
the production of the vasodilator, NO (Winters et al. 2000; Fruhbeck 1999).  In 
conscious rats, however, leptin failed to elicit a vasodilatory effect  (Gardiner et 
al. 2000).  In endothelial cells, leptin has been demonstrated to stimulate eNOS 
via Akt, in a mechanism independent of PI3K (Vecchione et al. 2002).  Whilst 
leptin stimulates the production of NO, a vasodilator, it has also been 
demonstrated to stimulate the release of endothelin-1 (ET-1), which is a 
vasoconstrictor (Quehenberger et al. 2002).     
The pro-inflammatory effects of leptin are thought to play a role in atherogenesis 
(Dubey & Hesong 2006).  Indeed, elevations in plasma leptin levels have been 
found to be associated with coronary artery calcification in type-2 diabetics and 
in non-diabetics (Reillt et al, 2004) (Qasim et al, 2008).  Whether leptin signalling 
contributes to the calcification process directly, however, has yet to be clarified.  Richard A Dixon  General Introduction 
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Nonetheless, leptin has been demonstrated to elicit  various effects on the 
vasculature that contribute to the development of atheroma (Beltowski 2006a).  
In endothelial cells,  for example,  as well as stimulating the  release of ET-1, 
leptin increases ROS production and promotes  cellular  proliferation 
(Quehenberger et al. 2002; Bouloumie et al. 1999).  Furthermore, leptin has 
been shown to promote thrombosis by inducing platelet aggregation (Maruyama 
et al, 2000).     
1.6.7.2 Leptin and myocardial fatty acid utilization 
Fatty acids (FA) are the principal “fuel” in the healthy heart, oxidation of which 
produces the bulk  of the ATP used by the contractile apparatus (Noh et al. 
2006). Leptin has been shown to increase fatty acid oxidation in the isolated 
working rat heart via a mechanism independent of changes in the AMPK-acetyl-
CoA carboxylase-malonyl-CoA axis  (Atkinson et al. 2002).  It is thought that 
hyperleptinaemia in the early stages of obesity may protect against  the 
accumulation of FAs in the heart, known as myocardial steatosis, by increasing 
FA oxidation (Yang & Barouch 2007).  In the later stages of obesity, however, it 
has been suggested that the development of leptin resistance leads to cardiac 
FA accumulation, lipotoxicity, contractile apparatus dysfunction and, ultimately, 
apoptosis of cardiomyocytes (Zhou et al. 2000).  Given that it is currently unclear 
whether leptin resistance occurs in the heart (see section 1.6.6),  further 
investigation is required in order to understand leptin’s role in obesity. Richard A Dixon  General Introduction 
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1.6.7.3 Effects of leptin on hypertrophy and remodelling 
There appears to be an ever growing amount of evidence indicating that leptin 
promotes cardiac hypertrophy. Serum leptin levels have been found to correlate 
with left ventricular hypertrophy (LVH) independent of BMI and blood pressure 
(Kartal et al. 2008).  Furthermore, Purdham et al demonstrated recently that a 
leptin receptor neutralising  antibody  inhibited  myocardial hypertrophy in rat 
hearts subjected to coronary artery ligation (CAL) (Purdham et al. 2008).  The 
mechanisms underlying leptin-induced hypertrophy, however, are still unclear.  
In cardiac myocytes leptin has been shown to induce MAPK and RhoA 
activation,  both of which are  thought to play roles  in promoting hypertrophy 
(Rajapurohitam et al. 2003; Tajmir et al. 2004; Zeidan et al. 2006).  In addition, 
leptin-induced hypertrophy was shown to occur following translocation of p38 
MAPK from the cytosol to the nucleus via a mechanism that was dependent on 
the presence of intact caveolae and Ras homolog/Rho-associated coiled coil–
containing protein kinase  (Rho/ROCK)  signalling  (Zeidan et al. 2008).  
Furthermore, in neonatal rat cardiomyocytes leptin-induced hypertrophy was 
demonstrated to be associated with increased ET-1 and ROS levels (Xu et al. 
2004).  It is clear that this is an area that needs more research as leptin may 
prove to be an important drug target in the setting of cardiac hypertrophy.  
1.6.8  Tissue protection 
Leptin has been demonstrated to have anti-apoptotic effects in various tissues.  
In the gut, for example, it has been found that leptin protects against I/R induced 
gastric erosions (Brzozowski et al., 2001).  In renal tissue, leptin was shown to Richard A Dixon  General Introduction 
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protect against I/R injury  by abrogating  the deleterious effects of TNF-α 
(Erkasap et al. 2003).   
In salivary gland acinar cells, leptin was found to protect against ethanol-induced 
cytotoxicity through a mechanism involving the activation of prostaglandin and 
NO synthase pathways by Src kinase (Slomiany & Slomiany 2008).  Protection 
of the small intestine by leptin was also found to be associated with increased 
NO  synthesis  as compared  with  control  (Hacioglu et al. 2005).  In hepatic 
stellate cells, leptin-induced protection against Fas-induced apoptosis was found 
to be dependent on the presence of the long, OB-RB form of the leptin receptor 
(Qamar et al. 2006).   
Recently, Tang has described how leptin’s pro-survival effects and ease of 
access to the brain make it a suitable candidate as a neuroprotective drug (Tang 
2008).  Leptin has, indeed, been used as a neuroprotectant in several studies 
utilising models of neurodegeneration.  In a model of Parkinson’s disease, for 
example, leptin was found to protect against 6-hydroxydopamine-induced 
dopaminergic cell death via ERK1/2 activation (Weng et al. 2007).  Furthermore, 
leptin  was  shown  to  protect  hippocampal  CA1 neurons against I/R injury via 
stimulation of both Akt and ERK 1/2 (Zhang & Chen 2008).  In another study 
using hippocampal neurons, leptin was shown to protect cells via JAK/STAT3 
stimulation and mitochondrial stabilisation (Guo et al. 2008).  Protection was lost 
when cells were treated with either the JAK/STAT inhibitor, AG490, or PI3K/Akt 
inhibitors (Guo et al. 2008).  Richard A Dixon  General Introduction 
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1.6.8.1 Cardioprotection 
Leptin  has been demonstrated to protect  cardiac myocyte cultures against 
hypoxia-induced damage (Erkasap et al. 2006).  Furthermore, leptin has been 
found to protect H9c2 rat cardiomyocytes against H2O2-induced apoptosis 
through  a mechanism  which involved the suppression of mitochondrial 
membrane potential changes and inhibition of cytochrome C release (Eguchi et 
al. 2008). Translocation of the pro-apoptotic factor BAX was also found to be 
inhibited by leptin administration (Eguchi et al. 2008).  In our laboratory, leptin 
was demonstrated to protect the isolated perfused Langendorff mouse heart 
against I/R injury, via activation of ERK 1/2 (Smith et al. 2006).  Leptin remains, 
however, to be tested in an in vivo model of I/R injury.  
Leptin has been the subject of intense study for the past 14 years and in 
addition to learning about its important role in energy homeostasis we now know 
that it also stimulates cellular survival in several tissues.  Further studies 
concerning the protective actions of leptin against myocardial I/R injury are a 
necessity to ascertain the clinical potential of this drug and therefore form the 
basis of the investigation presented in this thesis.            
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CHAPTER 2 - AIMS & HYPOTHESIS 
2.1  Aims 
 
Examine the signalling mechanisms underlying leptin-induced cardioprotection 
in vitro focusing on the p44/42 MAPK, PI3K-Akt and JAK/STAT pathways. 
Explore the importance of the OB-R and adiposity in leptin-induced 
cardioprotection in vitro. 
Investigate the cardioprotective effects of leptin in an in vivo model of ischaemia 
reperfusion injury. 
2.2  Hypothesis 
Leptin, via activation of the RISK pathway and JAK/STAT signalling cascade, 
protects the myocardium against I/R injury via activation of the leptin receptor 
(OB-R).  
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CHAPTER 3 - GENERAL METHODS 
3.1  Animals 
Prior to undertaking investigations using animals the appropriate education and 
training,  as directed by the Animals (Scientific Procedures) Act 1986, was 
sought.  Modules 1, 2, 3 and 4 (general principles) was successfully passed and 
subsequently a personal licence was awarded by the Home Office.  The licence 
allowed a number of procedures to be performed including all those performed 
whilst undertaking this thesis.  
Male Wistar, Zucker Lean (fa/+) and Zucker fatty (fa/fa) rats between the age of 
thee and four weeks were used in this study. All animals were obtained from 
Charles River UK Limited (Margate, UK)  and received humane care in 
accordance with The Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986 (The Stationary Office, London, UK). Animals were 
allowed to acclimatise for a minimum of 4-5 days prior to use. They were kept in 
cages of four and had free access to fresh water and standard pellet chow (RM1 
diet), and were subjected to a 12 hour light-dark cycle and maintained at 19-
22˚C and 55±10% humidity. 
3.2  Chemicals & Drugs Used 
Leptin
1
                                                 
1  It should be noted that human leptin and not rat leptin was used for all experiments, this will be 
discussed further in section 
  (human)  and triphenyltetrazolium chloride (TTC) were provided by 
Sigma-Aldrich Company Ltd (Gillingham, Dorset, UK).  Leptin was reconstituted 
as advised by Sigma by adding 0.5 ml of 0.2 μm-filtered 15 mM HCl. Once the 
protein was fully dissolved, 0.3 ml of 0.2 μm-filtered 7.5 mM NaOH was then 
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added (Sigma-Aldrich, 2009).  All constituents of  the Krebs-Henseleit buffer 
were supplied by BDH Laboratory supplies (Poole, Dorset, UK). Protein kinase 
inhibitors AG490, LY294002 (LY) and UO126 (UO) were obtained from Tocris 
Bioscience (Avonmouth, UK).  All  Western  blot reagents and tissue culture 
chemicals were provided by Sigma-Aldrich Company Ltd (Gillingham, Dorset, 
UK). The BCA protein assay  kit was purchased from Pierce Biotechnology 
(Rockford, IL, USA). Tetramethylrhodamine methyl ester (TMRM) was supplied 
by Molecular Probes (Eugene, OR, USA). 
3.3  Langendorff Isolated Perfused Rat Heart 
Rats were anaesthetised with Nembutal (sodium pentobarbital) (55 mg/kg intra-
peritoneally, Sagatal-Rhone, Merieux), and were given heparin sodium (300 IU 
intra-peritoneally, Multiparin CP Pharmaceuticals Ltd.) to prevent the formation 
of thrombi  in the heart and  blood  vessels.  When the rat was sufficiently 
anaesthetised, as indicated by the loss of the pedal withdrawal reflex, a trans-
abdominal incision was made and the thoracic cavity was exposed by a bilateral 
incision along the lower rib margin. The anterior thoracic cage was then 
reflected superiorly and the heart gently held between the fingers and excised. 
The heart was then immediately immersed in ice-cold (4°C) modified Krebs-
Henseleit bicarbonate buffer (containing NaCl 118mM, NaHCO3 24mM,  KCl 
4mM, NaH2PO4 1mM, CaCl2 1.8mM, MgCl2 1.2mM and glucose 10mM)  to 
arrest the heart and minimise ischaemic injury (Krebs & Henseleit 1932).  The 
heart was then mounted via the aorta onto a 14 gauge cannula (2mm external 
diameter; approximately 1.5mm internal diameter) connected to the perfusion Richard A Dixon  General Methods 
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apparatus (Figure 3.3.1 & Figure 3.3.2).  The time between excision of the heart 
and perfusion with oxygenated Krebs-Henseleit buffer was kept to a minimum to 
prevent ischaemic preconditioning of the myocardium.  The heart was perfused 
retrogradely via the aorta at a constant pressure of 100mm Hg with modified 
Krebs buffer as described above.  Retrograde perfusion via the aorta causes the 
closure of the aortic valve allowing the buffer to flow through  the coronary 
vessels and perfuse the myocardium.   Careful oxygenation of the buffer using a 
95% O2 / 5% CO2 gas mixture resulted in a stable pH of 7.4 ± 0.5, which was 
carefully monitored using a gas analyser (ABL 700 Radiometer, Denmark). Richard A Dixon  General Methods 
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Figure 3.3.1 - Diagram of the Langendorff apparatus used Richard A Dixon  General Methods 
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Figure 3.3.2 – Photograph of Langendorff isolated rat heart perfusion apparatus. 
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In  order to induce ischaemia this model requires that one or more of the 
coronary vessels is obstructed.  This is achieved by passing a length of 3.0 
Mersilk under the left anterior descending coronary artery (LAD) using a curved 
round bodied surgical needle.  The ends of the suture were placed through a 
snare constructed from the ends of two Gilson 1ml pipette tips (see Figure 3.3.4 
for photographs of the isolated rat heart preparation).   
Myocardial temperature was measured using a thermoprobe inserted into a 
small incision made in the base of the pulmonary trunk.  Temperature was 
maintained at 37 ± 0.5°C using a thermostatically-controlled water-jacket system 
(C-85A circulator, Techne, USA)  that entirely encased the glassware of the 
perfusion equipment.  Coronary flow rate (CFR) was measured by collecting the 
coronary effluent of a particular heart in a 15ml falcon tube for 30sec and then 
multiplying the resulting figure by two to obtain the value in ml per min.  Heart 
rate and developed pressure were measured using a latex water-filled balloon, 
constructed using the tip of a condom (Durex, UK), was inserted into the left 
ventricle subsequent to the removal of the left atrial appendage.  The balloon, 
connected to a pressure transducer which directed the signal to a chart recorder 
(Multitrace 2, Lectromed, UK), was inflated such that a left ventricular end 
diastolic pressure of 5-10mmHg was achieved (see Figure  3.3.5).   
After a stabilisation period of 40 min ischaemia was induced by tightening the 
suture around the LAD and clamping it with the snare.  The suture was tightened 
so that there was at least a 40% reduction in coronary flow and developed 
pressure.  Subsequent to 35 min of regional ischaemia the snare was released Richard A Dixon  General Methods 
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and the myocardium reperfused for a period of 120 min  (see  Figure  3.3.3).  
Reperfusion was confirmed by an increase in coronary flow and  cardiac 
function.  It is essential that the myocardium is reperfused for 120 min to ensure 
that  removal of dehydrogenase enzymes and cofactors  occurs: inadequate 
wash-out of dehydrogenase enzymes and cofactors as a result of the use of 
shorter reperfusion times leads to underestimation of the infarct size (Schwarz et 
al. 2000).  Left ventricular developed systolic and diastolic pressures, heart rate, 
myocardial temperature and coronary flow were noted at regular intervals.  The 
rate pressure product  (RPP)  was also recorded, which is the product of the 
diastolic pressure and heart rate, and is used as a measure of ventricular 
contractility. 
 
 
Figure 3.3.3 – Schematic of standard protocol for isolated rat heart I/R experiment.  Hearts were 
stabilised for 40min, subjected to 35min ischaemia and then reperfused for 120min. 
 
 
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
Standard Langendorff isolated heart protocol
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
Standard Langendorff isolated heart protocolRichard A Dixon  General Methods 
 
 
The Hatter Cardiovascular Institute  88 
   
 
Figure 3.3.4 – Isolated mounted rat heart photos demonstrating stages of ischaemia reperfusion 
protocol. Richard A Dixon  General Methods 
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Figure 3.3.5 – Example of a heart trace obtained using latex balloon inserted into the left ventricle 
during an ischaemia/reperfusion experiment.   Richard A Dixon  General Methods 
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3.3.1  Determination of infarct size  
Following the reperfusion-phase of the experiment the suture was pulled tight 
and the heart infused with 2ml saline solution containing 0.25% Evans blue 
(Sigma Chemicals, Poole, Dorset) to demarcate the non-ischaemic zone of the 
myocardium (Figure 3.3.).  The heart was then weighed and immediately frozen 
at -20°C.  After 1 to 4 hours at -20°C, the hearts were sliced from apex to base 
into 5 x 2mm-thick transverse sections, and incubated in a triphenyltetrazolium 
chloride (TTC) solution (1% in phosphate buffer, pH 7.4) at 37°C for 15 minutes.  
TTC reacts with the dehydrogenases still present in the non-infarcted tissue to 
produce the red-pigmented azo compound formazan. Infarcted regions of the 
tissue, by contrast, remain white due to the prior wash-out of the 
dehydrogenases during reperfusion (Figure 3.3.) (Vivaldi et al. 1985; Hausenloy 
et al. 2007).  Heart slices were then transferred to 10% formalin (BDH 
Laboratory supplies, Poole, UK) for 24 hours to bleach the infarcted tissue, thus 
improving the disparity between infarcted and viable tissue.  Heart slices were 
then placed between two sheets of transparent Perspex which were secured 
using bulldog clips.  Slices were then traced onto an acetate sheet using a fine 
permanent marker by a designated person who was blinded to the protocol each 
heart had been subjected to.  Subsequently, a computerised planimetry package 
(Summa Sketch III, Summagraphics, Seymour, CT, USA), was used to calculate 
the percentage of infarcted tissue within the volume of myocardium at risk, and 
the data expressed as an infarct-risk volume ratio (IS/AAR%) (Figure 3.3.6 & 
Figure 3.3.7). Richard A Dixon  General Methods 
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Figure 3.3.6 – Schematic of heart subjected to ischaemia/reperfusion injury infused with Evans blue 
dye. The blue area represents the tissue that was perfused throughout the experiment and therefore was not 
at risk.  The red and white area represents the portion of the heart that has been subjected to ischaemia and 
contains viable (red) and infarcted (white) tissue.  
 
Figure 3.3.7 - Heart slices(A) and computed planimetry(B).  Figure (A) shows heart slices which have 
been stained with TTC and bleached in formalin.  Figure B shows the digital analysis for heart slices, in 
which the yellow area corresponds to non-risk tissue, green to tissue at risk and red to infarct.   
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3.3.2  Exclusion criteria 
Hearts were excluded from the study if either the RPP was less than 17 mmHg 
min-1 or the coronary flow rate was less than 10 ml/min during stabilisation.  
Hearts were also excluded if there was no drop in pressure and coronary flow on 
induction of ischaemia.  It should be noted that a reduction in pressure is a 
reduction in left ventricular developed pressure. In addition hearts were 
excluded if sustained ventricular fibrillation occurred upon reperfusion, i.e. longer 
than 5min.  Finally, hearts with risk zone volumes of less than 40% or greater 
than 65% were also excluded. 
3.4  Preparation of Isolated Adult Rat Cardiomyocytes 
Hearts were mounted on a non-recirculating constant flow (14 ml/min) 
Langendorff apparatus following  excision from Wistar rats (for details of the 
excision  process  see  section  3.3).  The protocol as described previously in   
(Maddock et al. 2002),  involved the perfusion  of hearts with low-calcium 
containing  buffers based on Krebs-Ringer’s  (KR) buffer which consisted of 
116mM NaCl, 10 mM Glucose, 5.4 mM KCl, 0.9 mM Na2HPO4, 0.4 mM MgSO4, 
20  mM taurine  and 5 mM pyruvate  (Krebs & Henseleit 1932).  Hearts were 
initially perfused for 3-5 mins with “buffer 1”, which consisted of the KR buffer 
described above with the addition of 1 mg/ml BSA and 3.3 µmol/l EGTA.  The 
heart was then perfused for 10min with “buffer 2”, i.e. KR buffer with the addition 
of 1mg/ml collagenase (Type II LS004176, Worthington):  the collagenase 
breaks the peptide bonds  in collagen, a key component of  the  extracellular 
matrix, and promotes  the  separation of the myocytes  (Tytgat 1994).  The 
ventricles were then harvested by cutting away the atria which remained Richard A Dixon  General Methods 
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attached to the perfusion apparatus.  The ventricles were cut into strips, placed 
in a 50ml Falcon tube and incubated in ~15ml “buffer 2” at 37°C with shaking 
and bubbling with 100% O2.  After 10min the supernatant was discarded and the 
remaining undigested tissue was incubated for a further 20min in 15ml fresh 
“buffer 2” with shaking and O2.  Cells in solution were then transferred to a fresh 
tube and centrifuged at 600 rpm for 3min.  The pellet was then resuspended in 
15ml of “buffer 3”, i.e. KR buffer with 44μM calcium, and re-centrifuged. The 
pellet was then slowly resuspended, drop-wise, in M-199 plating medium 
(M7653, Sigma Chemicals, Poole, Dorset) to allow the cells to acclimatise to a 
higher calcium concentration.  The plating medium (40ml) was supplemented 
with the following additives:  1.0g BSA, 0.33g creatine, 0.31g taurine, 0.16g 
carnitine and 1 % pen-strep.  At all stages when cells were being transferred 
from tube to tube a plastic Pasteur pipette was used to avoid cell membrane 
rupture.  Isolation efficiency and cell viability were monitored at every stage 
during the protocol by visualising samples under a light microscopy.   
Preparations with less than 60-70% viable cells were excluded.  Viability was 
assessed by the visualisation of the isolated cardiomyocytes, i.e. viable 
cardiomyocytes are characterised by their elongated appearance, by contrast 
non-viable cells appear either contracted or rounded (see Figure 3.4.1) (Egorova 
et al. 2005).  Isolation efficiency was judged to looking at the sample to see how 
many dead cells were in the preparation.  Furthermore, cell counts were 
performed using a cell count chamber (see 
http://www.ruf.rice.edu/~bioslabs/methods/microscopy/cellcounting.html for a 
detailed explanation).  Richard A Dixon  General Methods 
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Figure 3.4.1 – Micrograph of isolated rat cardiomyocytes.  At the end of the isolation procedure 
preparations were examined by eye to estimate the percentage yield.  Non-viable cardiomyocytes were 
easily identified by their shortened or rounded appearance when compared to viable cells. 
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  Figure 3.4.2 – Cardiac myocyte isolation rig.  The rig has two buffer reservoirs, thus allowing an 
efficient transition from collagenase-free to collagenase-containing buffers. 
  
3.4.1  Preparation of cardiomyocytes for confocal microscopy 
A single 25mm diameter glass coverslip was placed in each well of a sterile six-
well plate.  The plate was then placed in a UV crosslinker to kill any bacteria 
present on the coverslips. To provide a structural scaffold for the cells to adhere 
to, 50μl laminin (1mg/ml diluted in 30 ml of distilled water, Sigma Chemicals, 
Poole,  Dorset)  was  pipetted  onto  each  coverslip.    200  μl  of  the  cell  solution 
(section  3.4)  was  then  pipetted onto the laminin coated  plates  which  were 
incubated at 37°C with 5% CO2  for 45-60 min (incubator CO28IR, New Richard A Dixon  General Methods 
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Brunswick Scientific, USA). The cells were then washed with 1ml M-199 plating 
medium, which was removed and replaced with 1ml fresh plating medium.  
Confocal microscopy was performed to investigate how leptin affects the 
opening of the MPTP (section 1.2.2.4) in isolated cardiomyocytes (Smith et al. 
2006).  Opening of the MPTP leads to a loss of mitochondrial potential.  To 
visualise this process tetramethyl-rhodamine methyl ester (TMRM), a cationic 
fluorescent dye that accumulates in the mitochondria due to its charge, was 
used (Ehrenberg et al. 1988).  Exposure of the TMRM dye to a laser leads to the 
generation of ROS in the mitochondria (Zorov et al. 2000). Increasing levels of 
ROS in the mitochondria ultimately leads to the induction of MPTP opening, 
which can be visualised as depolarisation of the mitochondria and dequenching 
of the TMRM fluorescence  (Davidson et al. 2006).  Coverslips containing 
isolated myocytes were incubated with TMRM  (3μM)  for 15 min, which is 
sufficient time for mitochondrial TMRM uptake.  Cells were then incubated for a 
further 10min in either (1) KH buffer (control), (2) KH buffer with 10μM leptin or 
(3) KH buffer with 0.2μM CsA.  CsA is an established inhibitor of pore opening 
and was therefore used as a positive control (Xie & Yu 2007).   
3.4.2  Confocal microscopy 
Confocal microscopic analysis was performed in the Department of Physiology 
in collaboration with Professor Michael Duchen,  head of the Mitochondrial 
Biology Group.  A Zeiss 510 CLSM microscope, fitted with a henna laser that 
was filtered to 543nm and TMRM fluorescence measured at 585 nm by using a 
long pass filter was used for all experiments  (Figure  3.4.3).  Following the Richard A Dixon  General Methods 
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incubation with TMRM and any drugs used, the cloverslips were placed upon 
the custom built housing of the microscope and the cells were visualised using a 
40x oil immersion objective.  Using the light microscope function, a small group 
of viable cells (usually 2-4) were selected and then the laser was turned on.  
Exposure of the cells to the laser in the  viewing field continued until 
mitochondrial depolarisation occurred.  The time from switching on the laser to 
mitochondrial depolarisation was recorded and used as a measure of cellular 
vulnerability.  A total of 12-20 cells from at least five hearts per group were 
analysed. 
Figure 3.4.3 – Confocal microscope and operating computer 
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3.5  Western Blotting 
3.5.1  Tissue collection 
Rat hearts were perfused for 40min to allow them to stabilise. Hearts were then 
subjected to 35min regional ischaemia and reperfused for 2.5, 5, 10, 15 and 
30min, at which time the risk zone was identified using Evans blue dye (see 
section 3.3).  This area was then excised, snap-frozen in liquid nitrogen using 
Wallenberg clamps to freeze/disrupt the tissue.  All samples were stored at -
80°C to await analysis.   
3.5.2  Protein extraction 
Proteins were extracted by homogenising  myocardial  samples  in an ice-cold 
suspension  buffer containing: 100mM NaCl, 10mM Tris (pH 7.6), 1mM 
ethylenediaminetetraacetic acid (pH 8.0), 2mM sodium pyrophosphate, 2mM 
sodium  fluoride,  2mM  β-glycerophosphate and a protease inhibitor cocktail, 
using a Plytron model T25 homogeniser (IKA Labortechnik T25, Janke & Kunkel 
GmbH & Co., Germany) set at 24000rpm. Samples were then spun at 11000rpm 
for 10min in a 5417R centrifuge (Eppendorf, UK) and the supernatants assayed 
for protein content using a bicinchoninic acid (BCA) assay (Pierce, UK).  The 
remaining supernatant was further diluted 1:1 in sample buffer: Tris 100mM (pH 
6.8), DTT 200mM, SDS 2%, bromophenol blue 0.2% and glycerol 20%, and 
subsequently boiled for 10 minutes at 100°C  in a DRI-Block  DB-2A heating 
block (Techne, USA).  Boiling the protein mixture in the presence of SDS 
denatures the protein and allows the detergent to bind to the polypeptide 
backbone.  SDS binds in a uniform manner and therefore the proteins take on a 
negative charge that positively correlates with its molecular weight.  Richard A Dixon  General Methods 
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3.5.3  Protein estimation 
The protein concentrations for samples were determined so that the amounts of 
protein  loaded onto polyacrylamide gels for  Western  blot  analysis could be 
standardised.  The bicinchoninic acid (BCA) protein assay works on the principle 
that peptide bonds associated with cysteine, tryptophan and tyrosine residues 
are capable of reducing Cu
2+ in a copper sulphate reagent to Cu
+ (Wiechelman 
et al. 1988).  Bicinchoninic acid is then able to bind to Cu
+ to give a purple 
colouration that is measurable in a linear manner at an absorbance of 562 nm 
using a spectrophotometer  (Jenway 6405 UV/Vis spectrophotometer). The 
protein contents of samples can then be measured by reference to a standard 
curve constructed using bovine serum albumin (BSA) (20-2000 μg/ml).  In this 
way protein concentrations for samples, expressed as μg/μl, are obtained. 
3.5.4  Polyacrylamide gel electrophoresis 
Polyacrylamide gels for protein  separation  were formed between two glass 
plates  that  were  cleaned with ethanol to remove dust particles, and were 
composed of a running gel and a stacking gel.  The 12.5% running gel consisted 
of 12ml ddH2O,  15ml  30%  acrylamide and 9ml running gel base [1.5M Tris, 
0.4% SDS in distilled water, pH 8.8].  Gel  polymerisation  was  triggered by 
adding  40μl  99%  tetramethylethylenediamine  (TEMED)  and  200μl  10% 
ammonium persulphate (APS).  On addition of the polymerisation agent the gel 
was poured and then left for 30min to set.   
To form the wells into which samples were loaded, plastic “combs” were placed 
above the running gel and a 5% stacking gel poured in to fill the space.  The Richard A Dixon  General Methods 
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stacking gel  consisted of 4.5ml ddH2O,  2ml  30%  acrylamide,  10μl  8% 
bromophenol blue and 1.5ml running gel base [0.5M Tris, 0.4% SDS in distilled 
water, pH 6.8 with HCl acid].   As for the running gel 12μL 99% TEMED and 
60μL  10%  APS  were added to cause the acrylamide to polymerise.  The 
stacking gel was then left for 15min to set, whereupon the combs were removed 
and the gel placed into the electrophoresis apparatus (Biorad, UK).  A running 
buffer consisting of glycine 14.42 g/l, SDS 1.0 g/l, Tris 3.0 g/l, distilled H2O 1.0 L 
was poured into the reservoir of the electrophoresis apparatus so that  the 
sample  wells were submerged.  Any air  bubbles  present  in the wells were 
removed using a 21 gauge needle.  Running buffer was added to the bottom of 
the  electrophoresis apparatus so that the bottom 3cm of the gels were 
submerged, this allows the electric current to be applied across the gel  and 
causes the negatively charged SDS-bound proteins to migrate. 
In order to establish the molecular weights of the proteins under investigation a 
molecular weight dual-colour protein marker (Precision Plus Protein Dual Colour 
Standards, Bio-Rad)  was  pipetted  (15μL)  into  the  first  well  of  each  gel  run.  
Quantities of sample equivalent to 30-60μg protein were then loaded into the 
subsequent wells.  Gels were left to run at 200 volts for 2-3hours or until the 
bromophenol blue marker had migrated sufficiently to ensure that the protein of 
interest could be visualised.  
3.5.5  Protein transfer 
After the completion of protein separation by electrophoresis, the stacking gel 
was trimmed off and the running gel was mounted in a transfer system Richard A Dixon  General Methods 
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containing transfer buffer (200ml methanol, 700ml de-ionised H20, 100ml 10x 
transfer buffer [glycine 14.4g/L, Tris 3 g/L, 1 litre ddH20]). Hybond ECL 
nitrocellulose membrane (Amersham, UK) was cut to the same size as the gel 
and placed on the gel. The gel and membrane were then placed between 2 
pieces of Whatman 4mm paper taking care to remove any air bubbles.   
Following this, the proteins were transferred to the membrane by passing a 
current of 140mA overnight (16-20 hours). Adequate transfer could be 
determined by staining the membrane with Ponceau Red (Sigma Chemicals, 
Poole, UK). 
3.5.6  Immunoblotting 
After the transfer had been completed membranes were washed three times in 
TBS-Tween (Tris 2.42 g, NaCl 8.0 g, pH 7.6 with HCl, 1 litre deionised H2O + 1 
ml Tween).  Membranes were then submerged in TBS-Tween  plus 5% milk 
solution to block non-specific protein binding.  After two hours membranes were 
washed three times for five minutes in TBS-Tween.  The membranes were then 
soaked in a primary antibody specific to the protein of interest at a dilution of 1 in 
1000 in a TBS-Tween solution plus 5% BSA for at least one hour.  A third set of 
washes was  then  performed before placing the membranes in secondary 
antibody solution (diluted of 1 in 1000 in TBS-Tween plus 5% milk) for at least 
two hours.  A final set of three five minute washes using TBS-Tween was then 
performed before submerging the membranes in an enhanced chemi-
luminescent (ECL) Western blotting detection reagent to visualise the protein 
bands on exposure of the membrane to Kodak Omat XR photographic film.  The Richard A Dixon  General Methods 
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film was developed using a Kodak XOMAT 1000 Film Developer (Serial No. 
2225; Kodak House, Hemel Hempstead, HP11JU).  All washes and antibody 
treatments were performed in plastic containers placed on a rocking platform 
(SSL4 see-saw rocker, Stuart)  set at approximately 60rpm.  Total and 
phosphorylated forms of Akt, p44/42 MAPK, AMPK, PTEN  and STAT3 were 
detected using specific primary and secondary antibodies (New England bio-
labs, UK).  
3.5.7  Quantification of bands 
The photographic film was  subsequently  scanned and the intensities of the 
protein bands, expressed as arbitrary units (a.u.), determined by computerized 
densitometry (NIH Image 1.63). The relative changes for the proteins of interest 
were then established  by  calculating  the ratios  of the phosphorylated versus 
total forms of the protein. 
3.6  Rat In Vivo Model of I/R Injury 
3.6.1  Model 
Male rats were anaesthetised by i.p. injection of 50mg/kg pentobarbitone 
(Sagatal-Rhone, Merieux) and secured to a pre-warmed (37°C) operation table 
(Peco services Ltd, Cumbria, UK)  by the forelimbs.  When  animals were 
sufficiently anaesthetised, as indicated by the loss of the pedal withdrawal reflex, 
a  tracheostomy  was performed using a 14 gauge catheter,  to allow artificial 
ventilation.  Animals were ventilated  with  room air supplemented with 100% 
oxygen using a small animal ventilator (Cat no. 50-1718, Harvard apparatus, 
Kent, UK) set to 70 cycles per min and a tidal volume of 2.0-3.0ml.  The carotid Richard A Dixon  General Methods 
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artery and jugular vein were then cannulated, in the case of the former to allow 
blood pressure to be monitored  via a pressure transducer,  and  the latter to 
provide a route for drug delivery.  When cannulating the carotid artery it was 
necessary to tie off the vessel using a 3.0 mersilk suture.  This served not only 
to prevent excessive blood loss, but also provided a useful harness by which the 
vessel could be slightly stretched and secured.  A small vessel clip was then 
applied to the vessel approximately 2cm down from the tie toward the posterior 
of the animal.  The combination of the tie and the clip permitted dissection of the 
vessel without blood loss.  A perpendicular incision was made into the vessel 
using micro-scissors (Harvard apparatus) and was made large enough so as to 
allow the introduction of a cannula constructed of a 20cm piece of Portex fine 
bore  tubing, with an inner diameter of 0.58m and outer diameter of 0.96mm 
(Smiths Medical International Ltd, UK),  connected to a 23  gauge  (blue) BD 
Microlance needle.  Prior to insertion the cannula was filled with heparinised 
saline, 0.2ml 5000 I.U./ml heparin (CP Pharmaceuticals Ltd, UK) in 50ml normal 
saline (0.9% NaCl in 1 litre distilled water), ensuring that air bubbles were not 
introduced and so avoiding air emboli entering the circulation.  Once in place the 
carotid cannula was connected to the pressure transducer, which was filled with 
distilled water. The jugular vein was cannulated in a similar fashion, although in 
this case the cannula  was constructed of a 15cm piece of Portex fine bore 
tubing, with an inner diameter of 0.40mm and an outer diameter of 0.8mm 
(Smiths Medical International Ltd, UK), connected to a 25-gauge (orange) BD 
Microneedle.  The jugular cannula remained connected to a  1ml syringe 
throughout the experiment to allow delivery of fluids and drugs.  To ensure that Richard A Dixon  General Methods 
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there was adequate  illumination during the operative procedures a Photonic 
PL2000 fibre optic lamp (Photonic, Vienna) was employed.     
Electrocardiographic  (ECG) recording  was achieved by attaching three 
electrodes to the animal.  Thus, two electrodes were attached to the forelimbs 
whilst a reference electrode was attached to a hind limb to dampen extraneous 
electrical  noise.  Arterial  BP, heart rate  and ECG were recorded using a 
PowerLab system connected to a computer (ADinstruments, Oxfordshire, UK).  
Body temperature was monitored via a temperature probe inserted into the anus 
and  maintained at 37 ± 1°C by regulating  the temperature of the operation 
platform.      
Following the procedures outlined above a left thoracotomy was performed and 
the fourth intercostal space was opened carefully to allow visualisation of the 
heart.  Upon visualisation of the left atrial appendage, either the 4
th or 5
th rib was 
cut to allow greater access to the thoracic cavity.  A 3.0 mersilk suture was tied 
around the rib, prior to making an incision into the thoracic muscle, in order to tie 
off the blood vessels in the region and to provide an anchor for holding  the 
operation site open.  During the thoracotomy a  Change-A-TIP hand held 
cauterisation device (Bovie Aaron Medical, USA) was used to cut through the 
pectoralis major and minor muscles and the intercostal muscle to minimise 
blood loss.   
Once sufficient visualisation of the heart had been achieved, the pericardium 
was gently opened using forceps to allow access to the heart.  A 16mm round Richard A Dixon  General Methods 
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bodied needle was used to place a 4.0 prolene suture under the LAD, entering 
just under the left atrium and exiting under the right pulmonary outflow tract.  
The vessel was occluded for 30min by tightening a snare constructed using two 
1ml Gilson pipette tips (see section 3.3 and Figure 3.3.4).  At the conclusion of 
the occlusion-period  the snare was  loosened and the area of ischaemic 
myocardium  reperfused for two hours  (Figure  3.6.3).  The pedal reflex was 
tested regularly throughout the procedure and additional pentobarbital was given 
as required.  Blood samples were taken at baseline, 15min into reperfusion and 
just prior to the end of reperfusion to monitor pH, CO2, O2 and blood glucose 
using a gas analyser (ABL 700 Radiometer, Denmark).   
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Figure 3.6.1 – Rat in vivo surgery (1).  (A) A tracheal intubation was performed to allow artificial 
respiration.  (B) The carotid artery was located and separated from its associated nerve.  The artery was 
tied off and a vessel clip placed about 1.5-2cm down from the suture.  This allows the vessel to be cut and 
the cannula positioned without the animal bleeding out.  (C) The cannula was positioned and secured in 
the vessel with a suture.  The Jugular vein was cannulated using the same method.  
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Figure 3.6.2 – Rat in vivo surgery (2).  (A)  Once the carotid artery was cannulated, the cannula was 
connected to a pressure transducer to record blood pressure and heart rate.  (B)  Pectoral muscles were cut 
using a cautery device and reflected to reveal the ribs. (C)  The 4
th intercostal space was carefully opened 
and once sufficient visualisation of the heart had been achieved the pericardium was gently opened using 
forceps.  A suture was then placed around the LAD to occlude the vessel.   
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Figure 3.6.3 – Schematic of standard rat in vivo protocol.  Hearts were stabilized for 25min and then 
subjected to 30min myocardial ischaemia followed by 120min reperfusion. 
 
3.6.2  Determination of infarct size  
At the end of the procedure the heart was excised and placed in iced saline, 
whereupon it was hung via the aorta on a Langendorff rig in a fashion similar to 
that described for the isolated perfused heart model (see section 3.3).  The heart 
was then perfused with approximately 15-20ml saline to remove blood cells and 
debris.  Once the saline ran clear from the heart the snare was retightened and 
the heart was infused with 1.5ml Evans blue dye to delineate the risk zone.  
Hearts were then frozen and subsequently analysed for infarct using a method 
identical to that used in the isolated perfused rat heart experiments (see section 
3.3.1).   
3.6.3  Exclusion criteria 
Hearts from animals that did not survive the entire 120min reperfusion period 
were excluded from the study.  In addition, if a drop in blood pressure was not 
observed upon tightening the suture (for the induction of ischaemia) the animal Richard A Dixon  General Methods 
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was excluded from the study.  Hearts were also excluded if they were found to 
have risk zones smaller than 40% or larger than 65%.   
3.7  Method of Randomisation 
In each set of experiments the animals were randomised to a particular group.  
This was carried out by writing the name of each group on a piece of paper, and 
repeating this for the number needed per group and then placing them in a bag.  
Animals were assigned to a group by selecting a piece of paper from the bag. 
3.8  Statistical Analysis 
Data are presented as mean±s.e.m. Generally comparisons between more than 
two groups were made using factorial, one-way analysis of variance (ANOVA) 
and the Fisher’s protected least significant difference post-hoc test.  In some 
cases (e.g. the MPTP data, see Chapter 8), however, the Kruskal-Wallis 
analysis of variance method was used followed by the Dunn multiple 
comparison test Where only two groups were compared the Student’s t-test was 
used. Differences were regarded as statistically significant if a value of p<0.05 
was obtained. 
 Richard A Dixon  Results 
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CHAPTER 4 - LEPTIN PROTECTS AGAINST I/R INJURY 
IN THE WISTAR RAT HEART 
4.1  Introduction 
In section 1.3.1 the phenomenon of preconditioning (IPC) was described.  IPC is 
very complex mechanistically and is yet to be fully understood.  IPC is, if not the 
most, one of the most effective methods of protecting myocardial tissue against 
reperfusion injury.  However, due to the unpredictable nature of myocardial 
infarctions, IPC is not a practical option with respect to the treatment of patients.  
Current research is aimed at finding therapeutic strategies that can equal the 
level of protection achieved by IPC. Therefore,  in the experimental setting 
protection afforded by IPC can be used as a good benchmark against which 
alternative therapies can be compared.       
Leptin has been shown to be protective against I/R injury in a variety of settings 
(Smith et al. 2006; Brzozowski et al. 2001; Zhang & Chen 2008).  In particular, in 
our laboratory it has be shown that leptin is protective against I/R injury in the 
isolated murine heart (Smith et al. 2006).  The concentration of leptin used in 
this study was chosen on the basis of concentrations previously reported to 
facilitate protection in alternative tissues and to activate relevant cell signalling 
pathways (Rajapurohitam et al. 2003; Tajmir et al. 2004). 
4.2  Aim 
The use of a model that is robust and reproducible is essential to 
pharmacological experiments.  Therefore, the first aim of the studies presented 
in this chapter was to establish that the isolated perfused rat heart model Richard A Dixon  Results 
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performed within acceptable parameters (see section 3.3.2) and responded 
appropriately to ischaemic preconditioning (IPC).  The second aim was to 
ascertain the optimal concentration of leptin with regard to its myocardial infarct-
limiting actions in the Langendorff isolated perfused rat heart when administered 
at reperfusion.   
4.3  Experimental Protocol & Materials 
4.3.1  Isolated Langendorff perfused rat heart 
All hearts were excised from Wistar animals according to section 3.3.  Control 
hearts were perfused for 40min with no intervention to allow stabilisation and 
then subjected to 35min regional index ischaemia (Figure 4.3.1).  Hearts in the 
ischaemic preconditioning (IPC) group were stabilised for 10min and then 
subjected to two cycles of 5min global ischaemia followed by 10min reperfusion 
(Figure 4.3.1).  After the preconditioning protocol had been applied, hearts in 
this group were subjected to 35min regional ischaemia.  Hearts in both groups 
were allowed to reperfuse for two hours following the index ischaemia.     
Individual groups were (original group sizes are shown in brackets): 
Control (n=8) – no drug, no IPC, 40min stabilisation 
IPC (n=8) – no drug, IPC protocol 2 cycles of 5min global ischaemia and 10min 
reperfusion prior to index ischaemia Richard A Dixon  Results 
 
 
The Hatter Cardiovascular Institute  112 
   
Figure 4.3.1 – Ischaemic preconditioning protocol. (A) Control (B) Ischaemic preconditioning protocol, 
incorporating two cycles of sublethal ischaemia and reperfusion prior to the index ischaemia. 
 
4.3.2  Leptin dose-response 
All hearts were prepared as described in section 3.3.   Hearts were perfused for 
40min to allow stabilisation and then subjected to 35min ischaemia, except 
those in the sham group were not made ischaemic (i.e. the suture surrounding 
the LAD was not tightened), but were perfused for the same period of time as 
control hearts. After the ischaemic insult, control hearts were reperfused for two 
hours to provide sufficient washout (see section 3.3).  Treated hearts were 
perfused with 0.1, 1, 10, 30 or 100nM leptin for 30min during the reperfusion-
period.  Leptin was placed into the rig 5min prior to reperfusion to ensure it 
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reached the heart immediately upon reperfusion.  Individual experimental groups 
were (original group sizes are shown in brackets):- 
Control  (n=7) – no drug, 40min stabilisation 
Sham (n=7) – no drug, no ischaemia, 40min stabilisation 
Leptin (0.1nm) (n=7) – administered 5min prior to, and up until 30min into the 
reperfusion-phase. 
Leptin (1nM)  (n=7)  -  administered 5min prior to, and up until 30min into 
reperfusion. 
Leptin (10nM) (n=7) - administered 5min prior to, and up until 30min into the 
reperfusion-phase. 
Leptin (30nM) (n=7) - administered 5min prior to, and up until 30min into the  
reperfusion-phase 
Leptin (100nM) (n=7) - administered 5min prior to, and up until 30min into the 
reperfusion-phase. 
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Figure 4.3.1 – Leptin treatment perfusion protocol.  (A) Ischaemic control hearts were subjected to the 
normal protocol (see section 3.4). (B) Sham hearts were perfused for the same period of time as the 
ischaemic control but were not rendered ischaemic.  (C)  Leptin-treated hearts were perfused as for the 
ischaemic control hearts, but leptin was administered 5min before ischaemia and continued until 30min 
into the reperfusion-phase.     
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4.4  Results 
4.4.1  Preconditioning 
4.4.1.1 Animal and Haemodynamic Data 
 
Table 4.4.1 demonstrates that there were no significant differences between the 
groups with respect to animal weight, ventricular volume or risk zone.  Baseline 
data relating to cardiac function  before ischaemia, as assessed by the rate 
pressure product (RPP) and coronary flow, were similar in both the experimental 
groups (see table 4.4.2 & 4.4.3). During in ischaemia, however, coronary flow 
and RPP declined  to a similar extent in both groups.   Cardiac function and 
coronary flow increased upon reperfusion, which indicated that  re-flow  was 
successful.  No significant differences were observed between groups with 
respect to coronary flow rate and RPP during reperfusion. 
 
Groups  Body Weight 
 
(g) 
Ventricular 
Volume 
(mm3) 
Risk Volume 
 
(%) 
Control  (n=10)  378.1±5.9  1791.3±50.3  52.0±2.1 
IPC  (n=6)  392.5±5.2  1881.6±85.2  51.7±1.9 
Table 4.4.1– Characteristics of animals in the treatment groups 
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Coronary flow rate (ml/min) 
 
 
 
 
Table 4.4.2 – Coronary flow rates of the different groups at various time-points during the ischaemia/reperfusion protocol. Values are as mean ±s.e.m. * = 
p<0.05 vs. control (students t-test).   
 
 
 
 
 
 
 
 
 
 
 
 
Stabilisation (ml/min)  Ischaemia (ml/min)  Reperfusion (ml/min) 
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=10) 
 
15.0 
±1.5 
13.2 
±1.2 
13.2 
±1.5 
12.9 
±1.4 
6.9 
±0.5 
7.0 
±0.6 
7.1 
±0.8 
12.3 
±1.4 
11.7 
±1.5 
11.3 
±1.4 
10.9 
±1.4 
10.6 
±1.5 
9.0 
±1.6 
9.0 
±1.6 
IPC 
(n=6) 
 
17.2 
±0.9 
17.0* 
±0.9 
15.8 
±1.3 
15.2 
±1.3 
8.7 
±1.2 
8.2 
±1.2 
7.9 
±1.6 
12.0 
±1.7 
11.1 
±1.5 
11.0 
±1.5 
10.4 
±1.5 
9.2 
±1.7 
8.8 
±1.7 
8.7 
±1.6  
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Rate Pressure Product (x 103mmHg/min) 
 
 
 
Table 4.4.3 – Rate pressure product of the different groups at various time-points during the ischaemia/reperfusion protocol.   
 
 
 
 
 
 
  Stabilisation  
(x 10
3mmHg/min)   
Ischaemia  
(x 10
3mmHg/min)   
Reperfusion 
(x 10
3mmHg/min)   
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=10) 
 
28250 
±2880 
30075 
±2891 
30042 
±3102 
31658 
±2859 
13550 
±1600 
19175 
±2839 
20808 
±1213 
22831 
±2586 
23050 
±2816 
21363 
±2290 
19242 
±2406 
18713 
±2907 
18483 
±2949 
16217 
±3148 
IPC 
(n=6) 
 
32530 
±1800 
33780 
±1570 
29100 
±4355 
25956 
±4663 
12366 
±2157 
15500 
±1762 
15150 
±2471 
21075 
±2458 
20858 
±1183 
22030 
±1746 
20554 
±1003 
20808 
±1836 
17600 
±893 
17833 
±1757 Richard A Dixon  Results 
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4.4.1.2 Exclusions 
There were two hearts excluded from the IPC group, one because the infarct 
size  exceeded that set for  the exclusion criteria  (see section 3.3.2)  and one 
because the risk zone was below 40%.  One heart was excluded from the 
control group due to excessive ventricular fibrillation occurring in ischaemia and 
which could not be terminated. Richard A Dixon  Results 
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Figure 4.4.1 - Infarct data for the control and preconditioned (IPC) Wistar rat hearts.   Hearts were 
randomly assigned to either the control or preconditioned groups.  N is equal to 10 in the control group 
and 6 in the IPC group.  Values are presented as % infarct developed in the risk zone (IS/AAR %) and 
expressed as mean ±s.e.m. * = p<0.01 vs. control (students t-test).  
 
4.4.1.3 IPC protects the Wistar rat heart against I/R injury 
Figure  4.4.1  shows the data obtained for Wistar rat hearts which had  been 
subjected to a control (n=10) or IPC protocol (n=6).  The IPC protocol was found 
to decrease the infarct size by approximately 112% (%I/R 26.4±3.2%, IPC vs. 
56.1±2.8%, control; P=<0.01) thus, confirming that the IPC protocol leads to 
protection and that the model to be used for subsequent experiments is viable. 
 
 Richard A Dixon  Results 
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4.4.2  Leptin dose-response 
4.4.2.1 Animal and Haemodynamic Data 
Table 4.4.4 demonstrates that there were no significant differences between the 
groups  with respect to animal  weights,  ventricular volume or myocardial risk 
zone.  . Baseline data relating to cardiac function before ischaemia, as assessed 
by the rate pressure product (RPP) and coronary flow, were similar in the 
experimental groups (see table 4.4.5 & 4.4.6). During in ischaemia, however, 
coronary flow and RPP declined to a similar extent in all the groups.  Cardiac 
function and coronary flow increased upon reperfusion, which indicated that re-
flow was successful.  No significant differences were observed between groups 
with respect to coronary flow rate and RPP during reperfusion. 
Groups  Body 
Weight 
(g) 
Ventricular 
Volume 
(mm
3) 
Risk Zone 
(%) 
 
Control (n=7)  425±13  2130±84  53.24±3.47 
Sham (n=5)  415±22  2074±38  49.15±2.58 
Leptin (0.1nM) (n=7)  428±16  2076±84  51.50±3.46 
Leptin (1nM) (n=6)  398±18  1928±62  47.26±3.81 
Leptin (10nM) (n=9)  396±17  2079±79  50.31±1.88 
Leptin (30nM) (n=8)  446±18  1949±69  53.70±43.22 
Leptin (100nM) (n=8)  400±30  2023.8±66  51.41±2.87 
 
Table 4.4.4 - Characteristics of the animals in the treatment groups.  Data are present as mean±s.e.m.  
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Coronary flow rate (ml/ml) 
 
 
Table 4.4.5 – Coronary flow rates (ml/min) of each group at various time-points during the ischaemia/reperfusion protocol. 
 
 
Stabilisation (ml/min)  Ischaemia (ml/min)  Reperfusion (ml/min) 
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=7) 
 
16.4 
±1.0 
15.0 
±1.2 
14.3 
±1.1 
14.1 
±0.9 
7.0 
±0.6 
7.9 
±0.6 
7.1 
±0.8 
12.0 
±1.0 
11.5 
±1.0 
11.3 
±1.2 
10.7 
±1.0 
10.3 
±1.0 
9.0 
±0.8 
8.1 
±0.9 
Sham 
(n=5) 
 
15.0 
±1.0 
14.9 
±1.2 
13.7 
±1.0 
13.1 
±0.9 
11.1 
±0.9 
10.6 
±0.9 
11.1 
±1.1 
11.8 
±1.0 
11.0 
±0.9 
10.1 
±0.9 
9.7 
±1.1 
9.4 
±1.2 
8.4 
±0.9 
7.6 
±0.8 
0.1nM Leptin 
(n=7) 
 
16.3 
±0.9 
14.7 
±0.9 
13.7 
±0.7 
13.4 
±1.1 
8.0 
±0.6 
8.0 
±0.5 
7.7 
±0.6 
11.0 
±1.3 
10.9 
±1.5 
9.7 
±1.6 
8.9 
±1.4 
8.1 
±1.1 
7.4 
±0.9 
7.2 
±1.0 
1nM Leptin 
(n=6) 
 
17.2 
±1.0 
16.8 
±1.1 
15.0 
±1.1 
13.3 
±0.6 
8.3 
±0.4 
8.3 
±0.6 
8.2 
±0.5 
11.5 
±0.8 
10.0 
±0.7 
9.8 
±0.7 
9.5 
±0.5 
9.3 
±0.4 
7.8 
±0.5 
6.7 
±0.3 
10nM Leptin 
(n=9) 
 
16.3 
±0.9 
14.0 
±1.0 
14.0 
±1.0 
14.1 
±1.1 
7.9 
±0.6 
8.0 
±0.5 
8.1 
±0.6 
11.1 
±0.7 
10.0 
±0.9 
8.9 
±0.7 
8.3 
±0.8 
7.6 
±0.7 
7.0 
±0.6 
5.6 
±0.5 
30nM Leptin 
(n=8) 
 
15.6 
±0.8 
14.6 
±0.9 
13.4 
±0.9 
12.7 
±0.9 
7.0 
±0.6 
7.4 
±0.5 
7.6 
±0.6 
11.0 
±0.7 
10.0 
±0.8 
9.9 
±0.6 
8.9 
±0.7 
8.3 
±0.7 
7.1 
±0.5 
5.9 
±0.7 
100nM Leptin 
(n=8) 
 
15.6 
±1.1 
15.2 
±1.0 
12.8 
±0.8 
12.9 
±0.7 
7.1 
±0.4 
7.4 
±0.4 
6.9 
±0.5 
10.2 
±0.7 
10.3 
±0.9 
8.7 
±0.9 
7.7 
±1.0 
7.0 
±0.9 
6.7 
±1.0 
6.3 
±0.8  
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Rate Pressure Product (x 103mmHg/min) 
  
  Stabilisation  
(x 10
3mmHg/min)   
Ischaemia  
(x 10
3mmHg/min)   
Reperfusion 
(x 10
3mmHg/min)   
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=7) 
 
35821 
±3324 
35554 
±3427 
33475 
±3851 
35504 
±4523 
14900 
±2631 
20025 
±2974 
19507 
±2453 
20425 
±6928 
21050 
±3434 
22432 
±2552 
20236 
±1756 
19975 
±2870 
17811 
±2070 
12900 
±2422 
Sham 
(n=5) 
 
33950 
±1537 
32836 
±1257 
31814 
±1115 
28588 
±1626 
25979 
±2492 
26214 
±2368 
24511 
±2441 
22170 
±1996 
21725 
±2576 
19436 
±1988 
20150 
±1975 
15821 
±2512 
16571 
±1940 
14525 
±1401 
0.1nM Leptin 
(n=7) 
 
38107 
±3553 
36264 
±4044 
36350 
±3046 
34211 
±3638 
14929 
±1954 
19629 
±2292 
21107 
±1798 
20186 
±2838 
21742 
±2160 
17664 
±2435 
18650 
±2988 
19429 
±2831 
15593 
±2090 
15703 
±2119 
1nM Leptin 
(n=6) 
 
39379 
±4255 
41233 
±2640 
 
39017 
±3724 
36413 
±3766 
15750 
±2003 
25425 
±3284 
21388 
±2385 
24233 
±1913 
20070 
±2906 
19940 
±2827 
19929 
±2333 
17542 
±1987 
16838 
±1586 
18350 
±3427 
10nM Leptin 
(n=9) 
 
36671 
±2310 
33921 
±2450 
31839 
±2630 
30811 
±2140 
17500 
±1159 
19993 
±1502 
19114 
±1282 
18492 
±1657 
19067 
±2806 
18629 
±2943 
17557 
±2455 
16700 
±2487 
15546 
±1775 
13533 
±1248 
30nM Leptin 
(n=8) 
 
31900 
±2890 
31850 
±2474 
30579 
±2305 
32975 
±3596 
14100 
±2272 
19029 
±1486 
18107 
±1735 
20240 
±1154 
17386 
±1560 
18650 
±1165 
18661 
±1684 
15636 
±1534 
13986 
±1209 
11129 
±1620 
100nM Leptin 
(n=8) 
 
42800 
±2078 
36407 
±1545 
34293 
±2340 
33286 
±2309 
13325 
±1545 
18829 
±1553 
19736 
±1312 
21175 
±1980 
18914 
±1491 
18621 
±1045 
18750 
±1328 
19057 
±1728 
15993 
±1390 
14529 
±1402 
 
Table 4.4.6 - Rate Pressure Product (x 103mmHg/min) of each group at various time-points during the ischaemia/reperfusion protocol. Richard A Dixon  Results 
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4.4.2.2 Exclusions 
There were three  exclusions in total, two in the sham group because  flow 
dropped below 10ml/min during reperfusion and one in the 0.1nM leptin group  
because no reduction of flow was observed upon tightening the suture around 
the LAD to induce ischaemia.   
4.4.2.3 Effect of leptin administered at a range of concentrations on 
myocardial infarct size 
 
Figure 4.4.2 – The influence of varying concentrations of leptin on infarct size in the Wistar rat 
heart.  A dose-response study was performed using five different concentrations of leptin.  The results of 
the leptin treated hearts were compared with data obtained for control and sham hearts.  10nM, 30nM and 
100nM concentrations of leptin were found to induce significant cardioprotection. Data are presented as 
mean±s.e.m (* = p<0.05, ** = p<0.01 vs. control) (one-way ANOVA).      
 
 
   Richard A Dixon  Results 
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Leptin perfused at 10nM  (n=9), 30nM  (n=8)  and 100nM (n=8)  was found to 
produce marked reductions in infarct size in the Wistar rat heart when compared 
to control (n=7) (53±3.2% control vs. 32.4±3.9%, 36.9±5.0% and 34.1±5.6% for 
10nM, 30nM and 100nM leptin, respectively, p=<0.01, p=<0.05 and p=<0.01).  
By contrast, leptin at 0.1nM  (n=7)  and 1nM (n=6)  failed to induce 
cardioprotection.  In addition, the results obtained with sham hearts indicated 
that a degree of infarction occurred purely as a result of the excision and normal 
perfusion of the heart.  Thus, in sham operated hearts infarct size reached 
approximately 10±1.2% as compared to 53±3.2% in control hearts.     
4.5  Discussion 
4.5.1  Ischaemic preconditioning of the isolated perfused Wistar rat 
heart 
The present study demonstrates that the isolated perfused rat heart model 
performed within acceptable and well documented parameters (de Leiris et al. 
1984).  In addition, the infarct data obtained indicated that Wistar rat hearts can 
be preconditioned with sublethal episodes of ischaemia as  demonstrated by 
Murray et al 1986.  
4.5.2   Leptin concentration response studies 
Leptin-induced protection against I/R injury has been demonstrated previously in 
various  tissues including the murine heart (Erkasap et al. 2006; Smith et al. 
2006).  Previous studies, however,  have  not  investigated the relationship 
between infarct size and leptin concentration.  Therefore, prior to embarking on 
the studies which formed the primary goal of this thesis i.e. an investigation into 
the mechanisms involved in leptin-induced cardioprotection, experiments were Richard A Dixon  Results 
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performed in Wistar rat hearts to identify concentrations of leptin that induced 
optimal protection against myocardial I/R injury.  Protection was observed with 
concentrations of leptin of 10nM, 30nM and 100nM, with 10 nM leptin yielding 
optimal extents of infarct size reduction. These data are consistent with the 
results obtained previously in the murine heart (Smith et al. 2006)  and, 
consequently, for comparative purposes, 10nM leptin was chosen  as the 
standard concentration for all subsequent experiments. 
The fact that leptin concentrations lower than 10nM did not elicit responses 
could be interpreted as indicating that leptin produces an “all or nothing” effect 
with respect to infarct size limitation.  However, as suggested previously for the 
adipocytokine, apelin, it is equally possible that the effects were missed, that is, 
if leptin concentrations between 1 and 10nM had been tested, infarct size 
reductions might have been seen over this range (Simpkin et al. 2007).   
It should also be noted that human leptin and not rat leptin was used in the 
experiments presented in this chapter.  This leads to the obvious concern that 
differences between the structure of rat and human leptin may alter the strength 
of leptin signalling achieved in the rat heart.  However, studies have revealed 
that leptin shows a high interspecies conservation, for instance human are rat 
leptin are 84% identical (Ogawa et al. 1995).  Furthermore, human leptin has 
been demonstrated  to be active in rodents. In mice and rats, for example, 
recombinant human leptin has been shown to reduce food intake and body 
weight and in the latter this effect was demonstrated to occur primarily in the 
arcuate nucleus (Verploegen et al. 1997; Satoh et al. 1997).  Considering that Richard A Dixon  Results 
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human leptin has been used to protect the mouse heart and now the rat heart 
(see dose response above) it was deemed that the recombinant human form of 
the molecule was active and sufficient to use in subsequent studies.          Richard A Dixon  Results 
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CHAPTER 5 - LEPTIN-INDUCED CARDIOPROTECTION 
VIA THE RISK PATHWAY 
5.1  Introduction 
Protection against myocardial ischaemia reperfusion injury, as stimulated by a 
range of cytokines, is associated with activation of the RISK pathway, which 
incorporates the PI3K-Akt and p44/42 MAPK signalling cascades, and inhibition 
of the MPTP  (see section 1.2) (Hausenloy & Yellon 2007b).  Leptin has been 
shown to protect against ischaemia reperfusion injury in a variety of settings 
including the brain (Zhang et al. 2007), gut (Brzozowski et al. 2001) and kidney 
(Erkasap et al. 2006).  Stimulation of the leptin receptor, particularly the long, 
OB-Rb isoform, has been directly associated with activation of the JAK-STAT, 
PI3K-Akt and p44/42 MAPK signalling cascades (Ning et al. 2006; Zabeau et al. 
2003; Harvey & Ashford 2003), all of which have been linked to cardioprotection 
(Hausenloy & Yellon 2006).  In cardiomyocytes it has been shown that leptin 
mediates cellular proliferation in a PI3K and MAPK-dependent manner (Tajmir et 
al. 2004).  Furthermore, leptin has been reported to activate Akt  and  p44/42 
MAPK in an isolated murine model of ischaemia-reperfusion injury (Smith et al. 
2006). In this study protein kinase activation was only examined at one time-
point,  i.e.,  10min into the  reperfusion-phase.  However, the time at which 
maximal phosphorylation/activation,  in response to leptin or many other 
cardioprotectants,  occurs during the reperfusion-phase  is uncertain  and  can 
therefore result in kinase phosphorylation being missed completely.  Different 
laboratories have often sampled the myocardium for Western blot analysis at 
different time-points during reperfusion  and this may explain some of the Richard A Dixon  Results 
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discrepancies observed.  In addition, kinase phosphorylation may respond to a 
stimulus at different times.  Furthermore, it cannot be assumed that different 
drugs activate the survival kinases at the same time-points.  For example, in a 
study in the murine heart, in which apelin was used as the stimulant, the time-
point at which maximal  phosphorylation of  Akt and p44/42 MAPK  occurred 
during the reperfusion-phase  was found to vary (Smith et al. 2007b).  The 
strongest  phosphorylation  signal  was found to occur between 2.5 and 5min, 
perhaps suggesting that sampling at later times e.g. 10-15min could result in a 
weaker phosphorylation response.  Zhao and colleagues found that leptin-
induced Akt phosphorylation was weak in hepatocytes, therefore, this may also 
be the case for cardiomyocytes  (Zhao et al. 2000).  It  is,  however,  entirely 
possible that this weak signal may have resulted from sampling at the wrong 
time-point.   
5.2  Aim  
The aim of the  studies described in this chapter was  to  investigate  leptin-
induced Akt and p44/42 MAPK phosphorylation in the setting of cardioprotection 
in more detail than previously.  Western blotting was performed to investigate 
directly the phosphorylation of the RISK pathway kinases Akt (at both the 
Ser473 and Thr308 phosphorylation sites) and  p44/42 MAPK  in response to 
leptin.  These studies were performed using tissue collected from Langendorff 
perfused Wistar rat hearts, with samples being collected at different time-points 
during  the  reperfusion-phase  so as to allow a temporal  analysis of kinase 
activation.   Richard A Dixon  Results 
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5.3  Experimental Protocol & Materials 
5.3.1  Protein kinase inhibitors 
Hearts from Wistar rats were excised and perfused according to the method 
described in section 3.3.  All hearts were stabilised for 40min and subjected to 
35min ischaemia followed by 120min reperfusion.  Both inhibitors investigated, 
i.e. the PI3K inhibitor LY294002 (15μM), and the p44/42 MAPK inhibitor UO126 
(10μM),  were dissolved in dimethyl sulphoxide (DMSO; final concentration 
0.02%). The vehicle, DMSO, was also tested alone to establish if it influenced 
infarct size itself.  Perfusion with all drugs was commenced 5min prior to the 
reperfusion period to ensure that a sufficient concentration of drug reached the 
heart immediately upon reperfusion
2
 
.  Individual groups were  (original group 
sizes are shown in brackets): 
Control (n=5) – no drug, 40min stabilisation. 
DMSO (0.02%) (n=5) – Vehicle administered 5min prior to reperfusion. 
LY (15μM) (n=5) – Drug administered 5min prior to reperfusion. 
UO (10μM) (n=5) - Drug administered 5min prior to reperfusion. 
Leptin (10nM) (n=5) – administered 5min prior to ischaemia up until 30min into 
reperfusion. 
                                                 
2 It should be noted that the following experiments were conducted alongside those employing AG490 that 
are presented in section 6.4.1.3, therefore the same control, DMSO and leptin treated groups appear again.  
The data were presented in this way to maintain consistency and separate the RISK and JAK/STAT data 
between different chapters.  Furthermore, it should be noted that these experiments were completed within 
a four week period. Richard A Dixon  Results 
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Leptin (10nM) plus LY  –  LY and leptin co-administered 5min prior to 
reperfusion 
Leptin (10nM) plus UO  –  UO  and leptin co-administered 5min prior to 
reperfusion 
 Figure 5.3.1 – Protocol for investigating the effects of RISK pathway inhibitors on infarct size. 
 
5.3.2  Western blots 
Hearts from Wistar rats were excised and perfused according to the method 
described in section 3.3.  All hearts were stabilised for 40min and then subjected 
to 35min ischaemia.  Hearts were then reperfused for 2.5, 5, 10, 15 or 30min, at 
which time the portion of the myocardium at risk was collected for analysis by 
Western blotting (see section 3.5).  Individual groups were as follows (original 
group sizes are shown in brackets):- 
2.5min reperfusion control (n=5) 
2.5min reperfusion with leptin (10nM) treated (n=5) 
5min reperfusion control (n=6) 
Treatment with kinase inhibitors
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination Leptin and/or inhibitors
35min
Treatment with kinase inhibitors
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination Leptin and/or inhibitors
35minRichard A Dixon  Results 
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5min reperfusion with leptin (10nM) treated (n=6) 
10min reperfusion control (n=6) 
10min reperfusion with leptin (10nM) treated (n=6) 
15min reperfusion control (n=6) 
15min reperfusion with leptin (10nM) treated (n=6) 
30min reperfusion control (n=5) 
30min reperfusion with leptin (10nM) treated (n=6) 
Figure 5.3.2 –Protocol for the collection of samples for Western blot analysis.  (A) Control protocol; 
hearts subjected to 40min stabilisation 35min ischaemia and 2.5, 5, 10, 15 or 30min reperfusion.  (B) 
Leptin-treated protocol hearts subjected to 40min stabilisation, 35min ischaemia and 2.5, 5, 10, 15 or 
30min reperfusion.  Leptin treatment began 5min before the commencement of reperfusion and continued 
until the point at which the heart was snap-frozen. 
Western blotting control sample
Stabilisation Ischaemia Reperfusion
40min 35min x min Sample collection
Western blotting leptin-treated sample
Stabilisation Ischaemia
Reperfusion
40min 35min
x min
Sample collection
Leptin treatment
x + 5min
Western blotting control sample
Stabilisation Ischaemia Reperfusion
40min 35min x min Sample collection
Western blotting leptin-treated sample
Stabilisation Ischaemia
Reperfusion
40min 35min
x min
Sample collection
Leptin treatment
x + 5minRichard A Dixon  Results 
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5.4  Results 
5.4.1  Protein kinase inhibitors 
5.4.1.1 Animal and Haemodynamic Data 
Table 5.4.1 demonstrates that there are no significant differences between the 
groups with respect to animal weight, ventricular volume or risk zone volume.  
Baseline data relating to cardiac function before ischaemia, as assessed by the 
rate pressure product (RPP) and coronary flow, were similar in all the 
experimental groups (see tables 5.4.2 & 5.4.3).  During in ischaemia, however, 
coronary flow and RPP declined to a similar extent in all groups.  Cardiac 
function and coronary flow increased upon reperfusion, which indicated that re-
flow was successful.  No significant differences were observed between groups 
with respect to coronary flow rate and RPP during reperfusion. 
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Groups  Body Weight 
(g) 
Ventricular 
Volume 
(mm
3)
 
Risk Zone 
(%)
 
Control (n=5)  417.6±6.1  2130.1±332.1  53.7±4.7 
DMSO (n=5)  390.0±28.0  2446.1±445.2  51.1±5.1 
LY (n=5)  379.8±22.7  2156.1±472.6  50.2±3.5 
UO (n=5)  415.0±17.6  2630.1±454.1  52.6±3.5 
Leptin (10nM) 
(n=10) 
385.2±11.5  2211.5±448.1  50.2±5.3 
Leptin + LY(n=5)  380.5±26.0  2608.1±344.2  49.89±1.9 
Leptin + 
UO(n=5) 
408±9.7  2578.0±362.1  50.0±1.4 
 
Table 5.4.1 – Table showing the characteristics of the animals in the different treatment groups. 
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Coronary Flow Rate (ml/min)   
 
 
Stabilisation (ml/min)  Ischaemia (ml/min)  Reperfusion (ml/min) 
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control  
(n=5) 
16.8 
±2.1 
 
16.0 
±2.1 
 
15.5 
±2.1 
 
15.2 
±2.1 
 
7.5 
±1.6 
 
8.3 
±1.6 
 
7.6 
±1.4 
 
13.7 
±0.9 
 
12.6 
±0.8 
 
12.3 
±0.9 
 
11.8 
±0.6 
 
11.2 
±0.7 
 
10.0 
±1.2 
 
9.5 
±1.1 
 
DMSO  
(n=5) 
15.5 
±1.6 
 
14.3 
±1.7 
 
13.0 
±1.4 
 
13.0 
±1.8 
 
7.0 
±1.1 
 
7.5 
±0.9 
 
7.1 
±1.0 
 
12.8 
±1.7 
 
12.7 
±1.3 
 
11.0 
±1.3 
 
10.0 
±0.9 
 
9.3 
±0.9 
 
7.8 
±0.6 
 
6.8 
±0.9 
 
LY 
(n=5) 
13.0 
±1.7 
 
12.6 
±1.3 
 
12.2 
±1.0 
 
12.2 
±1.0 
 
6.4 
±0.7 
 
6.5 
±0.9 
 
6.2 
±0.7 
 
11.2 
±0.9 
 
10.8 
±1.4 
 
9.3 
±0.6 
 
7.8 
±0.7 
 
6.8 
±0.7 
 
6.0 
±0.5 
 
5.4 
±0.5 
 
UO 
(n=5) 
14.6 
±1.0 
13.8 
±1.0 
 
12.6 
±1.2 
 
12.2 
±1.3 
 
6.7 
±0.9 
 
7.0 
±0.8 
 
7.0 
±0.8 
16.1 
±2.0 
15.8 
±2.5 
13.4 
±1.7 
11.2 
±1.4 
9.6 
±1.2 
8.0 
±1.5 
7.0 
±1.3 
Leptin 
(n=10) 
16.5 
±0.9 
 
15.5 
±1.0 
14.3 
±1.4 
13.8 
±1.5 
7.6 
±0.8 
7.5 
±0.9 
7.4 
±0.9 
12.0 
±2.7 
12.3 
±2.8 
11.0 
±2.7 
10.5 
±2.5 
10.4 
±2.6 
9.8 
±2.8 
9.0 
±2.7 
Leptin + LY 
(n=5) 
13.8 
±0.3 
 
13.4 
±0.7 
12.3 
±0.6 
10.8 
±0.8 
6.0 
±0.7 
5.5 
±0.5 
6.0 
±0.4 
10.0 
±0.8 
9.5 
±0.9 
9.3 
±0.9 
7.8 
±0.9 
6.9 
±1.0 
6.6 
±0.8 
5.3 
±0.9 
Leptin + UO 
(n=5) 
17.0 
±1.3 
 
15.8 
±1.2 
14.8 
±1.3 
14.1 
±1.5 
7.6 
±0.7 
8.3 
±1.1 
7.6 
±1.0 
16.0 
±1.9 
15.6 
±2.0 
13.6 
±2.0 
11.6 
±2.0 
9.6 
±1.5 
8.2 
±1.2 
8.0 
±1.5 
Table 5.4.2 – Coronary flow rate (ml/min) of each group at various time-points during the ischaemia/reperfusion protocol. 
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Rate Pressure Product (x 103mmHg/min) 
 
Table 5.4.3 - Rate Pressure Product (x 103mmHg/min) of each group at various time-points during the ischaemia/reperfusion protocol. 
 
  Stabilisation  
(x 10
3mmHg/min)   
Ischaemia  
(x 10
3mmHg/min)   
Reperfusion 
(x 10
3mmHg/min)   
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=5) 
33717 
±6529 
 
28958 
±4214 
 
30067 
±3147 
 
30820 
±4097 
 
9457 
±2154 
 
15583 
±2384 
 
15567 
±2536 
 
22433 
±3015 
 
19540 
±2163 
 
19883 
±2072 
 
20233 
±2791 
 
17833 
±2451 
 
18733 
±2376 
 
17125 
±1947 
 
DMSO 
(n=5) 
31650 
±5204 
 
31238 
±6530 
 
31719 
±4180 
 
30750 
±4493 
 
19188 
±11661 
 
17395 
±6965 
 
20788 
±3983 
 
22933 
±6769 
 
27800 
±3646 
 
22581 
±4550 
 
20588 
±3580 
 
18375 
±2392 
 
13725 
±4918 
 
15400 
±2459 
 
LY 
(n=5) 
29470 
±5834 
 
33090 
±6300 
 
28950 
±4102 
 
26260 
±4723 
 
14660 
±3818 
 
19425 
±5413 
 
21563 
±3033 
 
14500 
±6154 
 
14875 
±3127 
 
13775 
±2592 
 
15390 
±2335 
 
16420 
±1620 
 
11840 
±2124 
 
10400 
±3107 
 
UO 
(n=5) 
26680 
±3510 
 
26860 
±3487 
 
25430 
±3314 
 
25190 
±2625 
 
6760 
±1356 
 
14065 
±1824 
 
14700 
±1813 
 
22940 
±4079 
 
20160 
±3835 
 
23288 
±2234 
 
18630 
±1954 
 
16350 
±2559 
 
12840 
±1664 
 
10725 
±1289 
 
Leptin 
(n=10) 
38167 
±5868 
 
35250 
±3568 
 
33138 
±3110 
 
29158 
±1304 
 
11333 
±1202 
 
18100 
±2261 
 
15300 
±1060 
 
21013 
±1765 
 
22617 
±1433 
 
22369 
±2118 
 
21725 
±1996 
 
19825 
±2193 
 
19400 
±3439 
 
17500 
±3156 
 
Leptin + LY 
(n=5) 
34438 
±5142 
 
34350 
±5249 
 
31188 
±4634 
 
25883 
±3033 
 
12500 
±1127 
 
16200 
±2700 
 
17600 
±1955 
 
20283 
±1408 
 
19000 
±2003 
 
17850 
±2285 
 
20850 
±2573 
 
19250 
±2341 
 
17325 
±1841 
 
14350 
±2656 
 
Leptin + UO 
(n=5) 
30450 
±3669 
 
29030 
±2828 
 
31720 
±3035 
 
32145 
±3824 
 
14930 
±1885 
 
18160 
±5486 
 
21875 
±2444 
 
29250 
±2605 
 
25472 
±2428 
 
23740 
±3580 
 
20546 
±2595 
 
18520 
±2675 
 
14275 
±3372 
 
11760 
±2951 
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5.4.1.2 Exclusions 
One heart was excluded from the leptin group because of excessive ventricular 
fibrillation during the reperfusion-phase.  One heart was excluded from the 
control group because of poor function, i.e. it did not achieve the required RPP.  
Two hearts were excluded from the DMSO group, one because of low coronary 
flow and one because of poor function.  Finally, one heart was excluded from 
the leptin + LY group because of low coronary flow.  
5.4.1.3 Effect of protein kinase inhibitors LY294002 and UO126 on 
leptin-induced cardioprotection 
 
 
Figure 5.4.1 – Cardioprotection afforded by leptin (10nM) at reperfusion is abrogated by the 
protein kinase inhibitors LY (15μM) and UO (10μM) given at reperfusion. ** = p<0.01 vs. control 
(one-way ANOVA). 
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As seen with the concentration response study, 10nM (n=10) leptin significantly 
reduced infarct size as compared to control (n=5) (29.86±3.2% vs. 60.05±7.4%, 
**=p<0.01) (Figure 5.4.1).  The PI3K inhibitor, LY294002, significantly abolished 
the infarct-limiting effects of leptin when given in combination with leptin (n=5) 
(59.06±5.7% vs.  60.05±7.4%, LY plus leptin and control, respectively).  By 
contrast  LY294002  (n=5)  did not confer protection when administered alone 
(60.16±9.0% vs. 60.05±7.4%, LY and control, respectively).  UO126 (n=5), a 
p44/42 MAPK inhibitor, did not have any effect on IS when administered alone 
(57.38±7.7% vs. 60.05±7.4%, UO and control respectively).  When administered 
with leptin, however, UO126 (n=5)  abrogated  leptin-induced  cardioprotection 
(29.86±3.2%, leptin vs. 57.19±6.08%, leptin + UO).  DMSO (n=5), the inhibitor 
solvent, did not influence infarct size  significantly  when administered alone 
(55.04±2.3%, DMSO vs. 60.05±7.4%, control).   
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5.4.2  Western blotting 
5.4.2.1 Body weight of the animals in the different treatment groups 
 
Groups  Body Weight (g) 
2.5min Control (n=4)  385±15 
2.5min leptin (n=4)  397±12 
5min Control (n=6)  425.5±14 
5min leptin (n=6)  412.8±26 
10min Control (n=6)  419.6±21 
10min leptin (n=6)  387.6±24 
15min Control (n=5)  390.5±15 
15min leptin (n=6)  395.5±8 
30min Control (n=6)  405.5±20 
30min leptin (n=6)  416.9±17 
 
 
Table 5.4.4 - Table showing the characteristics of the animals in the different treatment groups 
included in the Western blot study. 
 
5.4.2.2 Exclusions 
One heart was excluded from the 5min control group due to excessive 
ventricular fibrillation  (VF).  One heart was excluded from the 10min leptin Richard A Dixon  Results 
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treated group due to poor function, i.e. did not achieve the required RPP.  Two 
hearts were excluded from the 15min control group, one due to poor flow and 
one due to excessive VF.  One heart was excluded from the 30min leptin group 
because of poor function.  
5.4.2.3 Leptin stimulates Akt/Serine-473 phosphorylation in hearts 
subjected to I/R injury 
 
 
 
 
Figure 5.4.2 – Akt/serine-473 phosphorylation in the presence and absence of leptin at different 
time-points during reperfusion.  Total and phosphorylated Akt/serine-473 were determined in extracts 
derived from rat hearts subjected to I/R under control conditions or in the presence of leptin (10nM). Data 
are presented as the ratio of phosphorylated to total Akt/serine-473 relative densitometry (RD) values 
(AU) normalised to control (untreated; 100%) and expressed as mean±s.e.m. (*=P<0.05 vs. control; n=4-
6) (one-way ANOVA). 
   
Maximal leptin-induced phosphorylation of Akt/Serine-473 did not occur until 
15min into the reperfusion-phase (control n=6, leptin n=6), when a statistically 
significant (p<0.05), 140% increase  was observed (Figure  5.4.2).  Non-
significant increases in Akt/Serine-473 phosphorylation of 88% and 111% were, 
however, also seen at 5 min (control n=6, leptin n=6) and 10 min (control n=5, 
leptin n=5)  reperfusion, respectively (Figure  5.4.2).  
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5.4.3 - Western blots showing phosphorylated Akt/Ser-473 and total Akt levels in tissue taken from Wistar hearts treated with and 
without leptin (10nM) at various time-points during reperfusion.Richard A Dixon  Results 
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5.4.2.4 Leptin stimulates Akt/Threonine-308 phosphorylation in hearts 
subjected to I/R injury 
 
 
 
 
Figure  5.4.4  –  Effect of  10nM  leptin on the  phosphorylation of Akt/threonine-308.  Total and 
phosphorylated Akt/threonine-308 were determined in extracts derived from rat hearts subjected to I/R 
under control conditions or in the presence of leptin (10nM).  Data are presented as the ratio of 
phosphorylated to total Akt/threonine-308 relative densitometry (RD) values (AU) normalised to control 
(untreated; 100%) and expressed as mean±s.e.m. (*=P<0.05 vs. control; n=4-6) (one-way ANOVA). 
 
 
A significant 178% increase (p=<0.05) in the phosphorylation of Akt/Thr308, was 
observed at 10min (n=4) into the reperfusion-phase.  At the 5 (n=6), 15 (n=6) 
and 30min  (n=6)  time-points  there were no significant changes in the 
phosphorylation status of the kinase. 
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5.4.5 - Western blots showing phosphorylated Akt/Thr-308 and total Akt levels in tissue taken from Wistar hearts treated with and 
without leptin (10nM) at various time-points during reperfusion. 
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5.4.2.5 Leptin stimulates p44/42 MAPK phosphorylation in hearts 
subjected to I/R injury 
 
 
Figure 5.4.6 - Effect of leptin (10nM) on (A) p44 and (B) p42 phosphorylation in Wistar rat hearts 
subjected to ischaemia–reperfusion.  Hearts were stabilised for 40min and then subjected to 35min 
ischaemia  followed by 2.5,5, 10, 15 or 30min  reperfusion.  Data are presented as the ratio of 
phosphorylated  to total p44 or p42 relative densitometry (RD) values (AU) normalised to control 
(untreated; 100%) and expressed as mean±s.e.m. (*=P<0.05, **=P<0.01 vs. control; n=4-6) (one-way 
ANOVA). 
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 5.4.7 - Western blots showing phosphorylated p44/42 MAPK and total MAPK levels in tissue taken from Wistar hearts treated with and 
without leptin (10nM) at various time-points during reperfusion. 
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Time  course experiments  revealed that  leptin-induced  significant 
phosphorylation of p44 at 5 (n=6) and 15min (n=6) reperfusion, 152% (p=<0.01) 
and 294%  (p=<0.05)  increases,  respectively, being observed.  Similarly, the 
phosphorylation of p42 was found to be increased by 248% and 342% at 5 (n=6) 
and 15min  (n=6),  respectively (p=<0.01) (Figure  5.4.4).  At 2.5min into the 
reperfusion-phase  there appeared  to be an increase in p44 and p42 
phosphorylation, however, upon statistical analysis these data were found to be 
non-significant.  At 10 (n=6)  and 30min (n=6)  significant changes in the 
phosphorylation status of p44 or p42 were not detected.  
5.5  Discussion 
It  has been  established in a variety of settings that leptin possesses  the 
signalling capacity to stimulate p44/42 MAPK phosphorylation.  Leptin has, for 
example, been shown to be protective in a cellular model of Parkinson’s disease  
via a p44/42 MAPK-dependent mechanism (Weng et al. 2007).  Leptin-induced 
phosphorylation of Akt occurs via activation of JAK2 and consequent activation 
of insulin receptor substrate (IRS), which in turn activates the PI3K-Akt cascade 
(Fruhbeck 2006).  This mechanism is evident in microglia, in which leptin-
induced interleukin-6 production can be inhibited by transfection with insulin 
receptor substrate (IRS)-1 small-interference RNA or by the administration of the 
PI3K inhibitor, LY294002.   
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5.5.1  Leptin-induced cardioprotection is abolished by the RISK 
pathway inhibitors LY294002 and UO126 
 
It was hypothesised that leptin-induced infarct size limitation in the Wistar rat 
heart relies on the activation of Akt and p44/42 MAPK.  This hypothesis was 
tested by the administration of LY294002, a PI3K inhibitor, and UO216, a p44/42 
MAPK inhibitor to hearts subjected to I/R injury in the presence and absence of 
leptin.  Indeed, leptin-induced cardioprotection was found to be abolished by the 
addition of these kinase inhibitors.  Having established that activation of these 
kinases is crucial to the mechanism underlying leptin-induced cardioprotection 
the decision was made to investigate the temporal nature of kinase 
phosphorylation/activation in relation to leptin–induced protection. 
5.5.2  Leptin-induced phosphorylation of Akt/Serine-473 and 
Akt/Threonine-308 in response to leptin 
It has been shown that the  treatment  of cardiac myocytes with leptin is 
associated with increased long-chain fatty acid (LCFA) uptake, together  with 
increased phosphorylation of both Akt/Ser-473 and Akt/Thr-308 (Palanivel et al. 
2006).  The role of Akt in leptin-induced cardioprotection, however, has not been 
resolved.  Conflicting data concerning the involvement of Akt in leptin-induced 
cardioprotection has been obtained (Smith et al. 2006).  Thus, despite  data 
being obtained indicating that leptin-induced cardioprotection was  blocked by 
LY294002, a PI3K inhibitor, significant Akt phosphorylation was not observed in 
response to leptin (Smith et al. 2006).  Nevertheless, this may have been a 
reflection of the timing of sample collection, together with the limited number of 
samples examined. Richard A Dixon  Results 
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In the present study, Western blotting revealed that Akt/Ser-473 phosphorylation 
was significantly increased at 15min into reperfusion.  Nevertheless, increases 
in phosphorylation, although non-significant, were also observed at the 5 and 
10min time-points.  By contrast the maximal phosphorylation signal for Akt/Thr-
308 was observed at 10min into the reperfusion-phase.  Phosphorylation of Akt 
at both the Ser-473 and Thr-308 sites is required for its full activation (Chan et 
al. 1999).  In cardiomyocytes subjected to simulated I/R injury both of these sites 
are phosphorylated and remain phosphorylated for over an hour into the 
reperfusion-phase (Mockridge et al. 2000a).  However, it is well known that the 
stimulus provided by I/R alone is not sufficient to confer cardioprotection, and 
therefore further phosphorylation/activation of Akt by either a pharmacological 
agent or a mechanical stimulus, such as IPC, is required to produce infarct-
limitation. In the present study it was shown that both the Ser-473 and Thr-308 
sites are phosphorylated to a significant degree, at 15min reperfusion, in hearts 
treated with leptin as compared to control hearts.  The differences with respect 
to the times at which maximal phosphorylation of the Ser-473 and Thr-308 sites 
occurred may reflect the mechanism involved in Akt activation, i.e. it is believed 
that the Thr-308 site is phosphorylated before the Ser-473 site.  Alternatively, 
maximal phosphorylation of both sites may occur at a time-point between 10 and 
15min, and therefore, has been missed in the tissue samples that were 
analysed.  Nevertheless, these data were consistent with those found by (Smith 
et al. 2006), i.e. leptin-induced cardioprotection could be abolished with a PI3K 
inhibitor and significant  phosphorylation  of the Ser-473 site was observed at   
15min into the reperfusion-phase as opposed to the earlier time-points assayed.   Richard A Dixon  Results 
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At 30min reperfusion Akt/serine-473 phosphorylation appeared to be depressed, 
although this change was not statistically significant.  This may be as a result of 
a negative feedback mechanism  employed to prevent excessive kinase 
phosphorylation/activation.  For example, full activation of Akt may, directly or 
indirectly, activate a phosphatase which dephosphorylates Akt at one or both of 
its sites, such as PH domain leucine-rich repeat protein phosphatase (PHLPP) 
(Gao et al. 2005).  Alternatively,  fully activated  Akt may be  degraded  via 
ubiquitin  mediated proteolysis  (Chain et al. 1995).  This type  of mechanism 
operates with respect to the negative regulation of Lyn protein-tyrosine kinase 
by c-Cbl ubiquitin protein ligase in mast cells (Kyo et al. 2003) and works by 
labelling aberrant or inappropriately active proteins which then undergo 
disassembly by proteosomal degradation.    
5.5.3  Phosphorylation of p44/42 MAPK in response to leptin-
treatment 
Significant increases in the phosphorylation of both p44 and p42 MAPK were 
observed at 5 and 15min into the reperfusion-phase  or  leptin  treatment  as 
compared to control, a result that is consistent with previously obtained data 
(Smith et al. 2006).  At 2.5min into the reperfusion-phase there appeared to be a 
leptin-stimulated increase in  p44/42 MAPK  phosphorylation, however,  these 
changes were not statistically significant.   
Although leptin increased  p44/42  MAPK phosphorylation at 5 and 15min 
reperfusion  as compared to control,  at 10min no  significant  change  in 
phosphorylation was observed between control and leptin treated samples.    Richard A Dixon  Results 
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This data may have occurred due to an error in sampling at this particular time-
point.  Alternatively, the phosphorylation response profile of control and leptin 
treated hearts that have undergone a I/R protocol may yield similar results at 
this specific time, i.e. 10min.  In addition, before discounting the data as 
erroneous it should be noted that several protein  kinases show a biphasic 
phosphorylation response profile.  In human embryonic kidney 293 (HEK293), 
for example,  MAPK has been shown to respond  in  such a manner.  The 
investigators performed a dose-response study of MAPK phosphorylation  as 
stimulated  by cadmium and mercury, the results showed two peaks of 
phosphorylation  similar to the result yielded above (Hao et al. 2009).   
Phosphorylation of p44 and p42 MAPK appears to be depressed at 30min when 
treated with leptin as compared to control, a similar result to that obtained for 
Akt.  This may be due to a negative feedback mechanism, similar to that 
described above (section 5.5.2).  A similar phenomenon is observed when 
treating macrophages with leptin, i.e. MAPK phosphorylation is decreased after 
a certain concentration threshold of leptin is reached   (O'Rourke & Shepherd 
2002). 
5.5.4  Limitations 
5.5.4.1 Western blotting 
The technique of Western blotting is associated with limitations, especially with 
regard  to the analysis of RISK kinase activation/phosphorylation.  Each blot 
corresponds to a sample of a heart  that has been  subjected to I/R injury.   
Sometimes large variations in the relative density values were obtained, which Richard A Dixon  Results 
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may account for some of the non-significant increases in kinase phosphorylation 
observed.  Increasing the number of samples that were analysed may have 
helped to reduce this variability. 
Furthermore,  Western  blotting samples are taken from the risk  zone  of the 
myocardium subjected to I/R injury (see section 3.3).  This method does not 
compensate for the differing ratio of infarct to viable heart tissue that may result 
when hearts are treated with a cardioprotectant as compared to control.   
Therefore, phosphorylation increases  detected in heart samples  that were 
treated pharmacologically may be the result of sampling a greater amount of 
viable tissue in a protected heart.  Separating viable tissue from infarcted tissue 
in each heart sample would help to ensure that equal amounts of viable tissue 
from hearts treated with and without leptin were assayed.      
5.5.4.2 Protein kinase inhibitors 
Data obtained in which PI3K and p44/42 MAPK were blocked in this study relies 
on the assumed specificity of the protein kinase inhibitors LY294002 and 
UO126, respectively.  The concentrations used in this study were the same as 
those used previously  in this laboratory  (Smith et al. 2006)  and have been 
demonstrated to be within the range known to produce inhibition of these 
kinases (Vlahos et al. 1994).  It should be noted that as well as inhibiting PI3K, 
LY294002 has been found to block the activation of the following kinases CK2, 
mTOR, PLK-1, PIM1, PIM3, HIPK2 and GSK3β (Bain et al. 2007).  It is therefore 
possible that one or more of these kinases may be involved in the mechanism of 
leptin-induced cardioprotection and therefore data collected using LY294002 as Richard A Dixon  Results 
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a PI3K antagonist may overestimate the role of PI3K-Akt in this process.  Future 
studies should employ either a more specific PI3K antagonist, if one is available 
or use another antagonist in simultaneous experiments with LY294002 to help 
elucidate the role of PI3K phosphorylation in leptin-induced cardioprotection.    Richard A Dixon  Results 
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CHAPTER 6 - LEPTIN-INDUCED CARDIOPROTECTION 
VIA THE JAK-STAT PATHWAY 
6.1  Introduction 
The JAK/STAT pathway, described in section  1.3.4.2, plays a pivotal role in 
modulating the expression of stress-responsive genes by transducing signals 
received at the cell membrane to the nucleus (Darnell, Jr. 1997).  JAK1 and 
JAK2 are expressed in cardiomyocytes (Pan et al. 1999), along with all seven 
isoforms of STAT (Xuan et al. 2001).  With regard to cardioprotection, there is a 
growing body of evidence indicating that the JAK-STAT pathway plays a role in 
I/R injury.  For example, it has been demonstrated in an in vivo rat model of I/R 
injury that I/R injury itself stimulates the phosphorylation of STAT1 and STAT3 
(McCormick et al. 2006).  It appears, however, that STAT1 and STAT3 play very 
different roles in the setting of myocardial injury.  Various studies have 
suggested that in the heart STAT3 acts to stimulate survival mechanisms, whilst 
activation of STAT1 appears to promote apoptotic cell death (Stephanou 2004).  
Thus, using an in vivo model of I/R injury hearts from rats with a cardiac-specific 
overexpression of constitutively active STAT3 were found to be less susceptible 
to infarction than control animals. (Osugi et al. 2002; Oshima et al. 2005).  It 
appears that STAT3 may also play an important role in IPost. Goodman et al 
demonstrated that IPost-enhanced functional recovery, which was associated 
with increases in STAT3 and Akt phosphorylation, was blocked in hearts from 
mice with a cardiac-specific STAT3 knockout (Goodman et al, 2008). Functional 
recovery and the increases in STAT3 and Akt phosphorylation seen in wild-type 
animals,  subjected to IPost  were  abrogated by the JAK2 inhibitor, AG490 Richard A Dixon  Results 
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(Goodman et al, 2008).  The downstream mechanisms activated by STAT3 are 
not yet well characterised, although a link between STAT3 phosphorylation and 
inactivation of Bax and caspase 3 (see section 1.2.3.2) has been demonstrated 
(Negoro et al. 2000). 
Leptin requires activation of JAK for downstream signalling (see section 1.6.5), 
however,  the role of STAT in leptin-induced protection is less well known 
(Fruhbeck 2006).  In a study from this laboratory involving the isolated perfused 
mouse heart,  STAT3 phosphorylation was not found to be increased when 
hearts were treated with leptin as compared to control (Smith et al. 2006).  It 
was, however, suggested that the maximal signal in response to leptin may have 
been missed, occurring earlier than the 10min reperfusion time-point at which 
samples were collected.  
6.2  Aim  
The aim of the studies described in this chapter was to investigate in more detail 
the role played by JAK/STAT signalling in leptin-induced cardioprotection, using 
the isolated perfused Wistar rat heart. 
6.3  Experimental Protocol & Materials 
6.3.1  JAK2 inhibition 
 
Hearts from Wistar rats were excised and perfused according to the method 
described in section 3.3.  All hearts were stabilised for 40min, subjected to 
35min regional ischaemia and then reperfused for two hours.  AG490 (5μM, final 
concentration), the JAK2 inhibitor, was dissolved in dimethyl sulphoxide (DMSO, Richard A Dixon  Results 
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final concentration 0.02%). The vehicle, DMSO, was also tested alone to 
establish if it influenced infarct size  by itself.  Drug containing buffers  were 
added to the perfusion apparatus 5min before reperfusion was commenced to 
ensure that the concentration of drug reaching the heart upon reperfusion had 
achieved the required level.  AG490 was administered by itself or with leptin 
(10nM).  Individual treatment groups were as follows (original group sizes are 
shown in brackets):- 
Control (n=6) – no drug 
DMSO (0.02%) (n=6) – drug administered for 5min prior to reperfusion. 
AG490 (5μM) (n=6) – administered 5min prior to reperfusion and up until 15min 
into the reperfusion-phase. 
Leptin (10nM) (n=6) – administered 5min prior to ischaemia and up until 30min 
into reperfusion. 
Leptin (10nM) with AG490  (10μM)  (n=6)  –  leptin administered with AG490 
5min prior to reperfusion.  AG490 was stopped  15min into the reperfusion-
phase.  Leptin was given until 30min into the reperfusion-phase. Richard A Dixon  Results 
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 Figure 6.3.1 - Protocol for investigating the effects of AG490, a JAK2 inhibitor, on leptin-induced 
infarct size reduction. 
 
6.3.2  Western blotting 
6.3.2.1 Leptin-induced STAT3 phosphorylation time-course 
Hearts from Wistar rats were excised and perfused according to the method 
described in section 3.3.  All hearts were stabilised for 40min and then subjected 
to 35min  regional  ischaemia  via coronary artery ligation (see section 3.3).  
Hearts were then reperfused for 2.5, 5, 10, 15 or 30min in the presence and 
absence of leptin (10nM), at which time the region of the myocardium at risk was 
collected, snap frozen and stored for subsequent analysis by Western blotting 
(see section 3.5).  Individual treatment groups were as follows (original group 
sizes are shown in brackets):- 
Control (n=5) - 2.5min reperfusion 
Leptin (10nM) (n=5) - 2.5min reperfusion 
Control (n=6) - 5min reperfusion 
Leptin (10nM) (n=6) - 5min reperfusion 
Treatment with JAK2 inhibitor (AG490)
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination Leptin and or AG490 treatment
35min
Treatment with JAK2 inhibitor (AG490)
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination Leptin and or AG490 treatment
35minRichard A Dixon  Results 
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Control (n=6) - 10min reperfusion 
Leptin (10nM) (n=6) - 10min reperfusion 
Control (n=6) - 15min reperfusion 
Leptin (10nM) (n=6) - 15min reperfusion 
Control (n=5) - 30min reperfusion 
Leptin (10nM) (n=6) - 30min reperfusion 
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Figure  6.3.2  –Protocol for the collection of samples for STAT3 determination by Western  blot 
analysis.  (A) Control protocol in which hearts were subjected to 40min stabilisation, 35min ischaemia 
and 2.5, 5, 10, 15 or 30min reperfusion.  (B) Leptin treatment protocol in which hearts were subjected to 
40min stabilisation, 35min ischaemia and 2.5, 5, 10, 15 or 30min reperfusion in the presence of leptin 
(10μM).  Leptin treatment was begun 5min before the commencement of reperfusion and continued until 
the point at which the heart was snap-frozen. 
  
6.3.2.2 Inhibition of leptin-induced STAT3 phosphorylation by AG490 
Hearts from Wistar rats were excised and perfused according to the method 
described in section 3.3.  All hearts were stabilised for 40min and then subjected 
to 35min ischaemia.  Hearts were then reperfused with leptin, AG490 or leptin 
plus AG490.  AG490 (5μM) was dissolved in dimethyl sulphoxide (DMSO; final 
concentration 0.02%).  Hearts were reperfused for a total of 2.5min, at which 
time the area of the myocardium at risk was collected, snap frozen and stored at Richard A Dixon  Results 
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-80°C for subsequent analysis by Western blotting (see section 3.5).  Individual 
groups were as follows (original group sizes are shown in brackets): 
Control (n=6)  
Leptin (10nM) (n=6) 
Leptin (10nM) plus AG490 (5μM) (n=6) 
AG490 (5μM) (n=6) 
Figure 6.3.3 – Protocol for investigating the influence of the JAK2 inhibitor, AG490 (5μM), on 
STAT3 phosphorylation in the presence and absence of leptin (10nM), as determined by Western 
blot analysis. 
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6.4  Results 
6.4.1  Influence of AG490 on leptin-induced cardioprotection 
6.4.1.1 Animal data and haemodynamic data 
Table 6.4.1 demonstrates that there are no significant differences between the 
groups with regard to body weight, ventricular volume or risk zone.  Baseline 
data relating to cardiac function before ischaemia, as assessed by the rate 
pressure product (RPP) and coronary flow, were similar in all the experimental 
groups (see tables 6.4.1 & 6.4.2 ).  During in ischaemia, however, coronary flow 
and RPP declined to a similar extent in all  groups.  Cardiac function and 
coronary flow increased upon reperfusion, which indicated that re-flow was 
successful.  No significant differences were observed between groups with 
respect to coronary flow rate and RPP during reperfusion. 
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Groups  Body Weight 
(g) 
Ventricular 
Volume 
(mm
3)
 
Risk Zone 
(%)
 
Control (n=5)  417.6±6.1  2130.1±332.1  53.7±4.7 
DMSO (n=5)  390.0±28.0  2446.1±445.2  51.1±5.1 
AG490 (n=5)  415.8±23.0  2811.5±323.3  52.8±2.7 
Leptin (n=10)  385.2±11.5  2211.5±448.1  50.2±5.3 
Leptin + AG490 
(n=4) 
380.0±26.0  2878.0±362.1  47.7±3.2 
Table  6.4.1  –  Characteristics of the animals in the treatment groups.  Data are expressed as 
mean±s.e.m. 
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Coronary flow rate (min/ml) 
 
Table 6.4.2 – Coronary flow rate (ml/min) of each group at various time-points during the ischaemia/reperfusion protocol. 
 
 
 
 
 
 
Stabilisation (ml/min)  Ischaemia (ml/min)  Reperfusion (ml/min) 
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=5) 
16.8 
±2.1 
 
16.0 
±2.1 
 
15.5 
±2.1 
 
15.2 
±2.1 
 
7.5 
±1.6 
 
8.3 
±1.6 
 
7.6 
±1.4 
 
13.7 
±0.9 
 
12.6 
±0.8 
 
12.3 
±0.9 
 
11.8 
±0.6 
 
11.2 
±0.7 
 
10.0 
±1.2 
 
9.5 
±1.1 
 
DMSO 
(n=5) 
15.5 
±1.6 
 
14.3 
±1.7 
 
13.0 
±1.4 
 
13.0 
±1.8 
 
7.0 
±1.1 
 
7.5 
±0.9 
 
7.1 
±1.0 
 
12.8 
±1.7 
 
12.7 
±1.3 
 
11.0 
±1.3 
 
10.0 
±0.9 
 
9.3 
±0.9 
 
7.8 
±0.6 
 
6.8 
±0.9 
 
AG490 
(n=5) 
16.4 
±0.5 
12.6 
±0.7 
11.6 
±0.7 
11.2 
±0.7 
6.0 
±0.3 
6.4 
±0.8 
6.1 
±0.9 
13.8 
±0.8 
13.2 
±0.8 
12.6 
±1.0 
9.6 
±0.5 
8.8 
±0.5 
8.2 
±0.7 
7.7 
±0.7 
Leptin 
(n=10) 
16.5 
±0.9 
15.5 
±1.0 
14.3 
±1.4 
13.8 
±1.5 
7.6 
±0.8 
7.5 
±0.9 
7.4 
±0.9 
12.0 
±2.7 
12.3 
±2.8 
11.0 
±2.7 
10.5 
±2.5 
10.4 
±2.6 
9.8 
±2.8 
9.0 
±2.7 
Leptin+AG490 
(n=4) 
16.2 
±1.2 
15.5 
±1.3 
15.2 
±1.3 
14.5 
±1.1 
7.3 
±0.6 
7.2 
±0.7 
6.9 
±0.7 
15.6 
±2.2 
17.0 
±2.3 
15.3 
±1.8 
13.2 
±1.7 
11.7 
±1.7 
10.5 
±1.7 
10.6 
±2.0  
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Rate pressure product (x 103mmHg/min) 
 
  Stabilisation  
(x 10
3mmHg/min)   
Ischaemia  
(x 10
3mmHg/min)   
Reperfusion 
(x 10
3mmHg/min)   
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Control 
(n=5) 
33717 
±6529 
 
28958 
±4214 
 
30067 
±3147 
 
30820 
±4097 
 
9457 
±2154 
 
15583 
±2384 
 
15567 
±2536 
 
22433 
±3015 
 
19540 
±2163 
 
19883 
±2072 
 
20233 
±2791 
 
17833 
±2451 
 
18733 
±2376 
 
17125 
±1947 
 
DMSO 
(n=5) 
31650 
±5204 
 
31238 
±6530 
 
31719 
±4180 
 
30750 
±4493 
 
19188 
±11661 
 
17395 
±6965 
 
20788 
±3983 
 
22933 
±6769 
 
27800 
±3646 
 
22581 
±4550 
 
20588 
±3580 
 
18375 
±2392 
 
13725 
±4918 
 
15400 
±2459 
 
AG490 
(n=5) 
23750 
±2839 
 
24690 
±1501 
 
24630 
±1418 
 
24150 
±2211 
 
8016 
±2791 
14990 
±1999 
 
16470 
±1640 
 
21050 
±1750 
 
22180 
±2504 
 
23380 
±2261 
 
19540 
±1678 
 
18380 
±1146 
 
15105 
±1567 
 
14620 
±2614 
 
Leptin 
(n=5) 
38167 
±5868 
 
35250 
±3568 
 
33138 
±3110 
 
29158 
±1304 
 
11333 
±1202 
 
18100 
±2261 
 
15300 
±1060 
 
21013 
±1765 
 
22617 
±1433 
 
22369 
±2118 
 
21725 
±1996 
 
19825 
±2193 
 
19400 
±3439 
 
17500 
±3156 
 
Leptin+AG490 
(n=4) 
27925 
±3231 
 
29467 
±2479 
 
29267 
±2198 
 
30025 
±2478 
 
12000 
±702 
 
19640 
±2146 
 
18317 
±1761 
 
16960 
±3502 
 
21992 
±1700 
 
22910 
±937 
 
18950 
±1431 
 
16900 
±1125 
 
15783 
±1599 
 
14683 
±2078 
 
Table 6.4.3 - Rate Pressure Product (x 103mmHg/min) of each group at various time-points during the ischaemia/reperfusion protocol. Richard A Dixon  Results 
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6.4.1.2 Exclusions 
 
One heart was excluded from the control group because of poor function, i.e. it 
did not achieve the required RPP.  Two hearts were excluded from the DMSO 
group and AG490, one because of low coronary flow and one because of poor 
function.  Finally, one heart was excluded  from the AG490 + leptin group 
because the risk zone was too small. 
 
6.4.1.3 AG490 abolishes leptin-induced cardioprotection 
 
Figure  6.4.1  –  Abrogation of leptin-induced protection by AG490. Infarct size is presented  as a 
percentage of the risk zone (%I/R).  Isolated rat hearts were reperfused with or without leptin (10nM) in 
the presence or absence of AG490 (5μM). The data are presented as mean ± s.e.m (*p<0.05 vs. control; n 
= 4-10) (one-way ANOVA).   
 
 
In hearts treated with leptin (10nM) (n=10) a significant reduction in infarct size, 
as compared with vehicle-treated control hearts (n=5), was observed (control, 
60.05±7.41%  vs.  leptin-treated, 29.9±3.24%, p<0.05, n=4-10) (Figure  6.4.1). 
The cardioprotective effect of leptin was found to be completely blocked by the Richard A Dixon  Results 
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JAK2 inhibitor, AG490 (n=4) (Figure 6.4.1). It should be noted that no difference 
in infarct size was seen between control hearts and hearts treated with DMSO 
alone (n=5) (0.02% final concentration); DMSO was used to dissolve AG490 
(Figure 6.4.1). 
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6.4.2  Leptin-induced STAT3 phosphorylation   
6.4.2.1 Body weights of animals in the different treatment groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.4.4 – Table showing the body weights of the animals used in the different treatment groups 
 
 
 
 
Groups  Body Weight 
(g) 
2.5min Control (n=4)  385±15 
2.5min leptin (n=4)  397±12 
5min Control (n=6)  425.5±14 
5min leptin (n=6)  412.8±26 
10min Control (n=6)  419.6±21 
10min leptin (n=6)  387.6±24 
15min Control (n=6)  390.5±15 
15min leptin (n=6)  395.5±8 
30min Control (n=5)  405.5±20 
30min leptin (n=6)  416.9±17 Richard A Dixon  Results 
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6.4.2.2 Exclusions 
One heart was excluded from the 5min control group due to excessive 
ventricular fibrillation.  One heart was excluded from the 10min leptin treated 
group due to poor function, i.e. did not achieve the required RPP.  Two hearts 
were excluded from the 15min control group, one due to poor flow and one due 
to excessive ventricular fibrillation (VF).  One heart was excluded from the 
30min leptin group because of poor function.  
6.4.2.3 Leptin-induced STAT3 phosphorylation  
 
Figure  6.4.2  -  Phosphorylation of STAT3/tyrosine-705 in the presence and absence of leptin at 
different time-points during reperfusion.  Total and phosphorylated STAT3 were determined in extracts 
derived from rat hearts subjected to ischaemia-reperfusion under control conditions or in the presence of 
leptin (10nM).  Data are presented as the mean ± s.e.m of relative densitometry values in arbitrary units (* 
p<0.001 vs. control; n = 5-6) (one-way ANOVA). 
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6.4.3 - Western blots showing phosphorylated STAT3 and total STAT3 levels in tissue taken from Wistar hearts treated with and without leptin 
(10nM) at various time-points during reperfusion.Richard A Dixon  Results 
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In time course experiments leptin was found to elicit a 171% increase in 
STAT3/tyrosine-705 phosphorylation at 2.5min reperfusion (p<0.001, n=5; see 
Figure 6.4.2). At the other reperfusion time-points examined (i.e. 5, 10, 15 and 
30 min reperfusion), however, significant changes in STAT3 phosphorylation 
were not detected (n=5-6; see Figure 6.4.2). 
6.4.3  Influence of AG490 on the leptin-induced increase in STAT3 
phosphorylation 
6.4.3.1 Body weights of animals in the different treatment groups 
 
Group  Body weight 
Control (n=5)  350±4.7 
Leptin (10nM) (n=5)  364±6.8 
AG490 (5μM) (n=5)  346±4.7 
AG490(5μM) +leptin (10nM) (n=4)  350±5.0 
Table 6.4.5 – Average body weight of the animals in the different treatment groups. 
 
Hearts were assigned randomly to one of four treatment groups.  Data analysis 
revealed that there were no statistical differences between the treatment groups 
with regard to body weight. 
6.4.3.2 Exclusions 
One heart was excluded from the leptin (10nM) treated group because coronary 
flow dropped below 10ml/min during stabilisation.  Richard A Dixon  Results 
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6.4.3.3 Leptin-induced STAT3 phosphorylation is inhibited by AG490 
  
Figure  6.4.4  -  Inhibition of leptin-induced STAT3 phosphorylation by AG490. Total and 
phosphorylated  STAT3  were  determined  in  extracts  derived  from  rat  hearts  subjected  to  ischaemia-
reperfusion with or without leptin (10nM) in the presence or absence of AG490 (5μM). Data are presented 
as the mean ± s.e.m of relative densitometry values in arbitrary units together with representative Western 
blots ( ***p<0.001, leptin vs. control, **p< 0.002, leptin vs. AG490 + leptin and *p<0.02, leptin vs. 
AG490; n = 4-5) (one-way ANOVA). 
 
As observed with the infarct data, the actions of leptin on STAT3 
phosphorylation at 2.5 min reperfusion were blocked by AG490 [leptin (n=5) vs. 
leptin+AG490 (n=4), p<0.002;  Figure  6.4.3]. AG490  (n=5)  was also found to 
inhibit STAT3 phosphorylation, albeit to a slightly  lesser extent, when 
administered alone [leptin (n=5) vs. AG490 (n=4), p<0.02; Figure 6.4.3].  Richard A Dixon  Results 
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6.4.4  Influence of AG490 on leptin-induced Akt/serine-473 
phosphorylation 
 
6.4.4.1 Body weights of the animals in the different treatment groups 
 
Group  Body weight (g) 
Control (n=5)  336.6±6.45 
Leptin (10nM) (n=5)  315.0±5.92 
AG490 (5μM) (n=6)  311.3±3.01 
AG490 (5μM) +leptin (10nM) (n=5)  324.5±7.25 
Figure 6.4.5 – Mean body weight of the animals in the treatment groups. 
 
Hearts were assigned randomly to one of four treatment groups.  Data analysis 
revealed that there were no statistical differences between the treatment groups 
with regard to body weight. 
6.4.4.2 Exclusions 
One heart from the control treated group was excluded due to poor function. 
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6.4.4.3 Leptin-induced phosphorylation of Akt/serine-473 is not affected 
by AG490 
 
Figure  6.4.5  –  Influence of the JAK2 inhibitor, AG490, on leptin-induced phosphorylation of 
Akt/serine-473.   The total and phosphorylated forms of Akt were determined in extracts derived from rat 
hearts subjected to ischaemia-reperfusion with or without leptin (10nM) in the presence and absence of 
AG490 (5μM).  Data are presented as the mean ± s.e.m of relative densitometry values in arbitrary units 
together with representative Western blots (*=p<0.05 vs. control; n=5-6) (one-way ANOVA). 
 
Leptin  (10nM)  elicited a 67% increase in Akt phosphorylation [p<0.05, leptin 
(n=5)  vs.  control  (n=5)].  AG490  (5μM)  failed to influence the  leptin (10nM)-
induced increase in Akt/serine-473 phosphorylation.  Interestingly, however, the 
administration of AG490 (5μM) by itself caused an increase in Akt/serine-473 
phosphorylation,  although this did not achieve statistical  significance.
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6.5  Discussion 
Cardiac JAK/STAT signalling was originally documented in a study in which rat 
cardiomyocytes were found to respond to treatment with leukaemia inhibitory 
factor with increased STAT3 activation  (Kunisada et al. 1996).  A subsequent 
study demonstrated that both STAT1 and STAT3 were activated in the heart in 
response to pressure overload hypertrophy (Pan et al. 1997).  Evidence 
indicating  that  the  JAK/STAT  pathway is involved  in cardioprotection was 
obtained in 2001.  Xuan and colleagues reported that the late phase of IPC was 
associated with JAK1 and JAK2 activation, resulting  in STAT1 and STAT3 
recruitment, and subsequent upregulation of nitric oxide synthase (iNOS) (Xuan 
et al. 2001).  The administration of the JAK2 inhibitor, AG490, prior to IPC was 
found to block these processes.  The work of Xuan et al was complimented by 
that of Hattori and co-workers, who reported that the early phase of IPC was 
associated with JAK/STAT activation, upregulation of bcl-2 and downregulation 
of Bax (Hattori et al. 2001).  These processes were, once again, abrogated by 
the administration of AG490.      
More recently, Lecour and colleagues demonstrated that mechanical IPC and 
pharmacological IPC, induced by tumour  necrosis factor-α  (TNF-α), were 
associated with early activation of STAT3 during the reperfusion-phase (Lecour 
et al. 2005).  Furthermore, the crucial role played by  STAT3 activation  in 
cardioprotection  was demonstrated in  studies conducted with cardiomyocytes 
from  cardiac-specific STAT3  knockout mice, which failed to respond to IPC 
(Smith et al. 2004).  These data were paralleled by the results of experiments Richard A Dixon  Results 
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carried out with  Langendorff perfused hearts, in which  infarct size limitation 
conferred by IPC in wild-type mice was found to be lost in hearts from cardiac 
specific STAT3 knock-out mice (Smith et al. 2004).  Very recent data indicates 
that IPC-induced cardioprotection is inhibited in STAT3 deficient and aged mice 
(Boengler et al. 2008a).  Noteworthy, is the observation that the loss of IPC-
induced protection in aged mice was  associated with decreased STAT3 
phosphorylation  (Boengler et al. 2008a).  Collectively these data provide 
evidence that JAK/STAT signalling plays a key role in myocardial preservation, 
and  also indicate a possible mechanism whereby myocardial damage may 
develop with age (Boengler et al. 2008b). 
6.5.1  Leptin-induced cardioprotection is blocked by AG490 
In the current study leptin-induced cardioprotection was  completely blocked 
when AG490 was administered at the same time as the adipocytokine, a result 
that confirms the findings of Xuan et al and provides additional evidence for the 
involvement of the JAK/STAT pathway in protection (Xuan et al. 2001).   
6.5.2  Leptin-induced STAT3 phosphorylation in Wistar rat hearts 
subjected to I/R injury  
STAT3 phosphorylation in response to leptin treatment appeared to occur early 
in the reperfusion-phase.  This was indicated by the observation that a marked 
increase in STAT 3 phosphorylation occurred 2.5min into reperfusion, following 
leptin administration.  Interestingly, the effect evoked by leptin was lost 5min into 
the reperfusion-phase, the extent of STAT3 phosphorylation returning to basal 
levels.  This change in STAT3 phosphorylation appears to occur very rapidly, 
especially when compared to the leptin-induced phosphorylation profiles Richard A Dixon  Results 
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obtained for PI3K and MAPK p44/42 (see Chapter 4), in which a gradual 
increase in phosphorylation levels is observed over 15min and then followed by 
a decline in phosphorylation.  Furthermore, this result appears to be in conflict 
with leptin-induced STAT3 phosphorylation in other cell types.  For example, 
leptin elicited a peak of STAT3 phosphorylation at 30 min in human hepatic 
stellate cells (Cao et al. 2004).  One must consider that the STAT3 response 
may occur at different speeds in different tissue of the body.  Alternatively, one 
should consider that STAT3 may play different roles in various tissues.  For 
example, recent data suggest that STAT3 may participate in signalling at or in 
the mitochondria.  Perhaps  in cardiomyoctyes  leptin elicits an early STAT3 
response via JAK2, which results in migration of STAT3 to the mitochondria at 
which point it may interact with and prevent opening of the MPTP.  
Subsequently, STAT3 may be degraded in cardiomyocytes, whereas in other 
tissues it may remain in the cell and therefore can be detected.  
Interestingly, it has been speculated that the increase in JAK/STAT activity that 
occurs following the reperfusion of the ischaemic myocardium is as a result of 
increased levels of reactive oxygen species (ROS), rather than the upregulation 
of growth factors or cytokines (Barry et al. 2007).  It is possible, therefore, that in 
the myocardium leptin may not activate STAT3 directly, but via increases in the 
tissue levels of ROS.  The data presented in this study compliment  those 
acquired previously in this laboratory, i.e. it was demonstrated previously that 
leptin treatment was not associated with increased STAT3 phosphorylation in 
the Langendorff isolated perfused murine heart at 10min reperfusion (Smith et Richard A Dixon  Results 
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al. 2006).  Given that  maximal STAT3 phosphorylation  in the rat heart was 
observed to occur  early  in the reperfusion-phase, i.e. at 2.5min, it is not, 
perhaps, surprising that increases in STAT3 phosphorylation were not seen in 
the murine heart (Smith et al. 2006). 
6.5.3  Leptin-induced STAT3 phosphorylation is blocked by AG490 
In this part of the study  the aim was to establish if leptin-stimulated  STAT3 
phosphorylation could be abolished by the administration of the JAK2 inhibitor, 
AG490. Thus, further evidence for the involvement of the JAK/STAT pathway in 
leptin-induced myocardial actions was sought.  Indeed, as observed by Xuan et 
al (Xuan et al. 2001) it was found that AG490, apart from abrogating the infarct-
reducing effects of leptin, also inhibited STAT3 phosphorylation  (Figure 6.4.3).  
This  finding suggests that  leptin  signalling  in the myocardium requires JAK2 
phosphorylation, which then leads to STAT3 activation downstream.  However, 
the role of STAT in leptin-induced cardioprotection has yet to be fully elucidated.  
For example, further studies with the STAT3 specific inhibitor, STATTIC, may 
lead to  a more comprehensive understanding of the role of the JAK/STAT 
pathway in cardioprotection (Schust et al. 2006). 
6.5.4  AG490 does not influence leptin-induced phosphorylation of 
Akt/serine-473  
In chapter 4  data are presented  that  indicate  that maximal leptin-induced 
phosphorylation of Akt/serine-473 occurred at 15min into the reperfusion-phase.  
By contrast, maximal leptin-induced STAT3 phosphorylation was found to occur 
earlier, i.e. at 2.5min into the reperfusion-phase.  One interpretation that can be 
placed on these data is that the JAK/STAT pathway operates upstream of the Richard A Dixon  Results 
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RISK  signalling  cascade.  This hypothesis is supported by recent data 
demonstrating that RISK signalling  induced by IPost  follows  activation of the 
JAK/STAT pathway, and that JAK/STAT phosphorylation in the absence of RISK 
activation is insufficient to provide protection (Goodman et al. 2008).  It must be 
noted, however, that this area of research is still  very much in its infancy, 
particularly in the context of cardioprotection, and that interactions between the 
JAK/STAT and RISK pathways remain to be fully elucidated.  Indeed, the data 
obtained in the present study would appear to be conflicting.  Whilst, JAK/STAT 
phosphorylation occurred earlier than Akt/serine473 phosphorylation (see 
section 5.4.2.3), indicating that JAK/STAT activation may precede that of Akt 
activation, the JAK2 inhibitor, AG490 failed to block Akt activation when 
administered at reperfusion.  When considering these data, however, it is 
important to take account of possible confounding factors such as  drug 
specificity, drug concentration used and the type of JAK2 inhibitor employed.   
In conclusion, the data presented in this chapter have clearly demonstrated a 
role for the JAK/STAT pathway in leptin-induced cardioprotection, where 
previously the function of STAT3 was unknown.  However, many questions 
currently remain unanswered with regard to the mismatch in timing between 
STAT3 and Akt phosphorylation.  One may speculate that the fact that the peak 
of STAT3 phosphorylation occurs much earlier than that of Akt indicates that 
STAT3 is a more important component than Akt in the mechanism that underlies 
the leptin-induced cardioprotection.  Furthermore, this might be, as speculated 
earlier in the chapter through direct modulation of the MPTP  by activated Richard A Dixon  Results 
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STAT3.  In this suggested mechanism, leptin binds its receptor, which in turn 
phosphorylates recruited JAK2 proteins, which leads to the recruitment of 
STAT3 proteins followed by their phosphorylation, dimerisation and migration to 
the mitochondrion.  However, this does by no means suggest the role of Akt is 
completely redundant in leptin-induced cardioprotection.  In a later wave to that 
of STAT3, Akt may be activated, by PI3K, and converge with STAT3 upon the 
mitochondrion to prevent MPTP opening.    
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CHAPTER 7 - LEPTIN-INDUCED CARDIOPROTECTION 
IN ZUCKER LEAN & ZUCKER FATTY RATS 
7.1  Introduction 
Leptin has been reported to confer protection against myocardial I/R injury via 
p44/42 MAPK and Akt signalling (Smith et al. 2006).  Studies in a variety of 
tissues have suggested that these  signalling pathways are activated through 
interaction between leptin and specific leptin receptors, designated OB-R 
(Fruhbeck 2006).  Six isoforms of the OB-R have been described, i.e. OB-Ra, 
OB-Rb, OB-Rc, OB-Rd, OB-Re and OB-Rf (Tartaglia et al. 1995).  The roles 
played by these receptors with regard to cardioprotection and other cardiac 
functions have yet to be determined.  It has, however, been established that OB-
Ra and OB-Rb  are expressed in the heart, with the OB-Ra  predominating 
(Purdham et al. 2004).  Nevertheless, it is the OB-Rb isoform, which possesses 
the longer C-terminal domain, that exhibits the greater signalling capacity and 
could, possibly, play the primary physiological role in the heart (Fruhbeck 2006).  
It is worth noting that whilst the OB-Ra isoform is capable of signalling  via 
MAPK, it does not possess the ability to stimulate STAT3 (Banks et al. 2000).  
STAT3 phosphorylation is controlled via a Tyr-(1138) residue, which is found 
exclusively in the long, OB-Rb, receptor isoform (Banks et al. 2000).  The 
importance of the OB-Rb isoform in leptin signalling is lent credence by the fact 
that the obese phenotype exhibited by the db/db mouse results from a mutation 
in the OB-Rb (Chen & Wang 2005).  In this study Zucker lean and Zucker fatty 
(fa/fa)  rats  were employed to investigate  how adiposity and OB-R status 
influence myocardial sensitivity to the protective actions of leptin.  The obese Richard A Dixon  Results 
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phenotype  in the fa/fa  rat is the result of a glutamine to proline  amino  acid 
substitution mutation at the 269 position in the C-terminal domain of all the leptin 
OB-R isoforms (Phillips et al. 1996).  This mutation has no effect on the leptin 
binding capacity of the receptor (Guan et al. 1997), but is thought to inhibit OB-R 
dimerisation, a prerequisite for downstream leptin signalling  (Kishimoto et al. 
1994).  
7.2  Aim 
The aim in this chapter was to establish the responsiveness of Zucker lean and 
fa/fa hearts to leptin-induced cardioprotection.  
7.3  Hypothesis 
Given the proposed physiological importance of the OB-Rb  isoform and its 
suggested  involvement in obesity, we hypothesised that leptin-induced 
cardioprotection is dependent on the presence on the myocardium of functional 
OB-R. This theory was investigated using hearts harvested from Zucker lean 
and fa/fa rats. Zucker lean rats express the functional OB-R (the results of the 
gene expression in these animals depends on whether animals are homozygous 
or heterozygous),  whereas  fa/fa  rats possess a mutation in the extracellular 
domain of the OB-R. 
7.4  Experimental Protocol & Materials 
7.4.1  Langendorff perfused rat hearts 
Hearts from Zucker lean and fa/fa rats were excised according to the protocol 
described in section 3.3.  Once mounted on the perfusion apparatus, hearts 
were stabilised for 40min and then subjected to 35min regional ischaemia Richard A Dixon  Results 
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induced by coronary artery ligation.  Hearts were then reperfused for 120min to 
ensure sufficient washout of enzymes and cofactors had occurred to enable 
accurate staining of infarcted and viable tissue (section 3.3).  Hearts from both 
Zucker lean and fa/fa  rats were reperfused in the presence and absence of 
leptin.  The groups examined were:- 
Zucker lean (n=6) - no drug (control) 
Zucker lean (n=6) - leptin administered 5min before reperfusion 
Zucker fatty (n=6) – no drug (control) 
Zucker fatty (n=6) – leptin administered 5min before reperfusion 
Figure  7.4.1  –  Protocol for investigating the cardioprotective effects of leptin in  Langendorff 
perfused hearts from Zucker lean and fa/fa rats. (A) Control-perfused with no drug.  (B) Leptin-
treatment given from 5min prior to and until 30min into the reperfusion-phase.  
A) Control
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
B) Leptin Treatment
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
Leptin treatment
35min
A) Control
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
B) Leptin Treatment
Stabilisation Ischaemia Reperfusion
40min 35min 120min
Infarct size 
determination
Leptin treatment
35minRichard A Dixon  Results 
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7.4.2  Western blotting 
Hearts from Zucker lean and fa/fa rats were extracted according to the protocol 
described in section 3.3.  Hearts were perfused on the Langendorff apparatus 
for 40min to allow stabilisation and then subjected to 35min regional ischaemia 
via coronary artery ligation.  Following ischaemia hearts were reperfused for a 
total of 15min in the presence and absence of leptin, after which time the 
ventricular tissue was harvested, snap-frozen and stored for subsequent 
Western blot analysis (see section 3.5).  Individual groups were as follows: 
Zucker lean (n=7) – no drug (Control) 
Zucker lean (n=7) – leptin (10nM) 
Zucker fatty (n=7) – no drug (Control) 
Zucker fatty (n=7) – leptin (10nM) Richard A Dixon  Results 
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Figure 7.4.2  – Protocol for the collection of Western blot samples from Zucker lean and fa/fa hearts 
subjected to I/R injury.  (A) Control hearts were subjected to 40min stabilisation, 35min ischaemia and 
15min reperfusion.  (B) Leptin-treated hearts subjected to 40min stabilisation, 35min ischaemia and 15min 
reperfusion with 10nM leptin.  Leptin treatment began 5min before the commencement of reperfusion and 
continued until the point at which the heart was snap-frozen. 
A) Control
Stabilisation Ischaemia Reperfusion
40min 35min 15 min Sample collection
B) Leptin treatment
Stabilisation Ischaemia Reperfusion
40min 35min
15 min
Sample collection
Leptin treatment
20min
A) Control
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40min 35min 15 min Sample collection
B) Leptin treatment
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7.5  Results 
7.5.1  Langendorff perfused rat hearts 
7.5.1.1 Body weights and haemodynamic data for the animals/hearts in 
the different treatment groups 
 
Groups  Body Weight 
(g) 
Ventricular 
Volume 
(mm
3) 
Risk Volume 
(%) 
Zucker lean 
(n=5)  
329.5±32.8 *  1771.2±256.2  49.5±3.5 
Zucker lean + 
leptin (10nM) 
(n=6) 
361.1±17.3 †  1870.5±342.2  53.9±4.5 
fa/fa 
(n=7) 
511.6±14.3 *  1910.4±287.2  51.2±3.2 
fa/fa + leptin 
(10nM) 
(n=6) 
514.9±22.7 †  1852.2±245.2  50.1±4.2 
Table 7.5.1 – Mean body weights, ventricular volumes and risk zones for the different treatment 
groups.  Data expressed are as mean±s.e.m. 
 
Animals were weighed prior to the excision of hearts for Langendorff perfusion.  
Table 7.5.1 demonstrates that there is a significant difference (*/†=p<0.0001) in 
body weight between the Zucker lean and fa/fa groups.  The increase in body 
weight seen in the fa/fa rat is directly related to the OB-R mutation which leads 
to dysfunctional energy homeostasis.  Interestingly, despite the increase in body 
weight in fa/fa animals no significant differences in ventricular volume or risk 
zone volume were apparent between the groups.    
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7.5.1.1.1 Coronary flow rate (ml/min) 
 
 
Stabilisation (ml/min)  Ischaemia (ml/min)  Reperfusion (ml/min) 
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Zucker lean 
(n=5) 
16.8 
±2.1 
 
16.0 
±2.1 
 
15.5 
±2.1 
 
15.2 
±2.1 
 
7.5 
±1.6 
 
8.3 
±1.6 
 
7.6 
±1.4 
 
13.7 
±0.9 
 
12.6 
±0.8 
 
12.3 
±0.9 
 
11.8 
±0.6 
 
11.2 
±0.7 
 
10.0 
±1.2 
 
9.5 
±1.1 
 
Zucker lean + 
leptin(10nM) 
(n=6) 
15.5 
±1.6 
 
14.3 
±1.7 
 
13.0 
±1.4 
 
13.0 
±1.8 
 
7.0 
±1.1 
 
7.5 
±0.9 
 
7.1 
±1.0 
 
12.8 
±1.7 
 
12.7 
±1.3 
 
11.0 
±1.3 
 
10.0 
±0.9 
 
9.3 
±0.9 
 
7.8 
±0.6 
 
6.8 
±0.9 
 
fa/fa (n=7)  13.0 
±1.7 
 
12.6 
±1.3 
 
12.2 
±1.0 
 
12.2 
±1.0 
 
6.4 
±0.7 
 
6.5 
±0.9 
 
6.2 
±0.7 
 
11.2 
±0.9 
 
10.8 
±1.4 
 
9.3 
±0.6 
 
7.8 
±0.7 
 
6.8 
±0.7 
 
6.0 
±0.5 
 
5.4 
±0.5 
 
fa/fa + leptin 
(10nM) (n=6) 
14.6 
±1.0 
13.8 
±1.0 
 
12.6 
±1.2 
 
12.2 
±1.3 
 
6.7 
±0.9 
 
7.0 
±0.8 
 
7.0 
±0.8 
16.1 
±2.0 
15.8 
±2.5 
13.4 
±1.7 
11.2 
±1.4 
9.6 
±1.2 
8.0 
±1.5 
7.0 
±1.3 
 
Table 7.5.2 – Coronary flow rate (ml/min) of each group at various time-points during the ischaemia/reperfusion protocol. 
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7.5.1.1.2 Rate pressure product (x 103mmHg/min) 
 
  Stabilisation  
(x 10
3mmHg/min)   
Ischaemia  
(x 10
3mmHg/min)   
Reperfusion 
(x 10
3mmHg/min)   
     Time(min) 
 
Groups 
 
10  20  30  40  5  15  30  5  15  30  45  60  90  120 
Zucker lean (n=5) 
35800 
±4582 
 
33850 
±4819 
 
30305 
±3838 
 
28570 
±4215 
 
15988 
±3141 
 
18970 
±3615 
 
16540 
±3285 
 
17280 
±2893 
 
17200 
±3180 
 
15710 
±2750 
 
15475 
±3016 
 
13320 
±3014 
 
10650 
±1894 
 
12325 
±1512 
 
Zucker lean + 
leptin(10nM) (n=6) 
35781 
±2128 
 
34550 
±2223 
 
33313 
±1681 
 
30653 
±2526 
 
18219 
±2138 
 
19371 
±2090 
 
19956 
±1482 
 
22821 
±2213 
 
24900 
±1983 
 
25831 
±1700 
 
24888 
±1733 
 
23075 
±1391 
 
17963 
±1228 
 
16629 
±1184 
 
fa/fa (n=7) 
44593 
±2617 
 
34693 
±3437 
 
29207 
±2701 
 
29464 
±3144 
 
13336 
±2128 
 
15714 
±2603 
 
16443 
±2499 
 
17500 
±3643 
 
20921 
±2544 
 
21367 
±1573 
 
19570 
±1742 
 
17983 
±999 
 
16214 
±1587 
 
13139 
±1820 
 
fa/fa + leptin 
(10nM) (n=6) 
38686 
±3836 
 
37843 
±3827 
 
39850 
±4681 
 
38633 
±4017 
 
10543 
±1970 
 
16264 
±2105 
 
16629 
±2540 
 
25050 
±580 
 
20704 
±2254 
 
19907 
±1880 
 
18271 
±1439 
 
18732 
±1332 
 
17451 
±1215 
 
14775 
±1756 
 
 
Table 7.5.3 - Rate Pressure Product (x 103mmHg/min) of each group at various time-points during the ischaemia/reperfusion protocol. 
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The haemodynamic data obtained did not reveal any significant differences 
between the groups during the stabilisation period.  By contrast, functional 
recovery, as indicated by the rate pressure product measurements, occurring 
during the reperfusion-phase appeared to be enhanced in hearts from Zucker 
lean animals when treated with leptin (n=6) as compared with hearts from fa/fa 
(n=7) (Figure 7.5.1).  
Figure 7.5.1 – Haemodynamic data for hearts in the Zucker lean and fa/fa treatment groups. 
 
7.5.1.2 Exclusions 
Two hearts was excluded from the Zucker lean group because the risk zones 
were too small.  One heart was excluded from the Zucker lean + leptin group 
due to low coronary flow.  One heart was excluded from the fa/fa group because 
of excessive ventricular fibrillation. 
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7.5.1.3 Effect of leptin on infarct size in hearts from Zucker lean and 
Zucker fatty animals 
Leptin (10nM), administered at reperfusion, substantially reduced infarct size in 
hearts from Zucker lean rats, which possess at least one functional copy of the 
OB-Rb gene, whilst hearts from fa/fa, which lack a functional OB-Rb, did not 
exhibit statistically significant decreases in infarct size when treated with leptin 
(10nM) (Figure 7.5.2). Thus, infarct size in leptin-treated Zucker lean rat hearts 
was 25.2±3.7% (n=6) as compared with 53.9±11.3% (n=5) in control (untreated) 
Zucker lean rat hearts (p<0.05), whilst infarct sizes for leptin-treated and control 
fa/fa hearts were 40.9±5.5% (n=6) and 50.4±5.0% (n=7), respectively. These 
data compare with infarct sizes of 32.4±3.9% and 53.2±3.2% (p<0.01) for leptin-
treated and control hearts from Wistar animals (Figure 7.5.2).  Regarding the 
data obtained with fa/fa hearts, no significant reduction in  infarct size was 
observed. 
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Figure 7.5.2 – Effect of leptin (10nM), perfused during reperfusion (120 min), on infarct size (as a 
percentage of the area at risk, IS/AAR%) in isolated hearts from Zucker lean and fa/fa subjected to 
I/R.  Values are expressed as mean ± s.e.m of 5-7 experiments (** P<0.01) (one-way ANOVA).     
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7.5.2  Western blotting  
7.5.2.1 Body weights for the animals in the different treatment groups 
 
 
Group  Body Weight (g) 
Zucker lean – no drug (n=5)  340.4±8.6 
Zucker lean – Leptin (n=5)  344.0±6.0 
fa/fa – no drug (n=5)  497.6±6.0 
fa/fa – leptin (n=5)  487.4±11.1 
 
Table 7.5.4 – Mean body weights for the animals different treatment groups.  Data are presented as 
mean±s.e.m. 
 
7.5.2.2 Exclusions 
There were no exclusions from the treatment groups. Richard A Dixon  Results 
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7.5.2.3 The influence of leptin on Akt/Ser-473 phosphorylation in Zucker 
lean and fa/fa rats 
 
 
 
Figure 7.5.3 – Akt/Ser-473 phosphorylation in hearts from Zucker lean and fa/fa rats following the 
administration of leptin.  Total and phosphorylated Akt/Ser-473  levels  were determined in extracts 
derived from rat hearts subjected to I/R injury in the presence and absence of leptin (10nM). Data were 
calculated as the ratio of phosphorylated to total protein relative densitometry values normalised to control 
(untreated, 100%).   Data are presented as the mean ± s.e.m of relative densitometry values in arbitrary 
units (*=p< 0.05, n = 5) (one-way ANOVA). 
 
 
In hearts isolated from Zucker lean animals leptin (n=5) elicited a small 20% 
increase in Akt/Ser-473 phosphorylation, as compared to control (n=5), however 
this change was insignificant.  In the hearts from fa/fa animals leptin (n=5) had 
no effect on Akt/Ser-473 phosphorylation compared to control (n=5) (untreated) 
hearts. 
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Figure 7.5.4 – Western blots showing phosphorylated Akt/Ser-473 and total Akt levels in tissue 
taken from Zucker lean and Zucker fa/fa hearts treated with and without leptin (10nM). Richard A Dixon  Results 
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7.5.2.4 The influence of leptin on Akt/Thr-308 phosphorylation in Zucker 
lean and fa/fa rat hearts  
 
 
Figure 7.5.5  – Leptin-induced phosphorylation of Akt/Thr-308 in Zucker lean and fa/fa rat hearts. 
Total  and  phosphorylated  Akt/Thr-308 levels were determined in extracts derived from rat hearts 
subjected to I/R injury in the presence and absence of leptin (10nM). Data were calculated as the ratio of 
phosphorylated to total protein relative densitometry  values normalised to control (untreated, 100%).     
Data are presented as the mean ± s.e.m (*=p< 0.05, n = 5) (one-way ANOVA). 
 
 
In isolated fa/fa hearts treated with leptin (n=5), no change was observed in the 
phosphorylation status of Akt/Thr-308, as compared to control (n=5).  However, 
in hearts from Zucker lean animals leptin  (n=5)  elicited a significant 43.9% 
(p<0.05)  increase in Akt/Thr-308  phosphorylation  when compared to control 
(n=5).   
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Figure 7.5.6 - Western blots showing phosphorylated Akt/Thr-308 and total Akt levels in tissue 
taken from Zucker lean and Zucker fa/fa hearts treated with and without leptin (10nM). Richard A Dixon  Results 
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7.5.2.5 The influence of leptin on p44/42 MAPK phosphorylation in 
Zucker lean and fa/fa rat hearts 
 
 
 
Figure 7.5.7  – Leptin-induced phosphorylation of p44 MAPK in Zucker lean and fa/fa rat hearts. 
Total and phosphorylated p44 MAPK levels were determined in extracts derived from hearts subjected to 
I/R  injury  in  the  presence  and  absence  of  leptin  (10nM).  Data were calculated as the ratio of 
phosphorylated to total protein relative densitometry values normalised to control (untreated, 100%).     
Data are presented as the mean ± s.e.m (*=p< 0.05, n = 5) (one-way ANOVA). 
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Figure 7.5.8  – Leptin-induced phosphorylation of p42 MAPK in Zucker lean and fa/fa rat hearts. 
Total and phosphorylated p42 MAPK levels were determined in extracts derived from hearts subjected to 
I/R  injury  in  the  presence  and  absence  of  leptin  (10nM).  Data were calculated as the ratio of 
phosphorylated to total protein relative densitometry values normalised to control (untreated, 100%).     
Data are presented as the mean ± s.e.m (*=p< 0.05, n = 5) (one-way ANOVA). 
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Figure 7.5.9 - Western blots showing phosphorylated MAPK p44/42 and total MAPK levels in tissue 
taken from Zucker lean and Zucker fa/fa hearts treated with and without leptin (10nM).   Richard A Dixon  Results 
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In hearts isolated from Zucker lean rats leptin (n=5) elicited significant increases 
in both p44 and p42 MAPK phosphorylation at 15min into the reperfusion-phase 
(97.1% and 158.1% respectively, p<0.05), when compared to untreated control 
hearts (n=5) (Figure 7.5.5 & Figure 7.5.6). By contrast, in hearts isolated from 
fa/fa  leptin  (n=5)  had no effect on p44 or p42 MAPK phosphorylation  when 
compared to untreated control hearts (n=5) (Figure 7.5.5 & Figure 7.5.6).  
7.6  Discussion 
As mentioned previously, the Zucker lean rat expresses the normal functional 
OB-R gene, whilst the fa/fa rat expresses a mutated non-functional form of the 
gene  (Chen & Wang 2005).  Absence of the functional  OB-R  results in the 
animal being unable to maintain normal energy homeostasis (Chen & Wang 
2005).  Consequently, this has made the Zucker rat  an invaluable tool for 
investigating OB-R signalling with respect to metabolic processes and disease 
(Chen & Wang 2005).  Six isoforms of the leptin receptor have been identified, 
OB-Ra,  OB-Rb, OB-Rc, OB-Rd, OB-Re and OB-Rf  (Lee et al. 1996).  The 
available literature concerning leptin signalling indicate that in order to elicit a full 
cellular response interaction between the adipocytokine and the long form of the 
leptin receptor (OB-Rb) is required (Fruhbeck 2006).  The OB-Ra isoform, which 
occurs in the heart at levels that exceed those of the OB-Rb, also may play a 
role in physiological mechanisms, although it has been shown to elicit weaker 
responses than those mediated by OB-Rb (Banks et al. 2000).   
The involvement of the OB-R in energy homeostasis has been well documented 
(Ahima 2006; Palkovits 2003). By contrast, its  role in myocardial function Richard A Dixon  Results 
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remains to be fully elucidated.  Thus, in the present study the Zucker rat was 
employed to investigate further the mechanisms underlying leptin-induced 
cardioprotection. Since leptin has been shown to be cardioprotective against I/R 
injury (Smith et al., 2006) and given that the OB-R has been demonstrated to be 
present in cardiac tissue, it was hypothesised that myocardial sensitivity to leptin 
may be related to adiposity and the presence of functional OB-R in the heart. 
7.6.1  Leptin protects against myocardial I/R injury in Zucker lean 
rats but not in fa/fa animals 
Leptin significantly protected hearts from Zucker lean animals against I/R injury 
and  to  similar  extents  to  those  seen with hearts from Wistar animals (see 
Chapter 4).  Both the Zucker lean rat and the Wistar rat express functional OB-
Rb receptors.  By contrast, hearts from fa/fa animals, which do not express the 
functional OB-R, did not respond significantly to leptin treatment.  It should be 
noted that there appears to be a small trend towards infarct size reduction with 
leptin treatment in the fa/fa heart.  This raises the possibility that leptin may be 
producing  an effect in the heart via a mechanism independent of the OB-R.  
However, assuming that the findings of the present study are valid, one might 
suggest that these data reflect the general lack of sensitivity to cardioprotective 
agents in these animals.  Nevertheless, evidence opposing this view has been 
presented, various agents having been found to reduce infarct size in the fa/fa 
heart.  Hexarelin, a synthetic enkephalin-derived peptide  was found to be 
protective in hearts from both Zucker lean and fa/fa rats (Gennaro-Colonna et al. 
2000).    Similarly, rosiglitazone, which protects the myocardium in normal Richard A Dixon  Results 
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animals (Gonon et al. 2007), was found to reduce infarct size in Zucker lean and 
fa/fa animals via Akt activation (Yue et al. 2005). 
7.6.2  Leptin stimulates Akt/Thr-308 phosphorylation in Zucker lean 
hearts but not in fa/fa hearts 
Contrasting with the results obtained with  hearts from Wistar animals  (see 
Chapter 5), leptin failed to stimulate a significant increase in Akt/Ser-473 
phosphorylation  in hearts from Zucker lean animals.  This observation  may 
relate to the fact that some Zucker lean animals possess only one copy of the 
functional OB-R gene, i.e. depending on whether they are heterozygous or 
homozygous for the gene,  resulting  in decreased  expression of functional 
receptors, and, consequently decreased leptin signalling.  The phosphorylation 
of Akt/Ser-473 in hearts from fa/fa, which do not express functional OB-R was 
also not altered.  Contrasting with the results obtained for Akt/Ser-473,  a 
significant increase in the phosphorylation of Akt/Thr-308 was observed in 
Zucker lean hearts treated with leptin.  Again, however, no increases were seen 
in  fa/fa  hearts.  Thus, results obtained with regard to leptin-induced 
phosphorylation of the Akt sites with Wister and Zucker lean hearts appeared to 
be conflicting. 
Current literature suggests that in the process of Akt activation the Akt/thr308 
site is the primary site of phosphorylation, which is followed by phosphorylation 
of the Akt/ser473 site (Balendran et al. 1999; Kumar & Madison 2005).  These 
phosphorylation reactions are catalysed by the enzymes PDK1  and PDK2, 
respectively (Balendran et al., 1999).  The aforementioned ambiguity observed Richard A Dixon  Results 
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in the data presented in this chapter, therefore, may reflect differences between 
the Wistar and Zucker lean rat hearts with respect to the time-points at which 
PDK1 and PDK2-catalysed phosphorylation of the Akt/thr308 and Akt/ser473 
sites occurred.  Hence, the time at which the Akt/thr308 site was phosphorylated 
in the Wistar rat heart may be earlier than that of the Zucker lean, and therefore 
missed by our experiments.  Similarly, the window of maximal activation of 
Akt/ser473 may have been later in the Zucker lean than the Wistar, and 
therefore possibly missed in the tissue samples.  Nevertheless, overall the 
phosphorylation of Akt was increased in the hearts from both types of animal 
when treated with leptin, indicating that Akt activation may be involved in the 
mechanism underlying leptin-induced cardioprotection. 
7.6.3  Leptin stimulates phosphorylation of p44/42 MAPK in hearts 
from Zucker lean animals but not fa/fa animals 
Significant increases in the  phosphorylation of p44 and p42 MAPK were 
observed in hearts from Zucker lean animals treated with leptin (Figure 7.5.5 & 
Figure 7.5.6).  Similar levels of phosphorylation were observed in hearts from 
Wistar animals.  By contrast, no  significant changes  in  the  phosphorylation 
states  of either p44 or p42 MAPK  were seen with  hearts from fa/fa  animals 
treated with leptin.  These results again reflect the fact that Zucker lean and 
Wistar animals produce functional OB-Rb and fa/fa do not.  
7.6.4  Conclusion   
Data in this chapter suggests  that  the  presence of the OB-R receptor is a 
prerequisite for leptin-induced cardioprotection.  With reference to the current 
literature, that indicate that the long OB-Rb isoform is required for full activation Richard A Dixon  Results 
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of leptin signalling  pathways, one could extrapolate that leptin-induced 
cardioprotection seen in Zucker lean animals is via the OB-Rb.  However, one 
cannot exclude the possibility that alternative OB-R isoforms may play a role in 
cardioprotective mechanisms.  It is known, for example, that cardiomyocytes 
express the OB-Ra isoform, which is also reported to be non-functional in the 
Zucker rat [Phillips et al., 1996].  The OB-Ra have been demonstrated to play 
various  roles in cellular processes  including  ventricular hypertrophy 
(Rajapurohitam et al. 2003; Phillips et al. 1996). Future studies utilising specific 
receptor  blockers or antibodies  directed at individual leptin receptors, which 
have only recently become available, will allow the roles of the different OB-R to 
be elucidated in greater detail.  Whatever the precise mechanisms involved, the 
fact remains that our data are consistent with  activation of myocardial leptin 
receptors being involved in leptin-induced myocardial protection.  Of the various 
leptin receptor-isoforms the OB-Rb is the most likely candidate, given that it is 
generally accepted that this isoform plays the primary functional role with 
respect to full leptin-induced cell signalling (Banks et al. 2000). 
7.6.5  Limitations 
It should be noted that in addition to being the obese  the  fa/fa  rat is 
hyperglycaemic.  It has been demonstrated  that in order to precondition the 
diabetic myocardium the IPC stimulus must be increased over that needed to 
protect the non-diabetic myocardium (Tsang et al. 2005).  This data, therefore, 
indicates that the diabetic myocardium may be compromised with respect to the 
signalling mechanisms that must be activated to achieve cardioprotection.  It Richard A Dixon  Results 
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should also be noted, however, that various studies have shown that for a given 
area at risk the diabetic myocardium is less susceptible to I/R injury than the 
non-diabetic myocardium  (Monteiro et al. 2005).  With respect to the data 
presented in this thesis, the fa/fa myocardium may have a lower response to 
leptin in terms of activating survival signalling pathways and consequently may 
be more difficult to protect.   
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CHAPTER 8 - LEPTIN-INDUCED INHIBITION OF MPTP 
OPENING 
8.1  Introduction 
 
In the study described in this chapter, the effects of leptin on MPTP opening 
were investigated with reference to obesity and OB-R status.  Opening of the 
MPTP during reperfusion of the ischaemic myocardium has been demonstrated 
to be an important determinant of cell death (Halestrap 2006).  Whilst the MPTP 
remains closed during ischaemia, the conditions that develop intracellularly on 
reperfusion result in pore opening, ultimately leading to necrosis and apoptosis 
(Halestrap et al. 1997b).  The aforementioned conditions include rectification of 
low intracellular pH, a decline in ATP levels and increases in intracellular ROS 
levels (Crompton & Andreeva 1993).  Recent studies indicate that inhibition of 
pore opening may underlie cardioprotection induced by IPC, IPost and various 
pharmacological agents (Lim et al. 2007a).    
The structure of the pore has yet to be fully elucidated.  Originally, it was thought 
to be a multi-component structure incorporating the following proteins adenine 
nucleotide translocase (ANT),  voltage dependent anion channel  (VDAC)  and 
cyclophilin D (Halestrap & Brennerb 2003; Vyssokikh & Brdiczka 2003).  More 
recently, however, it has been shown in studies utilising ANT and VDAC knock-
out mice that the pore can still be induced to form, perhaps indicating that these 
components are redundant (Juhaszova et al. 2008; Leung & Halestrap 2008). 
By contrast, it appears  that  the  cyclophilin D  component  is  vital for MPTP 
formation and function.  This finding is supported by various studies which Richard A Dixon  Results 
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demonstrated that MPT can be inhibited by agents that bind to cyclophilin D, 
such as Cyclosporin A (CsA) and sanglifehrin A (SfA) (Halestrap et al. 1997a; 
Clarke et al. 2002).  In the setting of myocardial I/R injury CsA  has been 
demonstrated to reduce reperfusion induced arrhythmias (Arteaga et al. 1992), 
normalise ATP/ADP ratios and AMP levels (Griffiths & Halestrap 1993), and limit 
infarction by up to 50% (Halestrap et al. 1997a).  In our laboratory it has been 
shown that cyclophilin D knockout mice, which are presumed to be dysfunctional 
with regard to pore formation, are less susceptible to myocardial I/R injury than 
wild-type animals (Lim et al., 2007).  Cardioprotective strategies such as IPC, 
IPost and diazoxide that protect the myocardium in wild-type animals, 
interestingly, conferred no protection in cyclophilin D knockout mice (Lim et al., 
2007).  These data indicate that  the  pore plays an important role in the 
underlying mechanisms of both mechanical and pharmacological 
cardioprotection.    
Stimulation of the RISK survival kinases has been linked to inhibition of the pore 
and cardioprotection.  Insulin-induced Akt activation in isolated cardiomyocytes, 
for example, was associated with a delay in the time to initiation of mitochondrial 
depolarisation, an indicator of pore opening (Davidson et al. 2006).  This delay 
was abolished by the administration of the Akt inhibitor, LY-294002 (Davidson et 
al. 2006).  However, despite establishing a link between RISK activation and 
inhibition of the pore, it still remains for the intermediate signalling steps to be 
elucidated.   Richard A Dixon  Results 
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Leptin has been reported to delay MPTP opening in cardiomyocytes isolated 
from Sprague Dawley rats (Smith et al. 2006).  In addition, pore opening was 
found to be abrogated by the administration of LY-294002 or MEK inhibitor 1, 
inhibitors of Akt and p44/42respectively, providing further evidence for a link 
between the RISK pathway and the MPTP (Smith et al. 2006).  These previous 
investigations were, however, conducted with lean animals expressing normal 
OB-R.   
8.2  Aim 
The aim of the present study, therefore, was to investigate the mechanisms 
underlying leptin’s actions on the pore further.  Thus, using cardiomyocytes 
isolated from fa/fa, Zucker lean and Wistar rat hearts, the influence of adiposity 
and OB-R status on MPTP opening induced by leptin was examined. 
8.3  Experimental Protocol & Materials 
8.3.1  Cardiomyocyte model of MPTP opening 
Adult rat cardiomyocytes were isolated from male fa/fa, Zucker lean and Wistar 
animals and seeded onto 25mm round cover-slips (see section 3.4.1).  MPTP 
opening was examined employing a model of oxidative stress (Davidson et al, 
2006).  Hence, seeded cardiomyocytes were incubated with the photoactive 
dye, TMRM, for 15min at room temperature.  The cells were then washed with a 
restoration buffer devoid of TMRM and visualised using confocal microscopy as 
described in section 3.4.2.  TMRM is a lipophilic cation and is therefore taken up 
by the mitochondria according to their membrane potential (Scaduto, Jr. & 
Grotyohann 1999).  Illumination of the dye with a laser causes the TMRM to Richard A Dixon  Results 
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react and produce ROS (Hausenloy et al. 2003).  The resulting oxidative stress 
causes MPTP opening and consequent collapse of the mitochondrial membrane 
potential, which can be visualised as a wave of depolarisation across the cell 
(Davidson et al. 2006) (see Figure 8.3.2).  The time (seconds) of laser exposure 
required to trigger the initiation of mitochondrial depolarisation was measured, 
being related to the quantity of accumulated ROS required to trigger opening of 
the MPTP (Davidson et al. 2006). 
 
Figure 8.3.1 – Protocol for investigating the effects of leptin (10nM) on MPTP opening.  (A)  Control 
cardiomyocytes were incubated in a buffer containing TMRM for 15min and then incubated with a 
restoration buffer for 10min.  (B) Leptin or CsA treated cells, by contrast, were also incubated in a 
TMRM-containing buffer, but were then incubated in either a restoration buffer containing leptin (10nM) 
or CsA (0.2μM).  The cells were then subjected to laser stimulation until the initiation of mitochondrial 
depolarisation could be visualized.       
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Figure 8.3.2 – Photographs showing the depolarisation of isolated rat cardiomyocytes in response to 
ROS.   
8.3.2  Experimental Protocol for Cardiomyocyte Studies 
After TMRM loading cells were randomly assigned to one of the treatment 
groups below.  Cells were incubated for 10min with the drug at room 
temperature and then subjected to the TMRM-oxidative stress protocol. 
Control – incubation in restoration buffer alone. 
Leptin – incubation with 10nM leptin.   
Cyclosporin A – incubation with 0.2μM CsA, an inhibitor of MPTP opening and 
used as a positive control. Richard A Dixon  Results 
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8.4  Results 
8.4.1  Exclusions 
A total of seven Wistar rat hearts were used for cardiomyocyte isolation of which 
3 were excluded due to poor yields of cells.  Six Zucker lean rat hearts were 
used of which one was excluded owing to poor yields.  Similarly, six fa/fa hearts 
were used and one was excluded due to a poor yield.  
8.4.2  Effect of leptin on MPTP opening in cardiomyocytes isolated 
from Wistar, Zucker lean and fa/fa hearts 
CsA, an established inhibitor of the MPTP, was used as a positive control in all 
isolated cardiomyocyte experiments. Leptin (10nM) and CsA (0.2μM) delayed 
the time to MPTP opening in cardiomyocytes isolated from Wistar rat hearts by 
43% (p<0.01) and 34.5% (p<0.01), respectively, as compared with cells treated 
with vehicle (Fig.6).  Similarly, leptin and CsA also delayed the time until MPTP 
opening in cardiomyocytes isolated from Zucker lean rat hearts i.e. by 30.9% 
(p<0.01) and 28.5% (p<0.01).  By contrast, whilst cardiomyocytes isolated from 
fa/fa rat hearts responded to CsA  with a delayed time to MPTP  opening 
(+20.3%, p<0.05), no changes were observed in leptin-treated cells (Fig.6). 
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Figure 8.4.1  – MPTP opening in cardiomyocytes isolated from Wistar, Zucker lean and Zucker 
fatty rat hearts.  Data are presented as the percentage increase in time to initiation of MPTP opening, 
indicated by mitochondrial depolarisation
3
 
.  Values are presented as mean±s.e.m (*=P<0.05, **=P<0.01) 
and were obtained with a total of 12-20 cells from at least five hearts per group (Kruskal-Wallis analysis 
of variance method). 
8.5  Discussion 
The MPTP, a non-selective pore that forms in mitochondrial membranes, has 
been shown to play a key role in the mechanisms leading to cell death in various 
pathological conditions, including  neurodegeneration,  brain injury, stroke and 
myocardial ischaemia reperfusion injury  (Youdim et al. 2005; Sullivan et al. 
2000; Friberg & Wieloch 2002; Halestrap et al. 2004).  Under normal conditions 
the mitochondrial membrane is only permeable to small ions and metabolites 
(Halestrap et al. 2002).  When the pore forms and opens, however, the free 
passage of molecules up to 1.5KDa  is permitted, leading to mitochondrial 
                                                 
3 It should be noted that due to large variations in the baseline time to cardiomyocyte depolarisation found 
on different days, the results were normalised so that the control was equal to 100%.  Therefore, any 
increase in time to depolarisation is reflected by a value over 100%.  Raw data are presented in an 
appendix at the end of this thesis.    Richard A Dixon  Results 
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uncoupling (Halestrap et al. 2002).  Due to increased osmolar load mitochondria 
swell and,  in some cases,  cytochrome C is released following mitochondrial 
membrane rupture (Buki et al. 2000).  Once released cytochrome C can bind 
with the cytosolic protein apaf1 forming an apoptosis-promoting complex known 
as the apoptosome, which triggers cell death in various tissues (Adrain et al. 
2006).  Inhibition of the pore, however,  both prior to ischaemia and at 
reperfusion, has been demonstrated to reduce myocardial infarction (Hausenloy 
et al, 2003).      
8.5.1  Leptin delays MPT in Zucker lean and Wistar rat 
cardiomyocytes but not in fa/fa cardiomyocytes 
In experiments with cardiomyocytes from Wistar rat hearts leptin was found to 
delay  MPTP  opening, as was the case for cells from Zucker lean  rat hearts 
(Chapter 7).  These  data  are,  therefore, consistent with the hypothesis that 
leptin-induced signalling, as indicated by increased Akt, p44/42 phosphorylation 
(see Chapter 5) and STAT3 (see Chapter 6), converges on the mitochondrion.  
It should be noted, however, that the cells from Zucker lean rat hearts still 
responded to leptin despite the apparent lack of Akt/Ser-473 phosphorylation 
seen in the western blotting studies presented in Chapter 7.  This can be 
reconciled in two ways. Firstly one should note that whilst phosphorylation was 
not seen at this time-point in reperfusion, i.e. 15  min, the data does not 
conclusively show that significant phosphorylation of Akt/Ser-473 does not occur 
at all.  For example, phosphorylation may have occurred prior to sampling and 
therefore may have been missed in our investigation.  Secondly, if Akt/Ser-473 
is not activated in Zucker lean hearts protection may occur via p44/42 MAPK Richard A Dixon  Results 
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and STAT3 pathways.  By comparison, it appears that these pathways have not 
been activated by leptin at all in the cells from fa/fa hearts.  Therefore, further 
investigation is needed to clarify the role of Akt in this process.  Nonetheless, 
this data shows that leptin signalling, be it via the RISK or JAK/STAT pathway is 
linked mitochondria, Figure 8.5.1 depicts this hypothesis. The fact that leptin did 
not produce a comparable effect on cardiomyocytes from fa/fa rats indicates that 
leptin-induced  signalling  with respect to MPTP  opening, is defective in these 
animals, thus providing further support for the notion that the OB-R plays a key 
role in leptin-mediated protection.  Cyclosporin A delayed MPT  in 
cardiomyocytes isolated from all three types of animal (Figure 8.4.1).  It should 
be noted, however, that the percentage delay produced by CsA  in  fa/fa 
cardiomyocytes appeared to be slightly less than that in cardiomyocytes from 
Wistar and Zucker lean animals.  This could indicate that fa/fa cardiomyocytes 
possess a generalised impairment with regard to mitochondrial function.  This 
idea  is supported by data indicating that  mitochondrial apoptotic signalling is 
increased in fa/fa cardiac muscle (Lu et al. 2007; Peterson et al. 2008). Further 
investigation,  therefore, is needed to establish  the  mitochondrial  functional 
capacity in cardiomyocytes from fa/fa hearts as compared with cells from normal 
hearts.  
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Figure 8.5.1 – Proposed signalling mechanisms underlying leptin-induced myocardial protection.  
Reperfusion of the myocardium after a period of ischemia results in MPTP  opening and subsequent 
mitochondrial uncoupling, ATP consumption and, ultimately, cell death.  It is hypothesized that binding of 
leptin by leptin receptors (OB-R) present on the cardiomyocyte leads to the phosphorylation of PI3K and 
subsequently Akt, and/or phosphorylation of Src homology 2 (SHP2) followed by growth factor receptor-
bound 2 (Grb2) and p44/42  MAPK  extracellular signal-regulated  (ERK  1/2).    Signalling  pathways 
downstream of these cascades then converge on the mitochondrion to inhibit MPTP opening and, as a 
consequence, prevent mitochondrial uncoupling and cell death.  If OB-R are absent or defective, these 
mechanisms would not be operative with the consequence that cell death would proceed unimpeded. Richard A Dixon  Results 
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CHAPTER 9 - LEPTIN-INDUCED MYOCARDIAL 
PROTECTION IN AN IN VIVO RAT MODEL OF I/R INJURY 
9.1  Introduction 
In addition to its  actions in the central nervous system with respect to the 
regulation of appetite and energy balance, leptin has been found to produce 
multiple effects in the peripheral tissues (Lee et al. 2008; Matarese et al. 2007a; 
Park et al. 2001; Harvey & Ashford 2003).  The administration of leptin in vivo, 
for example, has revealed that leptin is involved in a wide range of processes 
including  angiogenesis  (Anagnostoulis et al. 2008; Liapakis et al. 2008), 
neurogenesis (Garza et al. 2008) and lung development (Kirwin et al. 2006).  
Thus, it would appear that leptin functions as a mitogen through the activation of 
signalling pathways that have been implicated in protection against I/R injury.  
Leptin has been shown to influence cardiovascular function (see section 1.6.7).  
It has, for example, been found to  stimulate  NO  production  in  vascular 
endothelial cells (Winters et al. 2000) and to increase fatty acid oxidation in the 
heart  (Atkinson et al. 2002).  These observations,  coupled with reports that 
leptin acts through signalling pathways implicated in tissue protection led to the 
original hypothesis that leptin may act as a cardioprotective agent (Smith et al. 
2006).  Leptin is a  pro-inflammatory cytokine that has been linked to 
atherogenesis  (Loffreda et al. 1998),  heart failure (Abe et al. 2007)  and 
myocardial hypertrophy (Kartal et al. 2008; Purdham et al. 2008).  It is, however, 
important when considering the multiple actions of leptin to be aware of the fact 
that factors such as the concentrations of leptin employed, and whether 
treatment is given acutely or chronically can strongly influence outcomes.  In Richard A Dixon  Results 
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heart failure, for example, leptin secretion and signalling are increased after 
coronary artery ligation (CAL), resulting in activation of the JAK/STAT pathway 
and improved cardiac function (McGaffin et al. 2008).  By contrast, Purdham and 
colleagues demonstrated that the administration of leptin receptor antibodies, 
which block leptin signalling, following myocardial infarction decreased cardiac 
hypertrophy and improved function (Purdham et al. 2008). It appears, therefore, 
that  the  administration of leptin at specific time-points in  the development of 
heart failure may be protective.  Indeed, this is borne out by the observation that 
the administration of leptin at reperfusion in the isolated perfused mouse heart 
reduces myocardial I/R injury (Smith et al. 2006). 
Whilst the Langendorff isolated perfused heart is a convenient model for 
investigating the myocardial actions of drugs to the exclusion of humoral factors 
that may interfere with drug-induced responses, these same “interfering factors” 
may play important roles in modulating drug-induced actions. Leptin is 
functionally highly pleiotropic and, therefore, having shown that it reduces I/R 
injury  in vitro  it is important that the factors influencing leptin-induced 
cardioprotection are identified so that their involvement  in patients may be 
evaluated. In the present study, therefore, the effects of leptin on myocardial I/R 
injury in an in vivo rat model were investigated so that information that may 
prove relevant with regard to its clinical application might be obtained.     
9.2  Aim 
The aim in this chapter was to establish if leptin protects against myocardial I/R 
injury in an in vivo rat model.  Richard A Dixon  Results 
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9.3  Experimental Protocol & Materials 
9.3.1  Materials 
Sodium  pentobarbital  was obtained from Sagatal-Rhone, Merieux.  Heparin, 
used to prevent thrombosis, was obtained from Multiparin CP Pharmaceuticals 
Ltd.  Leptin and triphenyltetrazolium chloride (TTC) were provided by Sigma-
Aldrich Company Ltd (Gillingham, Dorset, UK).   
9.3.2  In vivo rat model of myocardial I/R injury 
Male rats were anaesthetised by i.p. injection of 50mg/kg sodium pentobarbital. 
When animals were sufficiently anaesthetised, as indicated by the loss of the 
pedal withdrawal reflex, a tracheal intubation was performed to allow artificial 
ventilation.  The carotid artery and jugular vein were then cannulated, in the 
case of the former to allow blood pressure to be monitored via a pressure 
transducer, and the latter to provide a route for drug delivery.  The jugular 
cannula remained connected to a 1ml syringe throughout the experiment to 
allow delivery of fluids (to maintain hydration) and drugs.  Electrocardiographic 
(ECG) recording was achieved by the  attachment of electrodes  to the two 
forelimbs and one hindlimb.  Left ventricular systolic and diastolic BP, heart rate 
and ECG were recorded using a PowerLab system connected to a computer 
(ADinstruments, Oxfordshire, UK).  Body temperature was monitored via a 
temperature probe inserted into the anus and maintained at 37 ± 1°C by 
regulating the temperature of the operation platform.  A left thoracotomy was 
then performed and the fourth intercostal space was opened carefully to allow 
visualisation of the heart.  The pericardium was then gently opened using Richard A Dixon  Results 
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forceps to allow access to the heart.  A 16mm round-bodied needle was used to 
place a 4.0 prolene suture under the LAD, entering just under the left atrium and 
exiting under the right pulmonary outflow tract.  The animal was stabilised for 
25min and then subjected to 30min ischemia followed by 120min reperfusion 
(see Figure 9.3.1)  
Figure 9.3.1  - Protocol for investigating the effects of leptin on myocardial I/R injury in an in vivo 
rat model. (A) Control rats were stabilised for 25min and then subjected to 35min ischaemia followed by 
120min reperfusion.  (B)  Rats subjected to an IPC protocol were stabilised for 5min followed by two 
cycles of 5min ischaemia and 5min reperfusion and then subjected to 35min ischaemia and 120min 
reperfusion.  (C) Rats were subjected to a protocol  identical to that of control experiments, but were given 
an intravenous bolus of leptin at 1min prior to reperfusion.  In all experiments at the end of reperfusion 
hearts were harvested and stored at -20°C to await analysis.  
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9.3.3  Treatment groups 
Wistar rats were randomly assigned to one of the following treatment groups 
(original group sizes are shown in brackets): 
Control  (n=5)  –  Rats were subjected to the standard I/R protocol (Figure 
9.3.1A) 
IPC (n=4) – Rats were subjected to an IPC protocol prior to the index ischaemia 
and reperfusion. 
10μg/kg  Leptin  treated  (n=5)  –  Rats were subjected to the standard I/R 
protocol, except that animals received an intravenous bolus of leptin (10μg/kg) 
1min prior to reperfusion. 
 
9.3.4  Exclusions 
One animal was excluded from the IPC group due to a small risk zone. 
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9.4  Results 
9.4.1  Leptin protects against myocardial I/R injury in an in vivo rat 
model  
 
Figure 9.4.1 – Effect of leptin, administered at reperfusion, on infarct size in an in vivo rat model of 
myocardial I/R injury.   Values are expressed as mean ± s.e.m  (n=3-5  for each group)  (one-way 
ANOVA). 
 
Leptin administered at 10 μg/kg (n=5) produced a significant 25.1% decrease in 
infarct size  when compared to control  (n=5)  animals  (50.9%±3.20  vs. 
68.0%±3.97, p=<0.05).  By contrast, IPC (n=3) decreases in infarct size that 
exceeded those seen with 10 μg/kg leptin were observed (IPC, 20.26%±1.83 vs. 
control, 68%±3.97, p=<0.001).   
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9.5  Discussion 
Recently, Purdham et al reported  that  antibodies directed against the  leptin 
receptor inhibited hypertrophy in the post-infarcted rat heart  (Purdham et al. 
2008).  These  data, perhaps,  lead one to conclude  that leptin  is essentially 
damaging to the cardiovascular system.  There is, however, a growing amount 
of data indicating that under certain conditions the administration of leptin can be 
protective (Qamar et al. 2006; Signore et al. 2008).  Indeed, this appears to be 
the case in relation to myocardial I/R injury (Smith et al. 2006; Eguchi et al. 
2008) and lipotoxicity (Unger 2005).  
9.5.1  Leptin protects the heart against I/R injury in an in vivo rat 
model  
Following on from the in vitro  studies  conducted previously in our laboratory 
(Smith et al. 2006) and those described in earlier chapters of this thesis, the 
data obtained in the present study with 10 μg/kg leptin clearly demonstrate that 
leptin is also able to protect the heart against I/R injury in vivo.  However, the 
decrease in infarct size by the administration of leptin at this particular 
concentration was relatively small when compared to the protection action of 
IPC.  Leptin at different concentrations may provide a greater cardioprotective 
effect.  Therefore, detailed dose-response studies, i.e. experiments performed 
with a wider range of leptin doses, should clarify this situation.  Whilst 10 μg/kg 
leptin produced a significant decrease in infarct size, IPC, used as a positive 
control, was found to elicit a greater protective effect (Figure 9.4.1), possibly 
indicating that leptin given at reperfusion is not as effective as IPC with respect 
to myocardial protection.  Alternatively, it could reflect the fact that the most Richard A Dixon  Results 
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effective dose of leptin has yet to be identified.  The doses of leptin used in the 
current study were extrapolated from a previous study which focused on the 
effects of leptin on NO synthesis (Fruhbeck 1999).  Thus, it was shown that 
significant dose-dependent increases in NO synthesis occurred with leptin when 
it was administered at 10μg/kg,  100μg/kg  and  1000μg/kg  (Fruhbeck 1999).  
Obviously,  with  the findings of the present study, one  has to consider the 
possibility that the doses of leptin that are effective at reducing infarct size may 
not coincide with those that increase NO production. 
9.5.2  Future directions 
The present study provides important preliminary data with respect to leptin’s 
potential as a cardioprotectant in the more physiological in vivo setting.  In the 
future, however, it is essential that detailed dose-response studies are carried 
out so that optimal doses of leptin can be identified.  Subsequently, studies 
focusing on the cellular signalling mechanisms activated by leptin in the in vivo 
setting need to be carried out so that the data obtained can be compared with 
those yielded by in vitro studies.  Ultimately, the studies conducted with in vivo 
models will establish if leptin might be considered as a potential future 
cardioprotective treatment in patients. Richard A Dixon  Summary & Conclusions 
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CHAPTER 10 - SUMMARY & CONCLUSIONS 
10.1  Summary of Findings 
 
Leptin administered at reperfusion reduced infarct size in an in vitro model of I/R 
injury in hearts from both Wistar and Zucker lean rats, but not in hearts from 
fa/fa animals.  
Leptin delayed the opening of the MPTP in cardiomyocytes from both Wistar 
and Zucker lean rats, but not from fa/fa animals. 
The effects induced by leptin were associated with the activation of the 
JAK/STAT and RISK pathways. 
Leptin administered at reperfusion was protective in an in vivo  rat model of 
myocardial I/R injury.   
10.2  Conclusions 
In this investigation the cellular mechanisms underlying the cardioprotective 
actions of leptin were investigated.  In addition, information was obtained which 
confirms previous findings made in this laboratory, namely that leptin-induced 
protection involves RISK pathway signalling (Smith et al. 2006).  Furthermore, 
data were obtained which may indicate that leptin administered at reperfusion 
protects against I/R injury via interaction with the OB-R.  Apart from the RISK 
pathway, the findings of the present investigation appear to indicate that 
JAK/STAT signalling also plays a significant role, this pathway being known to 
mediate the metabolic actions of leptin (Harvey & Ashford 2003).  Furthermore, 
the present study would suggest that the cardioprotective actions of leptin rely Richard A Dixon  Summary & Conclusions 
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upon the presence in the myocardium of a functional OB-Rb.  These data may 
have clinical relevance, especially in relation to patients with leptin resistance 
and/or hyperleptinaemia who are deficient or defective with respect to the leptin 
receptor.  Finally, leptin was shown to reduce I/R injury in an in vivo rat model of 
myocardial infarction.  Further investigations will provide additional information 
on the potential of leptin as a novel treatment against myocardial I/R injury.   
Reperfusion of the ischaemic myocardium is essential if damage to the heart is 
to be minimised (Piper et al. 2004).  The act of reperfusion itself, however, has 
been demonstrated to be associated with cardiac dysfunction and cell death 
(Manning & Hearse 1984; Piper et al. 1998; Yellon & Hausenloy 2007).  In this 
respect, the MPTP  represents an important target for cardioprotection 
(Halestrap et al. 2004).  It is now known that the conditions that occur following 
the reperfusion of the ischaemic myocardium, such as high levels of ROS and 
Ca
2+, trigger opening of the MPTP and lead to apoptotic signalling and cell death 
(Halestrap 2006).    Thus it could be hypothesised that leptin signalling in 
cardiomyocytes may occur via OB-Rb activation and subsequent JAK/STAT, 
PI3K-Akt and p44/42 MAPK  signalling, resulting in inhibition of MPT  and 
decreased infarct size.  
The adipocytokines were discovered relatively recently and leptin was the first of 
this group of hormones to be identified (Zhang et al. 1994).  Despite the fact that 
many of the central and peripheral actions of leptin have been identified much 
remains to be learnt regarding its cardiovascular actions.  Leptin is known to 
promote various processes which are detrimental to the cardiovascular system Richard A Dixon  Summary & Conclusions 
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(Purdham et al. 2008; Beltowski 2006a; Beltowski 2006b).  Paradoxically, 
however, leptin has also been shown to produce beneficial effects via 
stimulation of survival kinase pathways (Smith et al. 2006).  It has been 
reported, for example, that leptin signalling following a chronic ischaemic insult 
is associated with decreased cardiac dysfunction and remodelling (McGaffin et 
al. 2008).  Furthermore, it appears that the role of leptin in the promotion of 
coronary heart disease (CHD)  may have been overestimated.  Recent data 
suggest, for example, that the correlation between circulating leptin and CHD is 
moderate and  mostly dependent on BMI (Sattar et al. 2009).  It appears, 
therefore, that leptin and possibly other adipocytokines can act as protectants 
against cardiovascular pathologies.  Indeed, high BMI, which is associated with 
hyperleptinaemia, is associated with improved short-term outcomes with regard 
to cardiovascular mortality (Gruberg et al. 2002).  This phenomenon is known as 
the “obesity paradox.” Leptin, and other adipocytokines could, therefore, form 
part of an intrinsic protective mechanism in the heart.  It has been shown, for 
instance, that expression of leptin and OB-R are increased in response to I/R 
injury (Matsui et al. 2007).  The notion that hormones secreted by the heart act 
in an autocrine/paracrine fashion to protect the myocardium remains conjecture 
and   further investigation is needed to clarify the situation with regard to this 
hypothesis.        
10.3 Future Directions   
In future studies, the cardioprotective actions of leptin will need to be examined 
in more detail in in vivo models of I/R reperfusion injury so that a judgement can Richard A Dixon  Summary & Conclusions 
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be made as to its possible value as a therapeutic agent.  These studies should 
include detailed examinations of kinases activated by leptin, other than 
examined in this study, e.g. PTEN (Ning et al. 2006) and RhoA/ROCK (Zeidan 
et al. 2008), which are known to be modulated by leptin.  Such studies may help 
to  elucidate the mechanisms determining the beneficial  as  opposed to the 
detrimental actions of leptin in the heart.  Furthermore, the identification of the 
specific  OB-R  involved  in leptin-induced signalling should prove possible by 
employing  specific leptin receptor antibodies and blockers that have  recently 
become available (www.abbiotec.com).  Activation of the different populations of 
OB-R receptors could account for the high functional pleiotropy of leptin.  Hence, 
with the development of antagonists that target specific OB-R isoforms, it may 
be eventually prove possible to investigate in detail the physiological 
consequences of activating different OB-R subtypes. 
Employing STAT3 knockout mice will permit more detailed investigations of the 
role played by the JAK/STAT pathway in leptin-induced cardioprotection.  
Studies should also be directed at understanding how obesity influences leptin-
induced cardioprotection, cardioprotection with respect to hyperleptinaemia and 
leptin resistance.   
In conclusion, it is now recognised that adipose tissue is not merely an energy 
storage “depot” but, in  fact,  represents  the  body’s  largest endocrine organ. 
Further investigation of its principal products, i.e. the adipocytokines, will lead to 
a greater understanding of the many roles played by these substances, possibly Richard A Dixon  Summary & Conclusions 
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leading to the formulation of novel therapies for the treatment of cardiovascular 
disease and the metabolic syndrome.    
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APPENDIX 
 
The following section presents the raw data of chapter 8 (please see section 
8.4).  As aforementioned in the footnote on p.209 in section 8.4, a large amount 
of variation with respect to the baseline time to depolarisation of cardiomyocytes 
was observed.  Therefore, the average time taken for control myocytes to 
depolarise was used as 100% and each result was calculated with respect to 
this value and expressed as a percentage, i.e. if a treated cardiomyocyte took 
twice the time to depolarise as the control the value assigned to this 
cardiomyocyte would be 200%. The original data are presented in tables on the 
following 5 pages.  
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One  Wistar  Zucker Lean  fa/fa 
  Control  Leptin   CsA  Control  leptin  CsA  Control  Leptin A  CSA 
  126  180    151  220  173  114  183  157 
  140  151    169  326  234  181  145  160 
  98  151    171  263  261  200  196  210 
  120  150    181  338  311  175  106  163 
  33  106    265  348  401  177  104  143 
  41  173    118  232  328  204  179  202 
  74  165    167  263  322  126  254  261 
  167  163    192  289  429  155  75  143 
    106    238  277  541  167  160  218 
    98    216  269  189  155  177  212 
    192    167  303  180  183  147  230 
        216  261  189  196  169  140 
          344  224  128  110  185 
          413    194    238 
          326        216 
          405        246 
                   
Average  99.9  148.6    187.6  304.8  290.9  168.2  154.2  195.3 
0.1 – Table showing raw cardiomyocyte depolarisation data 
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Two  Wistar   Zucker Lean  fa/fa 
  Control  Leptin  CSA  Control  leptin  CsA  Control  Leptin  CsA 
  175  273  234  139  192  165  84  110  128 
  194  265  263  139  226  236  70  112  135 
  246  328  287  212  206  332  120  126  116 
  200  257  301  212  181  277  124  141  135 
  212  295  280  145  224  297  120  135  167 
  255  270  289  179  208  181  126  145  80 
  252  265  309  190  224  253  70  92  120 
  228  356  352  192  281  265  76  155  120 
  173  224  346  116  135  110  92  212  110 
  175  240  240  84  198  236  92  210  200 
  224  326  277  167  226  194  118  114  163 
  206  269  299  145  155  135  86.6  122  110 
    320  260  128  185  198  112  86.6   
    194    143  175  165  61  118   
    240    163  137  228  63  137   
    313    192  179      102   
    322            114   
                   
Average  211.7  279.8  287.5  159.1  195.8  218.1  94.3  131.3  132.0 
0.2 – Table showing raw cardiomyocyte depolarisation data 
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Three  Wistar  Zucker Lean  fa/fa 
  Control   leptin  CSA  Control  leptin  CsA  Control  leptin  CsA 
  102  86  153  135  181  183  86.6  82  133 
  60  92  153  175  242  232  80.7  100  165 
  106  122  206  163  297  228  110  78  202 
  80  140  139  169  230  269  126  110  181 
  100  100  145  226  185  187  126  118  161 
  112  191  100  90  191  157  133  82  147 
  112  163  208  198  263  206  124  84  151 
  126  108  165  183  263  315  139  120  159 
  70  126  190  216  151  185  165  68  153 
  106  120  126  147  175  206  147  68  200 
  114  150  145  173  216  151  92  80  102 
  65    90  151    192  84  80  130 
  70    129        116  65   
  80            85  90   
  86            85  102   
  98            84  110   
  112            145  110   
                   
Average  94.1  127.1  149.9  168.8  217.6  209.3  113.4  91.0  157.0 
0.3 – Table showing raw cardiomyocyte depolarisation data 
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Four  Wistar   Zucker Lean  fa/fa 
  Control  Leptin  CSA1  Control  leptin  CsA  Control  leptin  CsA 
  96.5  213  112  104  181  189  137  151  163 
  96.5  196  131  139  208  228  159  129.9  175 
  116  271  137  196  224  204  171  177  173 
  122  145  150  175  242  193  143  226  212 
  104  173  185  177  171  224  179  141  147 
  108  238  177  218  202  155  243  204  252 
  108  157  189  212  212  196  112  171  130 
  80  157  108  169  244  220  153  135  175 
  114  189  122  173  135  218  155  143  240 
  141  185  114  192  214  179  112  160  133 
  234  208  122  181  214  200  155  143  140 
  139  256  143  189  214  218  220  160  155 
  173  254  157      320  232  118   
    163  131        94  145   
    210  128        94  165   
              194     
               
Average  125.5  201.0  140.4  177.1  205.1  211.1  159.6  157.9  174.6 
0.4 – Table showing raw cardiomyocyte depolarisation data 
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Five  Zucker Lean  fa/fa 
  Control  leptin  CsA  Control  leptin  CsA 
  139  252  171  187  228  198 
  200  252  226  232  228  238 
  204  257  250  232  232  257 
  218  281  236  175  235  259 
  189  322  271  218  185  198 
  206  238  269  124  189  218 
  206  271  200  145  222  253 
  281  265  257  185  236  218 
  297  275  232  224  190  280 
  336  316  230  228  220  222 
  204  254  277  242  271  236 
  206  271  204  261  147  265 
  206  242    179  210  170 
  244  275    196  234  208 
  263  291    220  126  257 
    281      171   
          198   
             
  226.6  271.4  235.3  203.2  207.2  231.8 
 
 
      0.5 - Table showing raw cardiomyocyte depolarisation data 
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Abstract
Introduction Activation of the Reperfusion Injury Salvage
Kinase (RISK) pathway, which incorporates phosphatidyli-
nositol-3-OH kinase (PI3K)-Akt/protein kinase B (PKB) and
p44/42 mitogen-activated protein kinase (MAPK), underlies
protection against ischemia–reperfusion (I/R) injury. The
temporal nature of the activation of these RISK pathway
components during reperfusion is, however, uncertain. We
examined Akt and p44/42 phosphorylation in hearts
subjected to ischemia and varying periods of reperfusion
in the absence or presence of the putative cardioprotectant,
apelin-13. Akt activity was also measured.
Materials and methods Langendorff perfused C57Bl/6J
mouse hearts were subjected to 35 min global ischemia
followed by 0, 2.5, 5 or 10 min reperfusion with or without
1μMapelin-13.Basalandapelin-inducedphosphorylation of
Akt (at both the threonine 308 and serine 473 phosphory-
lation sites) and p44/42 during the reperfusion phase was
determined by Western blotting and Akt activity measured
using an Enzyme-Linked ImmunoSorbent Assay (ELISA).
Results Basal phosphorylation of both Akt and p44/42
increased progressively with time of reperfusion. Apelin
enhanced Akt and p44/42 phosphorylation at all reperfu-
sion time points. Akt activity did not change under basal
conditions but was increased by apelin at 5 min (NS) and
10 min (p<0.05) reperfusion.
Discussion We conclude that under basal conditions Akt
and p44/42 phosphorylation increases with time of reperfu-
sion but that this is not accompanied by increased kinase
(Akt) activity. On application of a cardioprotectant, however,
kinase phosphorylation and activity are enhanced suggesting
that it is the combination of these two mechanisms that may
underly the tissue preserving actions of such agents.
Key words myocardium.ischemia–reperfusioninjury.
salvagekinases.temporalchanges
Introduction
It is now generally accepted that phosphorylation of the
Reperfusion Injury Salvage Kinase (RISK) pathway compo-
nents Akt/protein kinase B (PKB) and p44/42 mitogen-
activated protein kinase (MAPK), is a vital step in the series
of events leading to myocardial protection against ischemia–
reperfusion (I/R) injury [1]. When the maximal phosphor-
ylation/activation of these kinases occurs during the
reperfusion phase is, however, open to conjecture. For
example, different laboratories often sample myocardium
for Western blot analysis at different time points. The
possibility that temporal differences occur between the two
kinases with regard to their activation has also not been
considered. In addition, it cannot be assumed that different
cardioprotective agents necessarily stimulate kinase activa-
tion at the same time points.
Avariety of chemically diverse substances protect against
myocardial injury, as evidenced by reduced infarct size,
including endogenous factors such as the adipocytokines
adiponectin and leptin [2, 3]. We have reported that another
Cardiovasc Drugs Ther (2007) 21:409–414
DOI 10.1007/s10557-007-6054-y
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J. C. Simpkin: R. A. Dixon:M. B. Cooper:D. M. Yellon (*)
The Hatter Cardiovascular Institute,
University College London Hospital and Medical School,
67 Chenies Mews,
London WC1E 6HX, UK
e-mail: d.yellon@ucl.ac.ukadipocytokine, namely apelin, also reduces infarct size [4].
Additionally, the administration of apelin within 5 min of
reperfusion following a period of lethal ischemia was found
to result in significant increases in the phosphorylation
states of Akt and p44/42 (increases that were abrogated by
LY294002 and UO126, inhibitors of Akt and p44/42, re-
spectively), although we did not establish if these increases
were maximal or not [4]. Furthermore, apelin was shown to
delay the opening of the mitochondrial permeability transi-
tion pore (MPTP) in rat cardiomyocytes via a mechanism
that was blocked by LY294002 and MEK inhibitor 1 [4].
Given our previous experience with apelin we, therefore,
decided to use this peptide as the cardioprotective agent in
the present study to investigate possible temporal changes
occurring with respect to kinase phosphorylation and
activity during reperfusion. Western blot analysis was used
to examine the phosphorylation of Akt, at both its threonine
308 and serine 473 phosphorylation sites, and p44/42 at four
time points (0, 2.5, 5 and 10 min) during the reperfusion
phase that follows a period of lethal ischemia. Additionally,
in the case of one of the kinases, i.e. Akt, a recently in-
troduced Enzyme Linked ImmunoSorbent Assay (ELISA)
was employed to investigate if Akt activity reflected the Akt
phosphorylation state.
Materials and methods
Animals The current study was carried out in accordance
withThe Guide for the care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication no.85–23, revised 1996) and was approved by
the UCL Hospitals Ethics Committee.
Murine Langendorff model of ischemia–reperfusion injury
Adult male C57Bl/6J mice (ca. 30 g) were given 100 U of
heparin by intraperitoneal injection prior to cervical disloca-
tion. Hearts were then excised and perfused retrogradely via
the aorta at a constant pressure of 100 mm Hg with
oxygenated Krebs-Henseleit buffer, pH 37°C [3, 5]. Myo-
cardial temperature (thermal probe) and heart rate (ventric-
ular balloon) were monitored throughout the perfusion
periods. Hearts underwent 30 min stabilisation followed by
35 min global ischemia (achieved by total perfusion arrest)
and 0, 2.5, 5 or 10 min reperfusion. Where necessary Krebs
buffer containing 1 μM apelin-13 was substituted for nor-
mal buffer at reperfusion, these hearts corresponding to the
cardioprotectant-treated group. Following the appropriate
reperfusion period hearts were snap-frozen and stored at
−80°C until analysis.
Western blot analysis Proteins from previously stored
cardiac samples (−80°C) were extracted by homogenisation
followed by high-speed centrifugation and the resultant
supernatants assayed for total protein using a bicinchoninic
acid (BCA) assay. Proteins were then separated by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to Hybond ECL nitrocellulose mem-
branes (Amersham Biosciences). Primary and secondary
antibodies (Cell Signaling Technology) and ECL Western
blotting reagent (Amersham Biosciences) were then used to
detect total and phosphorylated Akt and p44/42 MAPK; in
the case of Akt antibodies directed against both the threonine
308 and serine 473 phosphorylation sites were employed
[3, 5]. The nitrocellulose membranes were then exposed to
photographic film which was scanned and protein band
intensity, expressed as arbitrary units (AU), determined by
computerised densitometry (NIH Image 1.63).
Akt activity assay Myocardial samples were homogenised
as described above (see section on Western blotting) and Akt
in the supernatants extracted using a procedure that involves
incubation with an Akt antibody (Calbiochem) and adsorp-
tion of immunoprecipitated Akt onto Protein A/Protein G-
Plus agarose beads (Calbiochem). Akt activity was measured
using a recently described K-LISA ™ Akt activity assay kit
(Calbiochem), i.e. an ELISA-based activity assay that
employs a biotinylated peptide substrate that is phosphory-
lated on the second serine by Akt1, Akt2, Akt3, SGK (Serum
Glucocorticoid Kinase) and MSK1. The extracted tissue
samples were incubated together with biotinylated substrate
in the presence of ATP in the wells of a streptavidin-coated
96-well plate. The resultant phosphorylated substrate was
then detected with a phosphoserine detection antibody
followed by an HRP-antibody conjugate and colour devel-
opment with TMB substrate. The absorbance was then read
at 450/570 nm and enzyme activity expressed as optical
density per 10 mg protein.
Statistical analysis Data are given as mean±SEM. Compar-
isons between groups were made using factorial, one-way
analysis of variance (ANOVA). Where a significant F-value
was obtained the Fisher’s protected least significant differ-
ence post hoc test was used for between group comparisons.
Differences were regarded as statistically significant if a
value of p<0.05 was obtained.
Results
Akt phosphorylation Western blot analysis revealed that under
basal conditions (i.e. in the absence of 1 μM apelin-13) Akt
phosphorylation at the serine 473 site increased with time of
reperfusion compared to control (0 min reperfusion), increases
of 165% (p<0.001) and 249% (p<0.001) being recorded for 5
410 Cardiovasc Drugs Ther (2007) 21:409–414and 10 min, respectively (Fig. 1). In the presence of apelin-13,
Akt/serine 473 phosphorylation was enhanced relative to the
corresponding basal level by 70% (p<0.01), 25% (p<0.05)
and 34% (p< 0 . 0 0 1 )a t2 . 5 ,5 ,a n d1 0m i nr e p e r f u s i o n( F i g .1).
Akt/threonine 308 phosphorylation increased with time of
reperfusion by 271% (p<0.001) and 623% (p<0.0001) for 5
and 10 min, respectively, compared to control (0 min reper-
fusion; Fig. 2). On application of apelin-13 Akt/threonine 308
phosphorylation was increased relative to the corresponding
basal level by 117% (p<0.05) and 42% (p<0.05) at 2.5 and
5 min reperfusion (Fig. 2).
Total Akt levels did not differ markedly between the dif-
ferent groups (Figs. 1 and 2).
p44/42 phosphorylation As seen with Akt, p44 and p42
phosphorylation under basal conditions also increased with
time of reperfusion (Figs. 3 and 4). Thus, in the case of p44,
Fig. 1 Akt/serine 473
phosphorylation, determined by
Western blot analysis, under
basal conditions and in the
presence of the cardioprotectant
apelin-13 (1 μM). Hearts
underwent a protocol that in-
volved 30 min stabilisation
followed by 35 min global is-
chemia (achieved by total per-
fusion arrest) and 2.5, 5 or
10 min reperfusion with or
without apelin. P Phosphorylat-
ed and T total. Data (relative
density readings) are presented
as mean±SEM (single asterisk
denotes p<0.05, double
asterisk denotes p<0.01, single
dagger denotes p<0.001;
n=3–4)
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Fig. 2 Akt/threonine 308 phosphorylation, determined by Western blot
analysis, under basal conditions and in the presence of apelin-13 (1 μM).
Hearts underwent a protocol that involved 30 min stabilisation followed
by 35 min global ischemia (achieved by total perfusion arrest) and 2.5, 5
or 10 min reperfusion with or without apelin. P Phosphorylated and T
total. Data (relative density readings) are presented as mean±SEM
(single asterisk denotes p<0.05,single dagger denotes p<0.001,double
dagger denotes p<0.0001; n=3–4)
Cardiovasc Drugs Ther (2007) 21:409–414 411 411phosphorylation at 2.5, 5 and 10 min was increased by 29%
(NS), 310% (p<0.0001) and 485% (p<0.0001), respectively
(Fig. 3). With p42 increases of 28% (NS), 379% (p<0.0001)
and 692% (p<0.0001) were observed (Fig. 4). On addition
of apelin-13, p44 and p42 phosphorylation was increased
relative to the basal level (Figs. 3 and 4). These changes were
associated primarily with the p42 isoform, increases at 2.5
and 5 min reperfusion of 75% (p<0.05) and 47% (p<0.01),
respectively, being observed (Fig. 4). With p44 a less marked
but significant increase (+28%, p<0.05) was recorded at
5 min reperfusion only (Fig. 3). Again, as for total Akt, total
p44 and p42 levels did not exhibit significant differences
between the different groups (Figs 3 and 4).
Akt activity HavingestablishedthattheAktELISAwaslinear
on varying the amount of cardiac extract included in the assay
(data not shown), Akt activity under basal conditions and in
the presence of apelin-13 (1 μM) was investigated. Basal Akt
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Fig. 3 p44 phosphorylation,
determined by Western blotting,
in the absence and presence of
apelin-13 (1 μM). Hearts
underwent 30 min stabilisation
followed by 35 min global is-
chemia and 2.5, 5 and 10 min
reperfusion with or without
apelin. P Phosphorylated and
T total. Values (relative density)
are expressed as mean±SEM
(single asterisk denotes p<0.05,
double dagger denotes
p<0.0001; n=3–4)
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Fig. 4 p42 phosphorylation,
determined by Western blot
analysis, under basal conditions
and in the presence of the
cardioprotectant apelin-13
(1 μM). Hearts were perfused
for 30 min (stabilisation)
followed by 35 min ischemia
and 2.5, 5 or 10 min reperfusion
with or without apelin.
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are presented as mean±SEM
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double dagger denotes
p<0.0001; n=3–4)
412 Cardiovasc Drugs Ther (2007) 21:409–414activity was not found to vary with time of reperfusion and
was not different from that observed under control conditions
(0 min reperfusion; Fig. 5). With apelin-13 Akt activity was
increased over basal levels at 5 min (+ 32%, NS) and 10 min
(+100%, p<0.05) reperfusion (Fig. 5).
Discussion
In summary, this study has shown that under basal conditions
of ischemia–reperfusion (i.e. in the absence of the cardiopro-
tective agent apelin) phosphorylation of the RISK pathway
components, Akt and p44/42, increased in a time-dependent
fashionintheearlyminutesofreperfusion.Theseincreasesin
phosphorylation were, however, not accompanied by in-
creased kinase (i.e. Akt) activity. Contrasting with the results
obtainedunder basalconditions,theapplicationofapelinwas
found to result in not only increased Akt (serine 473 and
threonine 308) and p44/42 phosphorylation (i.e. relative to
the relevant controls for each reperfusion time-point) but also
increased Akt activity at 5 and 10 min reperfusion, being
statistically significant for the later time point.
We havereportedpreviouslythatapelin-13 administeredat
reperfusionreducesinfarctsizecomparedtocontrol(i.e.inthe
absence of apelin) and that this is associated with increased
Akt and p44/42 phosphorylation at 5 min reperfusion [4]. In-
terestingly, in the present study kinase phosphorylation was
found to increase progressively and, indeed, substantially
under basal (i.e. control) conditions with time of reperfusion.
Studies in which the cardioprotective effects of atorvastatin
were investigated yielded comparable findings for basal Akt
and eNOS phosphorylation [6]. One could suggest that such
increases reflect an attempt by the myocardium to protect
itself from I/R injury. It would appear, however, that in order
for significant myocardial preservation to occur a protective
agent, such as apelin, needs to be present [4]. Hence, the
elevations in kinase phosphorylation that take place under
basal conditions are, for whatever reason, not appropriate in
the context of RISK pathway-mediated cardioprotection. The
data obtained may also indicate that increased kinase phos-
phorylation is not necessarily accompanied by increased
kinase activity. It is conceivable that for kinase activity to be
elevated a threshold of phosphorylation must be exceeded,
such as that induced by a cardioprotective agent, i.e. kinase
phosphorylation under basal conditions may not be sufficient
to “kick-start” kinase activity. Previously, Goto et al. [7] have
invoked a similar scenario in relation to preconditioning of
the myocardium. It was demonstrated that a preconditioning
threshold needed to be surmounted in order for Gi protein-
receptor-stimulated release of endogenous cardioprotective
substances, such as adenosine, bradykinin, noradrenaline
and opioids, to occur at levels sufficient to reduce infarction
[7]. In the current study support for such a concept was
provided by the observations made when Akt phosphoryla-
tion (at serine 473 and threonine 308) and Akt activity were
compared at the different reperfusion time-points, a signif-
icant increase in Akt activity only being observed after
10 min treatment with apelin: of course, one cannot, exclude
the possibility that under normal circumstances a delay may
exist between kinase phosphorylation and activation of the
enzyme. A further point to be considered regarding basal
versus stimulus-induced kinase phosphorylation and infarc-
tion concerns the observation that although inhibitors of
RISK pathway kinases abrogate the reductions in infarct
size stimulated by cardioprotective treatments, including
apelin [4], these inhibitors do not increase infarct size under
basal conditions [1]. As these inhibitors substantially inhibit
kinase phosphorylation under basal conditions, as well as
that induced by cardioprotective agents, one might have
expected a concomitant increase in infarct size relative to
control. Nevertheless, this finding is consistent with the
proposal that basal kinase phosphorylation is not appropriate
in relation to RISK pathway-mediated cardioprotection.
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Fig. 5 Akt activity, as
determined by ELISA, in the
absence and presence of apelin-
13 (1 μM). Hearts underwent a
procedure which involved
30 min perfusion to achieve
stabilisation followed by 35 min
global ischemia (total perfusion
arrest) and 2.5, 5 or 10 min
reperfusion in the absence or
presence of apelin. Values
(optical density/10 mg protein)
are expressed as mean±SEM
(single asterisk denotes p<0.05;
n=3–4)
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pathway-mediated cardioprotection concerns the particular
isoforms of the kinases that are activated under different con-
ditions. Akt, for example, exists as three isoforms designated
Akt1,Akt2andAkt3[8]. When blotting for phospho-Akt we
used antibodies directed against both the threonine 308 and
serine 473 sites [9]. These antibodies recognize all three Akt
isoforms when phosphorylated at the appropriate sites. Akt1
signaling is generally recognized as playing an important
role in myocardial protection [10, 11], including in relation
to ischemia–reperfusion injury [12]. It is, however, possible
that factorswhich promotecellular survival maydoso viathe
phosphorylation of Akt2 and Akt3 also, ultimately leading to
increased Akt activity. In this regard, it should be noted that
whilst theAkt1 isoform predominates in theheart,substantial
expression of Akt2 also occurs, whilst Akt3 phosphorylation
is upregulated in diseased hearts [13, 14]. Therefore, phos-
phorylation of the Akt2 and Akt3 isoforms, in addition to
Akt1, might occur under specific conditions and influence
cardioprotective mechanisms.
An alternative possibility to be considered in attempting to
reconcile kinase phosphorylation with kinase activity con-
cernstheparticularsitesthatarephosphorylatedonthekinase.
As outlined above Akt can be phosphorylated at two sites and
it has been suggested that full Akt activation requires two
phosphorylationevents[9, 15]. Hence, this is the reason why
we blotted for both the serine 473 and threonine 308 phos-
phorylation sites in the present study. Interestingly, we found
that the increases, as induced by apelin, observed with re-
spect to threonine 308 phosphorylation appeared generally to
exceed those for serine 473 (i.e. at 2.5 and 5 min reper-
fusion). One could, therefore, hypothesise that phosphoryla-
tion of the threonine 308 site might represent a key step in
relation to Akt activation in the setting of cardioprotection,
although this will need to be investigated rigorously in order
to assess the relative contributions made by the two phos-
phorylation sites to cardioprotection. The fact remains, how-
ever, that we observed a temporal difference between peak
Akt phosphorylation, including that for the threonine 308
site, and maximal Akt activity.
Turning to p44/42, it is unfortunate that parallel measure-
ments of both the phosphorylation states and activities of this
kinase were not made under the different conditions
examined. The present study was, however,only preliminary
and as commercially available ELISA assays for p44/42
have now come “online” measurements will be carried out in
future investigations to establish if similar profiles to those
seen with Akt are obtained.
To conclude, we have obtained evidence that the phos-
phorylation of RISK pathway components and specifically
Akt does not necessarily equate with kinase activity. Impor-
tantly, kinase phosphorylation under basal conditions, even
if substantial, does not appear to be consistent with
cardioprotection and the introduction of an added stimulus
in the form of pre- or post-conditioning, or a pharmacolog-
ical agent is necessary in order to tip the balance in favour of
myocardial preservation. Future, more detailed studies in-
cluding measurements of p44/42 kinase activity, as well as
Akt activity, should resolve the situation with respect to the
relationship between the phosphorylation and activation of
RISK pathway components and cardioprotection.
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The Cardioprotective Actions of Leptin Are Lost in the
Zucker Obese (fa/fa) Rat
Richard A. Dixon, BSc, Sean M. Davidson, PhD, Abigail M. Wynne, MSc, Derek M. Yellon, DSc,
and Christopher C. T. Smith, PhD
Abstract: Protection against myocardial ischemia–reperfusion
injury, including that induced by leptin, involves activation of the
reperfusion injury salvage kinase pathway and inhibition of the
mitochondrial permeability transition pore. In the current study, we
explored the mechanisms underlying leptin-induced cardioprotection
further with reference to the leptin receptor (OB-R) and obesity. We
examined hearts from Wistar and Zucker lean rats that express
functional OB-R and Zucker obese (fa/fa) rats with nonfunctional
OB-R. In Langendorff experiments, leptin (10 nM) caused signiﬁcant
reductions in infarct size in hearts from Wistar (leptin treated,
32.4% 6 3.9% vs. control, 53.2% 6 3.2%, P , 0.01) and Zucker
lean animals (leptin treated, 25.2% 6 3.7% vs. control, 53.9% 6
11.3%, P , 0.01). By contrast, hearts from (fa/fa) did not exhibit
signiﬁcant decreases in infarct size. Leptin increased p44 and p42
phosphorylation in Wistar rat hearts by 103.9% (P , 0.05) and
157.3% (P , 0.001), respectively, and by 97.0% (P , 0.05) and
158.1% (P , 0.05) in hearts from Zucker lean rats. Akt/serine-473
phosphorylation was increased in Wistar hearts by 96.7% (P , 0.05),
whereas Akt/threonine-308 phosphorylation was elevated by 43.9%
(P , 0.05) in Zucker lean rat hearts. Leptin did not inﬂuence Akt or
p44/42 phosphorylation in (fa/fa) animals. On leptin treatment,
mitochondrial permeability transition pore opening was delayed
by 43% (P , 0.01) and 30.9% (P , 0.01), respectively, in
cardiomyocytes from Wistar and Zucker lean rat hearts but not in
cardiomyocytes from (fa/fa). This study provides the ﬁrst evidence
that myocardial sensitivity to the tissue preserving actions of leptin is
inﬂuenced by adiposity and OB-R status.
Key Words: ischemia–reperfusion injury, leptin, leptin receptor,
obesity
(J Cardiovasc PharmacolTM 2009;53:311–317)
INTRODUCTION
Reperfusion is required for salvage of the ischemic
myocardium to occur. Paradoxically, however, reperfusion
itself can lead to enhanced damage to the myocardium,
1 and
therefore, effective means of reducing this so-called ischemia–
reperfusion (I/R) injury are being actively sought. Various
treatments have been reported to protect against myocardial
I/R injury,
2–4 many of which have been shown to be associated
with activation of the reperfusion injury salvage kinase (RISK)
pathway, which incorporates phosphatidyl-inositol 3-OH
kinase (PI3K) cellular Akt/protein kinase B (Akt) and
p44/42 mitogen-activated protein kinase (MAPK) extracellular
signal–regulated MAPK (ERK 1/2),
5 opening of mitochondrial
ATP-sensitive potassium channels (KATP), and inhibition of
the mitochondrial permeability transition pore (MPTP).
6,7
Obesity, as reﬂected by excessive deposition of
abdominal fat, is reaching epidemic proportions.
8 Although
previously thought to be purely an energy storage depot,
adipose tissue is now recognized as being an active endocrine
organ producing a plethora of cytokines and other bioactive
molecules,
9 including the so-called adipocytokines. Leptin,
the 16-kDa product of the Obese (ob) gene, was the first
adipocytokine to be identiﬁed and is produced primarily by
white adipose tissue.
10 It has important roles in the control of
energy homeostasis and satiety
8 and also in bone forma-
tion,
11,12 blood pressure control,
13 hematopoiesis, and re-
production
14,15 and has been implicated in myocardial
infarction linked to obesity.
16 Previously, we demonstrated
that leptin reduces infarct size in the murine heart via
activation of PI3K-Akt and p44/42 and inhibits MPTPopening
in rat cardiomyocytes.
17 Interestingly, apart from adipose
tissue, leptin has been shown to be secreted by the heart in
response to I/R injury,
18,19 and we suggested that leptin-
induced cardioprotection might occur via an autocrine/para-
crine mechanism.
17
Six isoforms of the leptin receptor (OB-R) have been
identiﬁed, OB-Ra, OB-Rb, OB-Rc, OB-Rd, OB-Re, and OB-
Rf.
20 These isoforms share a highly conserved extracellular
leptin-binding domain but differ in the size of the intracellular
portion of the receptor,
21 this being reﬂected by differences in
their signaling capacities.
22 OB-Ra and OB-Rb expression
occurs to signiﬁcant extents in isolated cardiomyocytes.
19,23
It is, however, the OB-Rb that is believed to be the most
important isoform physiologically, particularly in relation to
metabolism.
21 A missense mutation within the OB-R has been
linked to the obese phenotype in the (fa/fa) Zucker rat.
24 This
mutation does not render the receptor incapable of binding
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components, a prerequisite for cell signaling initiated by the
activation of this class of receptors.
25,26 Although the role of
the Ob-R in hypothalamic function and energy balance has
been extensively investigated, the part it plays in cardiac
function remains to be fully elucidated.
Given that leptin protects the myocardium against I/R
injury
17 and that OB-R expression has been detected in the
heart, we hypothesized that leptin’s effectiveness as a cardio-
protective agent is related to adiposity and the presence on the
myocardium of functional OB-R. This theory was investigated
using hearts harvested from Wistar, Zucker lean, and Zucker
obese (fa/fa) rats; Wistar and Zucker lean rats express the
normal OB-R gene, the extents of gene expression in the latter
depending upon whether animals are heterozygous or
homozygous, whereas fa/fa possess a mutation in the
extracellular domain of all the OB-R isoforms.
24
MATERIALS AND METHODS
Animals
Male Wistar rats and Zucker obese (fa/fa) rats and their
lean (fa/+) littermates (aged circa 4 months) were used in these
studies and were obtained from Charles River UK. Animals
were treated in accordance with the Animals (Scientiﬁc
Procedures) act 1986 published by the UK Home Ofﬁce and
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Heath (Publication
No. 85-23, revised 1996).
Langendorff Isolated Perfused Rat
Heart Model
Langendorff experiments were carried out as described
previously.
27 Rats were anesthetized with sodium pentobarbi-
tal by intraperitoneal injection (50 mg/kg). Heparin was
administered concomitantly to prevent thrombus formation
(300 IU). Heartswere rapidlyexcisedand placed in an ice-cold
buffer and then perfused retrogradely via the aorta at a constant
pressure of 100 mm Hg with a modiﬁed Krebs–Henseleit
buffer consisting of: NaCl 118 mM, NaHCO3 25 mM, KCl
4.8 mM, MgSO4 1.2 mM, KH2PO4 1.2 mM, CaCl2 1.7 mM,
and glucose 11 mM and aerated with carbogen pH 7.3–7.5 at
37C. Temperature was monitored via a probe inserted into an
incision made in the pulmonary trunk and hearts maintained at
37 6 0.5C. Heart rate was monitored via a latex intra-
ventricular balloon inﬂated, so that an end-diastolic pressure of
5–10 mm Hg was achieved. Hearts underwent a stabilization
period of 40 minutes followed by 35 minutes of regional
ischemia and 120 minutes of reperfusion. Regional ischemia
was induced by total occlusion of the left anterior descending
coronary artery and achieved by tightening a 3.0 silk suture
that had been placed previously around the vessel, until
a substantial reduction in heart rate and coronary ﬂow was
observed. At reperfusion, hearts were perfused with normal
buffer or a buffer containing leptin with or without 15 mM
LY294002 (PI3K inhibitor) or 10 mM UO126 (MAPK
inhibitor) for the ﬁrst 30 minutes of reperfusion. At the end
of the reperfusion period, the risk zone was established by
retightening the suture and by the introduction of 5% Evans
blue dye into the aorta. Hearts were immediately frozen
at 220C and subsequently cut into 2-mm slices. Heart slices
were then incubated in a 1% triphenyltetrazolium chloride
solution to stain viable tissue. Slices were analyzed using
a computerized planimetry package (Summa Sketch II;
Summagraphics, Seymour, CT). Infarct size was expressed
as a percentage of area at risk (IS/AAR%). The risk zones for
both Wistar and Zucker hearts were between 40% and 75% of
the area of the left ventricle.
Western Blotting
Rat hearts were perfused for 40 minutes to allow them to
stabilize and then subjected to 35 minutes of regional ischemia
(as described above). Hearts were then reperfused for 15
minutes at which time theventricular tissue at risk was excised
and snap frozen in liquid nitrogen before being stored at
280C to await analysis. On analysis, the proteins were
extracted by homogenizing samples on ice in a buffer
containing: 100 mM NaCl, 10 mM Tris (pH 7.6), 1 mM
EDTA (pH 8.0), 2 mM sodium pyrophosphate, 2 mM sodium
ﬂuoride, 2 mM b-glycerophosphate, and a protease inhibitor
cocktail. Samples were then centrifuged at 12,900 3 g for
10 minutes and the supernatants assayed for protein content
using a bicinchoninic acid assay. Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis was then used to separate
the proteins, 30–60 mg of total sample protein being loaded
per well. Subsequent to separation, the proteins were trans-
ferred to Hybond-enhanced chemiluminescence nitrocellulose
membranes. Total and phosphorylated Akts (serine-473 and
threonine-308) and p44/42 MAPK were detected using
appropriate primary and secondary antibodies (Cell Signaling
Technology, Hitchin, United Kingdom) and an enhanced
chemiluminescence blotting reagent (Amersham Biosciences,
Little Chalfont, United Kingdom). The nitrocellulose mem-
branes were then exposed to photographic ﬁlm, which was
scanned, and the intensities of the protein bands, expressed as
arbitrary units, determined by computerized densitometry
(National Institutes of Heath Image 1.63). The relative
amounts of phosphorylated and total proteins were then
calculated correcting for differences in protein loading as
established by probing for b-actin (Abcam, Cambridge,
United Kingdom).
Isolated Cardiomyocytes
Ventricular cardiomyocytes were isolated from Wistar,
Zucker lean (fa/+), and fa/fa rat hearts as described
previously.
28 A procedure involving the perfusion of hearts
with a buffer solution containing collagenase (280 U/mg) was
used to isolate cardiomyocytes, 1.5–3 million cells being
routinely obtained per heart. In a model of oxidative stress,
cells were loaded with a dye, tetramethylrhodamine methyl
ester (TMRM), for 15 minutes, which was then exchanged
for saline. Upon laser stimulation, TMRM generates mito-
chondrial reactive oxygen species (ROS), mimicking the burst
of ROS that occurs as a consequence of reperfusing the
ischemic myocardium. Thus, MPTP opening is indicated
by the dequenching of TMRM associated with mitochondrial
depolarization. The times (seconds) until mitochondrial
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experiment, and the data obtained after drug treatments were
normalized versus control (untreated). Leptin (10 nM) was
added to the buffer containing TMRM to investigate the
inﬂuence of these agents on MPTP opening. Cyclosporin
(CsA) (200 nM), a recognized inhibitor of the MPTP, was used
as a positive control.
Statistical Analysis
Data are presented as mean 6 SEM. Generally,
comparisons between more than 2 groups were made using
factorial 1-way analysis of variance and the Fisher protected
least signiﬁcant difference post hoc test. In some cases (eg, the
MPTP data), however, the Kruskal–Wallis analysis of variance
method was used followed by the Dunn multiple comparison
test. Where only 2 groups were compared, the Student t test
was used. Differences were regarded as statistically signiﬁcant
if a value of P , 0.05 was obtained.
RESULTS
Effect of Leptin, Administered at a Range of
Concentrations, on Myocardial Infarct Size
Before carrying out studies with hearts from Zucker
animals, experiments were performed in Wistar rat hearts to
identify a leptin concentration that produced optimal pro-
tection against I/R injury. Thus, leptin perfused at 10, 30 and,
100 nM and produced marked reductions in infarct size in the
Wistar rat heart (Fig. 1). By contrast, leptin at 0.1 and 1 nM
failed to induce cardioprotection. As leptin at the higher
concentrations produced similar levels of protection, 10 nM
leptin was chosen as the standard concentration for all
subsequent experiments.
Effect of the Protein Kinase Inhibitors
LY294002 and UO126 on
Leptin-induced Cardioprotection
As seen previously in the mouse heart,
17 LY294002, the
PI3K inhibitor, blocked 10 nM leptin-induced protection in the
Wistar rat heart (Fig. 2). Similarly, the p44/42 MAPK
inhibitor, UO126, also blocked leptin-induced protection.
The inhibitors and their solvent (0.02% dimethyl sulfoxide)
did not inﬂuence infarct size when administered by themselves
(Fig. 2).
Effect of Leptin on Infarct Size Limitation in
Hearts From Zucker Lean and fa/fa Rats
Leptin (10 nM), administered at reperfusion, sub-
stantially reduced infarct size in hearts from Zucker lean rats,
which express the normal OB-R gene (Fig. 3). By contrast,
hearts from fa/fa, which lack functional OB-R, did not exhibit
statistically signiﬁcant decreases in infarct size, although
a trend toward infarct size reduction was noted (Fig. 3).
Effect of Leptin, Administered at Reperfusion,
on the Phosphorylation of Akt and
p44/42 MAPK
Western blot analysis revealed that leptin treatment of
Wistar rat hearts was associated with statistically signiﬁcant
increases in the phosphorylation of Akt/serine-473, p44, and
p42 but not Akt/threonine-308 (Table 1). Contrasting with the
observations made with Wistar cardiac samples, signiﬁcant
changes in Akt/serine-473 phosphorylation were not seen in
leptin-treated Zucker lean rat hearts (Table 1). A statistically
signiﬁcant increase in Akt/threonine-308 phosphorylation
was, however, detected (Table 1). Signiﬁcant leptin-induced
increases in p44 and p42 phosphorylation were also observed
in Zucker lean rat hearts (Table 1). In fa/fa hearts,
phosphorylation of Akt/serine-473, Akt/threonine-308, p44
MAPK, and p42 MAPK was unaltered by leptin treatment
(Table 1).
Effect of Leptin on MPTP Opening in
Cardiomyocytes Isolated From Wistar, Zucker
Lean, and fa/fa Rat Hearts
CsA, an established inhibitor of the MPTP, was used as
a positive control in all isolated cardiomyocyte experiments.
Leptin (10 nM) and CsA (200 nM) delayed the time to MPTP
opening in cardiomyocytes isolated from Wistar rat hearts as
compared with cells treated with vehicle (Fig. 4). Similarly,
FIGURE 1. The inﬂuence of leptin, perfused during reperfusion
(120 minutes), at 0.1, 1.0, 10, 30, and 100 nM, on infarct size
as a percentage of the area at risk (IS/AAR%) in isolated
perfused Wistar rat hearts. Values are expressed as mean 6
SEM of 5–9 experiments (*P , 0.05, **P , 0.01).
FIGURE 2. The inﬂuence of LY294002 and UO126 (inhibitors
of PI3K and p44/42 MAPK, respectively) on infarct size (as
a percentage of the area at risk, IS/AAR%) reduction induced
by 10 nM leptin, perfused during reperfusion (120 minutes) in
isolated perfused Wistar rat hearts. Values are expressed as
mean 6 SEM of 4–9 experiments (**P , 0.01).
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cardiomyocytes isolated from Zucker lean rat hearts. By
contrast, although cardiomyocytes isolated from fa/fa rat
hearts responded to CsA with a delayed time to MPTP
opening, no changes were observed in leptin-treated cells
(Fig. 4).
DISCUSSION
Leptin, an adipocytokine linked to obesity and
metabolic disease, protects against I/R injury in various
organs including kidney,
29 brain,
30 and gut.
31 We reported that
leptin also reduces myocardial injury, its cardioprotective
actions being exerted through PI3K-Akt and p44/42 MAPK
activation and MPTP inhibition.
17 In the present study, we
focused on factors that may determine myocardial sensitivity
to the cardioprotective actions of leptin. Consequently,
contrasting with the ﬁndings obtained with hearts from Wistar
and Zucker lean rats that possess functional OB-R, we
demonstrated that infarct size, RISK pathway activation, and
ROS-induced MPTP opening in hearts from Zucker obese
(fa/fa) animals, which are compromised with respect to the
OB-R, were unaffected by leptin treatment. These data indicate
that adiposity and/or OB-R status may inﬂuence myocardial
responsiveness to leptin.
Dose-response studies performed with isolated hearts
from Wistar rats indicated that 10 nM leptin, a concentration
equivalent to a pharmacological dose and comparable to serum
concentrations occurring in obese humans,
32 yielded optimal
extents of infarct size reduction, data consistent with ﬁndings
made in the murine heart.
17 The fact that leptin concentrations
lower than 10 nM did not elicit responses could be interpreted
as indicating that leptin produces an ‘‘all or nothing’’ effect
with respect to infarct size reduction. However, as suggested
previously for the adipocytokine, apelin,
33 it is equally
possible that the effects were missed, that is, if leptin
concentrations between 1 and 10 nM had been tested, infarct
size reductions might have been seen over this range.
Nevertheless, the fact remains that 10 nM leptin yielded an
optimal response and was consequently chosen for all
subsequent experiments involving hearts from Wistar and
Zucker lean and fa/fa rats.
As described earlier, the Zucker lean rat expresses the
normal fully functional OB-R gene, whereas the fa/fa rat is
compromised with respect to the Ob-R, a mutation within the
extracellular domain rendering it nonfunctional. The use of
Zucker lean and fa/fa animals has, therefore, proved valuable
in studying metabolic processes and disease and in gauging
the importance of the OB-R with respect to leptin-mediated
mechanisms. We found that, as observed with hearts from
Wistar animals, hearts from Zucker lean rats responded to
leptin treatment with signiﬁcant reductions in infarct size. By
contrast, hearts from obese fa/fa rats did not respond to leptin
with statistically signiﬁcant decreases in infarct size, although
a small trend toward infarct size reduction was seen. This trend
raises the possibility that if leptin concentrations had been
increased above 10 nM, protection might have been achieved.
Alternatively, the involvement of mechanisms, other than
those relating to Ob-R activation, in leptin-induced cardio-
protection might be indicated. If, however, it is assumed that
our ﬁndings are valid and that leptin is, indeed, ineffective in
reducing infarct size in the fa/fa rat heart, one could suggest
that this reﬂects a general lack of sensitivity to cardioprotective
agents in these animals, possibly as a consequence of changes
in cardiomyocyte plasma membrane lipid composition.
Nevertheless, evidence opposing this view has been obtained,
various agents having been found to protect the fa/fa rat heart.
De Gennaro-Colonna et al
34 demonstrated that hexarelin,
a synthetic enkephalin-derived peptide, exerted a cardiopro-
tective effect in both lean and obese Zucker rats. Similarly,
rosiglitazone, which protects the myocardium in normal
animals,
35 was found to reduce infarct size in lean and obese
Zucker animals via Akt activation.
36
FIGURE 3. Effect of leptin (10 nM), perfused during reperfusion
(120 minutes), on infarct size (as a percentage of the area at
risk, IS/AAR%) in isolated hearts from Zucker lean (fa/+),
Zucker fatty (fa/fa), and Wistar rats. Values are expressed as
mean 6 SEM of 5–7 experiments (**P , 0.01).
TABLE 1. Summary of Western Blot Data
Wistar fa/+ fa/fa
Control Leptin Control Leptin Control Leptin
Akt/Ser-473 phosphorylation 100 6 9.6 196.7 6 33.5* 100 6 5.6 121.1 6 10.5 100 6 7.6 100.6 6 28.8
Akt/Thr-308 phosphorylation 100 6 15.2 123.5 6 25.4 100 6 8.2 143.9 6 15.4* 100 6 17.6 105.7 6 30.7
p44 phosphorylation 100 6 14.1 203.9 6 41.3* 100 6 10.3 197 6 33.6* 100 6 13.0 92.4 6 21.2
p42 phosphorylation 101.1 6 12.9 257.3 6 48.1† 100 6 10 258.1 6 52.9* 100 6 10.8 85.2 6 22.8
The effect of leptin (10 nM) treatment on Akt/serine-473, Akt/threonine-308, p44, and p42 phosphorylation in hearts from Zucker lean (fa/+), Zucker fatty (fa/fa), and Wistar
rats was examined. Data were calculated as the ratio of phosphorylated to total protein, relative densitometry values normalized to control (untreated, 100%). Values are mean 6 SEM
(*P , 0.05, †P , 0.001, leptin vs. control; n = 5–10).
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leptin-induced cardioprotection may be inﬂuenced by factors
such as the metabolic state and myocardial OB-R status. Given
its proposed primacy with respect to full cell signaling and the
physiological actions of leptin,
21,37 it is tempting to suggest
that the OB-Rb plays the principal role in relation to its
cardioprotective effects. One, however, cannot exclude the
possibility that other Ob isoforms may be involved in cardiac
function. It is, for example, known that in addition to Ob-Rb,
cardiomyocytes express Ob-Ra, which may also modulate
cellular processes
19,23 and are defective in the Zucker rat.
24
Ob-Ra, which,interestingly, are expressed at higher levels than
Ob-Rb in the normal heart,
18 have been linked to ventricular
hypertrophy and activation of p38 and p44/42, signaling
pathways implicated in cardioprotection.
23 We would suggest,
therefore, that the cardioprotective actions of leptin could, to
some extent, relate to Ob-Ra activation and p44/42 phosphor-
ylation, which, as discussed below, was observed on leptin
treatment. Studies involving the use of leptin receptor–
blocking peptides or antileptin receptor antibodies may help to
resolve the issue as to which OB-R subtype is responsible for
modulating the leptin-induced actions observed or, indeed, if
the OB-R is involved at all. Purdham et al,
38 for example,
reported that treatment of rats with a nonspeciﬁc leptin
receptor–neutralizing antibody reduces hypertrophy and
hemodynamic dysfunction in the postinfarcted heart. Recently,
speciﬁc antileptin receptor antibodies have come on line,
including antibodies against OB-Rb, which should make the
task of identifying the receptors involved in mediating the
cardiovascular actions of leptin easier.
Using pharmacological kinase inhibitors, data were
obtained indicating that the infarct reducing effects of leptin in
the Wistar rat heart involved PI3K-Akt and p44/42 MAPK
activation, a ﬁnding consistent with results obtained pre-
viously in the murine myocardium.
17 Meanwhile, Western blot
analysis conﬁrmed that Akt, as indicated by Akt/serine-473
phosphorylation, and p44/42 are involved in leptin-induced
cardioprotection in the Wistar rat heart, a ﬁnding which, again,
coincided with our previous observations made in the murine
myocardium.
17 Intriguingly, however, although leptin reduced
infarct size in Zucker lean rat hearts and increased p44 and p42
phosphorylation to extents comparable to those seen in Wistar
hearts, Akt/threonine-308 phosphorylation, rather than Akt/
serine-473 phosphorylation, was signiﬁcantly enhanced: It is
possible that these data reﬂect temporal differences between
Wistar and Zucker lean rats with respect to the phosphory-
lation of Akt at its 2 phosphorylation sites. Regarding the Akt
and p44/42 Western blot data obtained with fa/fa hearts, these
can be interpreted as indicating that leptin-stimulated
cardioprotection is dependent upon the presence of OB-R
on the myocardium, although a generalized inﬂuence of
obesity on cardiac function cannot be excluded. Thus, leptin
treatment not only failed to reduce infarct size in these animals
but also was not associated with RISK pathway activation, as
evidenced by our failure to detect increases in Akt (serine-473
and threonine-308) and p44/42 phosphorylation. Of course,
the cardioprotective actions of leptin may involve the
FIGURE 4. The times until the initiation of mitochondrial
depolarization, that is, MPTP opening, in the presence and
absence of leptin (10 nM) in cardiomyocytes isolated from
Zucker lean (fa/+), Zucker fatty (fa/fa), and Wistar rat hearts.
Values are presented as mean 6 SEM (*P , 0.05, **P , 0.01)
and were obtained with a total of 12–20 cells from at least
5 hearts per group.
FIGURE 5. Proposed cell signaling mechanisms underlying
leptin-induced myocardial protection. Reperfusion of the
myocardium after a period of ischemia results in MPTP
opening and subsequent mitochondrial uncoupling, ATP
consumption, and, ultimately, cell death. It is hypothesized
that binding of leptin by leptin receptors (OB-R) present on the
cardiomyocyte leads to the phosphorylation of PI3K and
subsequently Akt/protein kinase B (Akt) and/or phosphoryla-
tion of Src homology phosphatase 2 (SHP2) followed by
growth factor receptor–bound protein 2 (Grb2) and p44/42
MAPK extracellular signal–regulated MAPK (ERK 1/2). Signaling
pathways downstream of these cascades then converge on the
mitochondriontoinhibit MPTPopeningand,asaconsequence,
prevent mitochondrial uncoupling and cell death. If OB-R are
absent or defective, these mechanisms would not be operative
withthe consequence that cell death would proceed unimpeded.
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candidate for future investigation being the Janus kinase-
signal transducers and activators of transcription (JAK/STAT)
pathway, which mediates many of the metabolic actions of
leptin
21,22 and has been implicated in cardioprotection.
39,40
As described above, the infarct and Western blot data
obtained may be consistent with OB-R activation, playing
a role in leptin-induced cardioprotection. It has been proposed
that signaling via the RISK pathway ultimately converges on
the mitochondrion, resulting in MPTP inhibition.
28,41 Evi-
dence for such a mechanism has come from studies focusing
on MPTP opening in isolated cardiomyocytes.
6 Indeed, it has
been suggested that the MPTP may represent an essential
regulatory component with respect to mitochondrial function
and a key target in relation to cardioprotection.
6 Studies in
cyclophilin-D knockout mice have provided strong evidence
for the MPTP playing a key role in cell death.
42 Previously, we
reported that leptin delayed MPTP opening in cardiomyocytes
from Sprague-Dawley rats and that this was blocked by
LY294002 and MAPK/ERK kinase (MEK) inhibitor 1.
17 In
experiments with cardiomyocytes from Wistar rat hearts, we
again found that leptin delayed MPTPopening, aswas the case
for cells from Zucker lean rat hearts, consolidating our
previous evidence that leptin-induced signaling, as indicated
by increased Akt and p44/42 phosphorylation, converges on
the mitochondrion
17 (proposed steps involved in leptin-
induced signaling in the myocardium are shown in Fig. 5).
The fact that leptin did not produce a comparable effect on
cardiomyocytes from fa/fa rats indicates that leptin-induced
signaling, with respect to MPTP opening, is defective in these
animals, thus, perhaps, providing further support for the notion
that the OB-R plays a role in leptin-mediated protection.
To conclude, wewould suggest that the data presented in
this article have implications for protection against myocardial
injury, especially with respect to individuals with obesity or
exhibiting leptin resistance and/or hyperleptinemia.
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